Patent Application
20100016401
The present invention relates to novel 3-aza-bicyclo[3.1.0]hexane derivatives of formula (I) and their use as pharmaceuticals. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more compounds of formula (I), and especially their use as orexin receptor antagonists.
Orexins (orexin A or OX-A and orexin B or OX-B) are novel neuropeptides found in 1998 by two research groups, orexin A is a 33 amino acid peptide and orexin B is a 28 amino acid peptide (Sakurai T. et al., Cell, 1998, 92, 573-585). Orexins are produced in discrete neurons of the lateral hypothalamus and bind to G-protein-coupled receptors (OX1 and OX2 receptors). The orexin-1 receptor (OX1) is selective for OX-A, and the orexin-2 receptor (OX2) is capable to bind OX-A as well as OX-B. Orexins are found to stimulate food consumption in rats suggesting a physiological role for these peptides as mediators in the central feedback mechanism that regulates feeding behaviour (Sakurai T. et al., Cell, 1998, 92, 573-585). On the other hand, it was also observed that orexins regulate states of sleep and wakefulness opening potentially novel therapeutic approaches to narcolepsy as well as insomnia and other sleep disorders (Chemelli R. M. et al., Cell, 1999, 98, 437-451).
Orexin receptors are found in the mammalian brain and may have numerous implications in pathologies as known from the literature.
The present invention provides 3-aza-bicyclo[3.1.0]hexane derivatives, which are non-peptide antagonists of human orexin receptors. These compounds are in particular of potential use in the treatment of e.g. eating disorders, drinking disorders, sleep disorders, or cognitive dysfunctions in psychiatric and neurologic disorders.
Up to now, several low molecular weight compounds are known having a potential to antagonise either specifically OX1 or OX2, or both receptors at the same time. Piperidine derivatives useful as orexin receptor antagonists are disclosed in WO2001/96302.
The present invention describes for the first time 3-aza-bicyclo[3.1.0]hexane derivatives as orexin receptor antagonists.
i) A first aspect of the invention consists of a compound of the formula (I)
wherein
X represents C(O) or SO2;
A represents aryl or heterocyclyl, wherein the aryl or heterocyclyl is unsubstituted or independently mono- or di-substituted, wherein the substituents are independently selected from the group consisting of (C1-4)alkyl, (C3-6)cycloalkyl, (C2-6)alkynyl, hydroxy-(C1-4)alkyl, hydroxy-(C2-6)alkynyl, trimethylsilyl-ethynyl, (C3-6)cycloalkylethynyl, (C1-4)alkoxy, trifluoromethyl, trifluoromethoxy, NR2R3, N(R2)C(O)R3, C(O)NR2R3, and halogen;
B represents a hydrogen atom or an aryl- or heterocyclyl-group, wherein the aryl or heterocyclyl is unsubstituted or independently mono-, di-, or trisubstituted, wherein the substituents are independently selected from the group consisting of (C1-4)alkyl, (C3-6)cycloalkyl, (C1-4)alkoxy, methoxy-(C1-4)alkoxy, cyano, trifluoromethyl, trifluoromethoxy, NR2R3, N(R2)C(O)R3, C(O)NR2R3, and halogen; or B represents a 2,3-dihydro-benzo[1,4]dioxinyl group;
or A and B together represent a tricyclic group;
n represents 0 or 1;
R1 represents aryl or heterocyclyl, wherein the aryl or heterocyclyl is unsubstituted or independently mono-, di-, or trisubstituted wherein the substituents are independently selected from the group consisting of (C1-4)alkyl, (C2-6)alkynyl, (C3-6)cycloalkyl, (C1-4)alkoxy, (C1-4)alkylthio, halogen, hydroxy, cyano, trifluoromethyl, trifluoromethoxy, NR2R3, N(R2)C(O)R3, COOR2, and C(O)NR2R3; or R1 represents a heterocyclyl-ethenyl-, a heterocyclyl-(C1-4)alkyl or an aryloxy-(C1-4)alkyl-group, which groups are unsubstituted or independently mono- or di-substituted at the aryl- or heterocyclyl-part wherein the substituents are independently selected from the group consisting of (C1-4)alkyl, (C1-4)alkoxy, halogen, trifluoromethyl, trifluoromethoxy, and NR2R3; or R1 represents a 2,3-dihydro-benzofuranyl-, a benzo[1,3]dioxolyl-, a 2,3-dihydro-benzo[1,4]dioxinyl-, a 4-oxo-4H-chromenyl-, a 2H-chromenyl, a chromanyl-, a 4H-benzo[1,3]dioxinyl-, a 2,3-dihydro-thieno[3,4-b][1,4]dioxinyl-, a morpholin-4-yl-phenyl-, a piperazin-1-yl-phenyl-, a 3,4-dihydro-2H-benzo[1,4]oxazinyl-, a 3-oxo-3,4-dihydro-2H-benzo[1,4]oxazinyl- or a 2,3,6,7-tetrahydro-benzo[1,2-b;4,5-b′]difuranyl-group, wherein said groups are unsubstituted or independently mono- or di-substituted wherein the substituents are independently selected from the group consisting of (C1-4)alkyl, (C1-4)alkoxy, and halogen;
R2 represents hydrogen or (C1-4)alkyl; and
R3 represents hydrogen or (C1-4)alkyl.
The compounds of formula (1) may contain one or more stereogenic or asymmetric centers, such as one or more asymmetric carbon atoms. Substituents at a double bond or a ring may be present in cis-(=Z-) or trans (=E-) form unless indicated otherwise.
The compounds of formula (I) may thus be present as mixtures of stereoisomers or preferably as pure stercoisomers. Mixtures of stercoisomers may be separated in a manner known to a person skilled in the art.
Any reference to a compound of formula (I) is to be understood as referring also to salts (especially pharmaceutically acceptable salts) of a compound of formula (I), respectively, as appropriate and expedient.
The term “pharmaceutically acceptable salts” refers to non-toxic, inorganic or organic acid and/or base addition salts. Reference can be made to “Salt selection for basic drugs”, Int. J. Pharm. (1986), 33, 201-217.
The term “halogen” means fluorine, chlorine, bromine, or iodine, preferably fluorine or chlorine.
The term “(C1-4)alkyl”, alone or in combination, means a straight-chain or branched-chain alkyl group with 1 to 4 carbon atoms. Examples of (C1-4)alkyl groups are methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, sec.-butyl or tert.-butyl. Preferred are methyl and ethyl.
The term “(C3-6)cycloalkyl”, alone or in combination, means a cycloalkyl group with 3 to 6 carbon atoms. Examples of (C3-6)cycloalkyl groups are cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl. Preferred is cyclopropyl.
The term “(C1-4)alkoxy”, alone or in combination, means a group of the formula (C1-4)alkyl-O— in which the term “(C1-4)alkyl” has the previously given significance, such as methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec.-butoxy or tert.-butoxy. Preferred are methoxy and ethoxy.
The term “aryl”, alone or in combination, means a phenyl or a naphthyl group. Preferred is a phenyl group. The aryl group may be unsubstituted or independently mono-, di-, or trisubstituted wherein the substituents are independently selected from the group consisting of (C1-4)alkyl, (C3-6)cycloalkyl, (C2-6)alkynyl, hydroxy-(C1-4)alkyl, hydroxy-(C2-6)alkynyl, trimethylsilyl-ethynyl, (C3-6)cycloalkyl-ethynyl, (C1-4)alkoxy, trifluoromethyl, trifluoromethoxy, methoxy-(C1-4)alkoxy, cyano, (C1-4)alkylthio, hydroxy, COOR2, NR2R3, N(R2)C(O)R3, C(O)NR2R3, and halogen.
In case “A” represents “aryl” the term preferably means the above-mentioned group which is unsubstituted or independently mono- or di-substituted, wherein the substituents are independently selected from the group consisting of (C1-4)alkyl, (C3-6)cycloalkyl, (C2-6)alkynyl, hydroxy-(C1-4)alkyl, hydroxy-(C2-6)alkynyl, trimethylsilyl-ethynyl, (C3-6)cycloalkyl-ethynyl, (C1-4)alkoxy, trifluoromethyl, trifluoromethoxy, NR2R3, N(R2)C(O)R3, C(O)NR2R3, and halogen. Especially, the substituents are independently selected from the group consisting of (C1-4)alkyl, (C3-6)cycloalkyl, (C1-4)alkoxy, trifluoromethyl, trifluoromethoxy, NR2R3, N(R2)C(O)R3, C(O)NR2R3, and halogen. Especially preferred examples wherein “A” represents “aryl” are unsubstituted or mono-substituted phenyl, wherein the substituent is (C1-4)alkyl. In another embodiment, especially preferred examples wherein “A” represents “aryl” are mono-, or di-substituted phenyl, wherein one substituent is selected from the group consisting of (C2-6)alkynyl, and (C3-6)cycloalkyl-ethynyl; and the other substituent (if present) is selected from the group consisting of (C1-4)alkyl, (C1-4)alkoxy, and trifluoromethoxy (especially (C1-4)alkyl). In addition to the above-mentioned substituents, the substituent “A” is also substituted by the substituent “B”, whereby, in case B represents aryl or heterocyclyl, B is preferably attached in ortho position to the point of attachment of the group X. Examples wherein “A” represents “aryl” are phenyl, naphthyl, 2-methylphenyl, 3-methylphenyl, 4-methylphenyl, 3-trifluoromethyl-phenyl, 2-trifluoromethoxyphenyl, 2-(cyclopropyl-ethynyl)-4-methylphenyl, 2-(ethylethynyl)-4-methylphenyl, and 2-(isobutyl-ethynyl)-4-methylphenyl.
In case “B” represents “aryl” the term preferably means the above-mentioned group which is unsubstituted or independently mono-, di-, or trisubstituted, wherein the substituents are independently selected from the group consisting of (C1-4)alkyl, (C3-6)cycloalkyl, (C1-4)alkoxy, methoxy-(C1-4)alkoxy, cyano, trifluoromethyl, trifluoromethoxy, NR2R3, N(R2)C(O)R3, C(O)NR2R3, and halogen. Especially, the substituents are independently selected from the group consisting of (C1-4)alkyl, (C3-6)cycloalkyl, (C1-4)alkoxy, trifluoromethyl, trifluoromethoxy, NR2R3, N(R2)C(O)R3, C(O)NR2R3, and halogen. Preferred examples wherein “B” represents “aryl” are unsubstituted or independently mono-, di-, or trisubstituted phenyl (preferred mono-substituted phenyl), wherein the substituents are independently selected from the group consisting of (C1-4)alkyl, (C1-4)alkoxy, trifluoromethyl, and halogen. In addition to the above-mentioned substituents, the substituent “B” is attached to the substituent “A”. Examples wherein “B” represents “aryl” are phenyl, 2-methylphenyl, 3-methylphenyl, 4-methylphenyl, 3,4-dimethylphenyl, 2,3-dimethylphenyl, 4-ethylphenyl, 3-isopropylphenyl, 2-methoxyphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 2-trifluoromethylphenyl, 3-trifluoromethylphenyl, 4-trifluoromethylphenyl, 3-trifluoromethoxyphenyl, 4-fluoro-3-methylphenyl, 3-cyanophenyl, and 3-(2-methoxyethoxy)-phenyl.
In case “A” and “B” both represents “aryl” the combination “A-B” preferably means a biphenyl group which is unsubstituted or independently mono- or di-substituted for “A” and unsubstituted or mono-, di- or trisubstituted for “B”, wherein the substituents are independently selected from the group consisting of (C1-4)alkyl, (C3-6)cycloalkyl, (C1-4)alkoxy, trifluoromethyl, trifluoromethoxy, NR2R3, N(R2)C(O)R3, C(O)NR2R3, and halogen. Preferred examples wherein “A” and “B” both represents “aryl” are biphenyl groups which are unsubstituted or independently mono- or di-substituted for “A” and unsubstituted or mono-, di- or trisubstituted for “B”, wherein the substituents are independently selected from the group consisting of (C1-4)alkyl, (C1-4)alkoxy, trifluoromethyl, and halogen. Especially preferred examples wherein “A” and “B” both represents “aryl” are biphenyl groups which are unsubstituted or mono-substituted with methyl for “A” and unsubstituted or mono-, di- or trisubstituted for “B”, wherein the substituents are independently selected from the group consisting of (C1-4)alkyl, (C1-4)alkoxy, trifluoromethyl, and halogen.
Examples are:
whereby in the above examples the phenyl ring representing “A” may also be further mono-substituted with methyl.
In case R1 represents “aryl” the term preferably means the above-mentioned groups which are unsubstituted or independently mono-, di-, or trisubstituted wherein the substituents are independently selected from the group consisting of (C1-4)alkyl, (C2-6)alkynyl, (C3-6)cycloalkyl, (C1-4)alkoxy, (C1-4)alkylthio, halogen, hydroxy, cyano, trifluoromethyl, trifluoromethoxy, NR2R3, N(R2)C(O)R3, COOR2, and C(O)NR2R3. Especially, the substituents are independently selected from the group consisting of (C1-4)alkyl, (C3-6)cycloalkyl, (C1-4)alkoxy, halogen, hydroxy, cyano, trifluoromethyl, trifluoromethoxy, NR2R3, N(R2)C(O)R3, and C(O)NR2R3. Preferred examples wherein “R1” represents “aryl” are unsubstituted or independently mono-, di-, or trisubstituted phenyl (preferred mono-substituted phenyl), wherein the substituents are independently selected from the group consisting of (C1-4)alkyl, (C1-4)alkoxy, halogen, hydroxy, cyano, trifluoromethyl, trifluoromethoxy, and COOR2. Examples wherein R1 represents “aryl” are phenyl, naphthyl, 2-chloro-4,5-difluorophenyl, 3-bromo-6-chlorophenyl, 2-chloro-5-trifluoromethylphenyl, 2-chlorophenyl, 4-chlorophenyl, 2,4-dichlorophenyl, 3,4-dichlorophenyl, 2-chloro-4-fluorophenyl, 2-chloro-3-fluorophenyl, 2-chloro-3-methylphenyl, 3-chloro-2-methylphenyl, 4-fluorophenyl, 2-fluoro-5-methylphenyl, 3-fluoro-2-methylphenyl, 3-fluoro-6-methoxyphenyl, 3-fluoro4-methoxyphenyl, 2-bromo-5-methylphenyl, 2-bromo-3-methylphenyl, 2,5-dimethylphenyl, 3,4-dimethylphenyl, 3,5-dimethylphenyl, 2-methyl-4-methoxyphenyl, 3-methyl-4-methoxyphenyl, 4-ethylphenyl, 4-tert.-butylphenyl, 2-hydroxyphenyl, 3-hydroxyphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 2,3-dimethoxyphenyl, 2,4-dimethoxyphenyl, 3,4-dimethoxyphenyl, 2,5-dimethoxyphenyl, 3,5-dimethoxyphenyl, 3,5-dichloro-4-hydroxyphenyl, 3-iodophenyl, 3-bromophenyl, 3-cyanophenyl, 4-cyanophenyl, 3-ethynylphenyl, 4-methyl-3-trifluoromethylphenyl, 4-methoxy-3-trifluoromethylphenyl, 3-trifluoromethylphenyl, 4-trifluoromethylphenyl, 3-methoxycarbonylphenyl, and 4-dimethylaminophenyl.
The term “aryloxy-(C1-4)alkyl” means a (C1-4)alkyl group as previously defined in which one hydrogen atom has been replaced by a group of the formula aryl-O— wherein “aryl” has the meaning as defined previously and is unsubstituted or independently mono- or di-substituted wherein the substituents are independently selected from the group consisting of (C1-4)alkyl, (C1-4)alkoxy, halogen, trifluoromethyl, trifluoromethoxy, and NR2R3. Examples wherein R1 represents “aryloxy-(C1-4)alkyl” are naphthalen-2-yloxy-methyl, 2-methoxy-phenoxy-methyl and 3-methoxy-phenoxy-methyl.
The term “heterocyclyl”, alone or in combination, means a 5- to 10-membered monocyclic or bicyclic aromatic ring containing for example 1, 2 or 3 heteroatoms selected from oxygen, nitrogen and sulfur which may be the same or different. Examples of such heterocyclyl groups are furanyl, oxazolyl, isoxazolyl, oxadiazolyl, thienyl, thiazolyl, isothiazolyl, thiadiazolyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, pyridyl, pyrimidyl, pyridazinyl, pyrazinyl, indolyl, isoindolyl, benzofuranyl, isobenzofuranyl, benzothiophenyl, indazolyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl, benzotriazolyl, benzoxadiazolyl, benzothiadiazolyl, quinolinyl, isoquinolinyl, naphthyridinyl, cinnolinyl, quinazolinyl, quinoxalinyl, phthalazinyl, pyrazolo[1,5-a]pyridyl, pyrazolo[1,5-a]pyrimidyl, imidazo[1,2-a]pyridyl or imidazo[2,1-b]thiazolyl. The above-mentioned heterocyclyl groups may also be independently mono-, di-, or trisubstituted wherein the substituents are independently selected from the group consisting of (C1-4)alkyl, (C3-6)cycloalkyl, (C2-6)alkynyl, hydroxy-(C1-4)alkyl, hydroxy-(C2-6)alkynyl, trimethylsilyl-ethynyl, (C3-6)cycloalkylethynyl, (C1-4)alkoxy, trifluoromethyl, trifluoromethoxy, methoxy-(C1-4)alkoxy, cyano, (C1-4)alkylthio, hydroxy, COOR2, NR2R3, N(R2)C(O)R3, C(O)NR2R3, and halogen.
In case “A” represents “heterocyclyl” the term preferably means the above-mentioned groups which is unsubstituted or independently mono- or di-substituted (preferred unsubstituted or mono-substituted) wherein the substituents are independently selected from the group consisting of (C1-4)alkyl, (C3-6)cycloalkyl, (C2-6)alkynyl, hydroxy-(C1-4)alkyl, hydroxy-(C2-6)alkynyl, trimethylsilyl-ethynyl, (C3-6)cycloalkylethynyl, (C1-4)alkoxy, trifluoromethyl, trifluoromethoxy, NR2R3, N(R2)C(O)R3, C(O)NR2R3, and halogen. Especially, the substituents are independently selected from the group consisting of (C1-4)alkyl, (C3-6)cycloalkyl, (C1-4)alkoxy, trifluoromethyl, trifluoromethoxy, NR2R3, N(R2)C(O)R3, C(O)NR2R3, and halogen. In another embodiment, the substituents are independently selected from the group consisting of (C1-4)alkyl, hydroxy-(C1-4)alkyl, hydroxy-(C2-6)alkynyl, trimethylsilyl-ethynyl, (C1-4)alkoxy, NR2R3, and halogen. In a further preferred embodiment, in case “A” represents “heterocyclyl” the term means a 5- to 6-membered monocyclic heterocyclyl as defined above which is unsubstituted or independently mono- or di-substituted (preferred unsubstituted or mono-substituted) wherein the substituents are independently selected from the group consisting of (C1-4)alkyl, hydroxy-(C1-4)alkyl, hydroxy-(C2-6)alkynyl, trimethylsilyl-ethynyl, (C1-4)alkoxy, NR2R3, and halogen. Preferred examples wherein “A” represents “heterocyclyl” are unsubstituted or mono-substituted heterocyclyl as mentioned above (preferred thiazolyl, especially preferred thiazol-4-yl) wherein the substituent is selected from (C1-4)alkyl, (C1-4)alkoxy, halogen (especially bromo), and NR2R3 (especially the substituent is selected from (C1-4)alkyl and NR2R3). In another embodiment the substituent is selected from hydroxy-(C1-4)alkyl, and hydroxy-(C2-6)alkynyl. In addition to the above-mentioned substituents, the substituent “A” is also substituted by the substituent “B”, whereby, in case B represents aryl or heterocyclyl, B is preferably attached in ortho position to the point of attachment of the group X.
Particular examples wherein “A” represents “heterocyclyl” and one of the substituents is represented by “B” are:
Further particular examples are:
Further particular examples are:
In case “B” represents “heterocyclyl” the term preferably means the above-mentioned groups which is unsubstituted or independently mono-, di-, or trisubstituted (preferred mono- or di-substituted) wherein the substituents are independently selected from the group consisting of (C1-4)alkyl, (C3-6)cycloalkyl, (C1-4)alkoxy, methoxy-(C1-4)alkoxy, cyano, trifluoromethyl, trifluoromethoxy, NR2R3, N(R2)C(O)R3, C(O)NR2R3, and halogen. Especially, the substituents are independently selected from the group consisting of (C1-4)alkyl, (C3-6)cycloalkyl, (C1-4)alkoxy, trifluoromethyl, trifluoromethoxy, NR2R3, N(R2)C(O)R3, C(O)NR2R3, and halogen. In addition to the above-mentioned substituents, the substituent “B” is attached to the substituent “A”. Examples wherein “B” represents “heterocyclyl” are pyrazolyl (especially 2-methyl-pyrazole-5-yl or pyrazole-5-yl), pyridyl (especially 3-pyridyl), thienyl (especially 4-methyl-thien-2-yl) and thiazolyl (especially 2-aminothiazol-4-yl).
In case R1 represents “heterocyclyl” the term preferably means the above-mentioned groups which is unsubstituted or independently mono-, di-, or trisubstituted (preferred unsubstituted or mono-substituted) wherein the substituents are independently selected from the group consisting of (C1-4)alkyl, (C2-6)alkynyl, (C3-6)cycloalkyl, (C1-4)alkoxy, (C1-4)alkylthio, halogen, hydroxy, cyano, trifluoromethyl, trifluoromethoxy, NR2R3, N(R2)C(O)R3, COOR2, and C(O)NR2R3. Especially, the substituents are independently selected from the group consisting of (C1-4)alkyl, (C3-6)cycloalkyl, (C1-4)alkoxy, halogen, hydroxy, cyano, trifluoromethyl, trifluoromethoxy, NR2R, N(R2)C(O)R3, and C(O)NR2R3. In a further preferred embodiment, in case R1 represents “heterocyclyl” the term means the above-mentioned groups which are unsubstituted or independently mono-, di-, or trisubstituted (preferred unsubstituted or mono-substituted) wherein the substituents are independently selected from the group consisting of (C1-4)alkyl, (C1-4)alkoxy, and halogen. In another embodiment, the substituents are independently selected from the group consisting of (C1-4)alkyl, trifluoromethyl, and halogen. In a further preferred embodiment, in case R1 represents “heterocyclyl” the term means the above-mentioned groups which are unsubstituted or independently mono-, di-, or trisubstituted (preferred unsubstituted or mono-substituted) wherein the substituent is methyl. Preferred examples wherein “R1” represents “heterocyclyl” are unsubstituted or independently mono-, di-, or trisubstituted (preferred unsubstituted or mono-substituted) heterocyclyl; wherein the heterocyclyl is selected from the group consisting of furanyl, oxazolyl, isoxazolyl, thiazolyl, pyrrolyl, pyrazolyl, pyridyl, pyrimidyl, indolyl, benzofuranyl, benzothiophenyl, indazolyl, benzimidazolyl, benzisoxazolyl, benzothiazolyl, benzoxadiazolyl, benzothiadiazolyl, quinolinyl, isoquinolinyl, naphthyridinyl, quinoxalinyl, pyrazolo[1,5-a]pyridyl, pyrazolo [1,5-a]pyrimidyl, imidazo[1,2-a]pyridyl and imidazo[2,1-b]thiazolyl (especially imidazo[2,1-b]thiazolyl); wherein the substituents are independently selected from (C1-4)alkyl, trifluoromethyl, and halogen.
Examples wherein R1 represents “heterocyclyl” are:
In another embodiment, preferred examples wherein R1 represents “heterocyclyl” are imidazo[2,1-b]thiazolyl and imidazo[1,2-a]pyridyl (especially imidazo [2,1-b]thiazolyl).
The term “heterocyclyl-ethenyl” means an ethenyl group in which one hydrogen atom has been replaced by a heterocyclyl group as previously defined. The heterocyclyl group may be unsubstituted or independently mono- or di-substituted wherein the substituents are independently selected from the group consisting of (C1-4)alkyl, (C1-4)alkoxy, halogen, trifluoromethyl, trifluoromethoxy, and NR2R3. An example is 2-furanyl-ethenyl.
The term “heterocyclyl-(C1-4)alkyl” means a (C1-4)alkyl group as previously defined in which one hydrogen atom has been replaced by a heterocyclyl group as previously defined. The heterocyclyl group may be unsubstituted or independently mono- or di-substituted wherein the substituents are independently selected from the group consisting of (C1-4)alkyl, (C1-4)alkoxy, halogen, trifluoromethyl, trifluoromethoxy, and NR2R3. An example is 2,5-dimethyl-thiazol-4-ylmethyl.
The term “tricyclic group” means a fluorenyl, a carbazolyl, a dibenzofuranyl, or a dibenzothiophenyl group which groups are unsubstituted or independently mono- or di-substituted wherein the substituents are independently selected from the group consisting of (C1-4)alkyl, (C3-6)cycloalkyl, (C1-4)alkoxy, halogen, cyano, trifluoromethyl, trifluoromethoxy, NR2R3, N(R2)C(O)R3, and C(O)NR2R3. An example is a fluorenyl group.
2,3-Dihydro-benzofuranyl-groups as used for the substituent R1 are preferably unsubstituted, or di-substituted in position 2 with methyl.
Benzo[1,3]dioxolyl-groups as used for the substituent R1 are preferably unsubstituted, or di-substituted in position 2 with fluoro.
4H-Benzo[1,3]dioxinyl-groups as used for the substituent R1 are preferably unsubstituted, or mono-substituted in position 6 with fluoro.
3,4-Dihydro-2H-benzo[1,4]oxazinyl-, and 3-oxo-3,4-dihydro-2H-benzo[1,4]oxazinyl-groups as used for the substituent R1 are preferably unsubstituted, or mono-substituted on the nitrogen atom with methyl.
2,3-Dihydro-benzo[1,4]dioxinyl-, 4-oxo-4H-chromenyl-, 2H-chromenyl, chromanyl-, 2,3-dihydro-thieno[3,4-b][1,4]dioxinyl-, morpholin-4-yl-phenyl-, piperazin-1-yl-phenyl-, and 2,3,6,7-tetrahydro-benzo[1,2-b;4,5-b′]difuranyl-groups as used for the substituent R1 are preferably unsubstituted.
The term “NR2R3” means for example NH2 and N(CH3)2 (especially NH2).
The term “N(R2)C(O)R3” means for example N(CH3)C(O)CH3.
The term “C(O)NR2R3” means for example C(O)N(CH3)2.
The term “COOR2” means for example COOCH3.
The term “(C2-6)alkynyl”, alone or in combination, means a straight-chain or branched-chain alkynyl group, preferably a straight-chain or branched-chain alkyn-1-yl group, with 2 to 6 carbon atoms. Examples are ethynyl, ethyl-ethynyl, or isobutyl-ethynyl.
The term “hydroxy-(C1-4)alkyl” means a (C1-4)alkyl group as defined before which is substitued with hydroxy. An example is 3-hydroxy-n-propyl.
The term “hydroxy-(C2-6)alkynyl” means a (C2-6)alkynyl group as defined before which is substitued with hydroxy. An example is hydroxymethyl-ethynyl.
The term “(C3-6)cycloalkyl-ethynyl” means an ethynyl group which is substituted with a (C3-6)cycloalkyl group as defined before. An example is cyclopropyl-ethynyl.
The term “methoxy-(C1-4)alkoxy” means for example 2-methoxy-ethoxy.
The term “(C1-4)alkylthio” means a group of the formula (C1-4)alkyl-S— in which the term “(C1-4)alkyl” has the previously given significance, such as methyl-thio.
ii) A further embodiment of the invention relates to compounds according to embodiment i), wherein the stereogenic centers are in a relative cis-configuration
iii) A further embodiment of the invention relates to compounds according to embodiments i) or ii), wherein at least one, preferably all of the following characteristics are present:
X represents C(O) or SO2;
A represents aryl or heterocyclyl, wherein the aryl or heterocyclyl is unsubstituted or independently mono- or di-substituted, wherein the substituents are independently selected from the group consisting of (C1-4)alkyl, (C3-6)cycloalkyl, (C1-4)alkoxy, trifluoromethyl, trifluoromethoxy, NR2R3, N(R2)C(O)R3, C(O)NR2R3, and halogen;
B represents a hydrogen atom or an aryl- or heterocyclyl-group, wherein the aryl or heterocyclyl is unsubstituted or independently mono-, di-, or trisubstituted, wherein the substituents are independently selected from the group consisting of (C1-4)alkyl, (C3-6)cycloalkyl, (C1-4)alkoxy, trifluoromethyl, trifluoromethoxy, NR2R3, N(R2)C(O)R3, C(O)NR2R3, and halogen;
or A and B together represent a tricyclic group;
n represents 0 or 1; and
R1 represents aryl or heterocyclyl, wherein the aryl or heterocyclyl is unsubstituted or independently mono-, di-, or trisubstituted wherein the substituents are independently selected from the group consisting of (C1-4)alkyl, (C3-6)cycloalkyl, (C1-4)alkoxy, halogen, hydroxy, cyano, trifluoromethyl, trifluoromethoxy, NR2R3, N(R2)C(O)R3, and C(O)NR2R3; or R1 represents a heterocyclyl-ethenyl-, a heterocyclyl-(C1-4)alkyl or an aryloxy-(C1-4)alkyl-group, which groups are unsubstituted or independently mono- or di-substituted at the aryl- or heterocyclyl-part wherein the substituents are independently selected from the group consisting of (C1-4)alkyl, (C1-4)alkoxy, halogen, trifluoromethyl, trifluoromethoxy, and NR2R3; or R1 represents a 2,3-dihydrobenzofuranyl-, a benzo[1,3]dioxolyl-, a 2,3-dihydro-benzo[1,4]dioxinyl- or a 4-oxo-4H-chromenyl group, wherein said groups are unsubstituted or mono-substituted at the aromatic ring with substituents independently selected from the group consisting of (C1-4)alkyl, (C1-4)alkoxy, and halogen;
R2 represents hydrogen or (C1-4)alkyl;
R3 represents hydrogen or (C1-4)alkyl.
iv) A further embodiment of the invention relates to compounds according to any one of embodiments i) to iii), wherein at least one, preferably all of the following characteristics are present:
A represents heterocyclyl, wherein the heterocyclyl is unsubstituted or mono-substituted, wherein the substituent is selected from the group consisting of (C1-4)alkyl, and NR2R3;
B represents aryl, wherein the aryl is unsubstituted or independently mono-, di- or trisubstituted, wherein the substituents are independently selected from the group consisting of (C1-4)alkyl, (C1-4)alkoxy, trifluoromethyl, and halogen; and
R1 represents aryl or heterocyclyl, wherein the aryl or heterocyclyl is unsubstituted or independently mono-, di-, or trisubstituted wherein the substituents are independently selected from the group consisting of (C1-4)alkyl, (C1-4)alkoxy, and halogen; or R1 represents a 2,3-dihydro-benzofuranyl-, a benzo[1,3]dioxolyl- or a 2,3-dihydrobenzo[1,4]dioxinyl-group.
v) A further embodiment of the invention relates to compounds according to any one of embodiments i) to iv), wherein at least one, preferably all of the following characteristics are present:
A represents an oxazolyl, a thiazolyl, a pyrimidyl or a pyrazinyl group, wherein said groups are unsubstituted or mono-substituted, wherein the substituent is selected from the group consisting of (C1-4)alkyl, and NR2R3;
B represents phenyl, wherein the phenyl is unsubstituted or independently mono- or di-substituted, wherein the substituents are independently selected from the group consisting of (C1-4)alkyl, (C1-4)alkoxy, trifluoromethyl, and halogen; and
R1 represents a phenyl, a naphthyl, a benzofuranyl, a imidazo[2,1-b]thiazolyl, a imidazo[1,2-a]pyridyl, a pyrazolo[1,5-a]pyridyl, a thiazolyl, a isoxazolyl, a pyrazolyl, an indolyl, an indazolyl, a benzimidazolyl or a benzothiophenyl group, wherein said groups are unsubstituted or independently mono- or di-substituted wherein the substituents are independently selected from the group consisting of (C1-4)alkyl, (C1-4)alkoxy, and halogen; or R1 represents a 2,3-dihydro-benzofuranyl-, a benzo[1,3]dioxolyl- or a 2,3-dihydro-benzo[1,4]dioxinyl-group.
vi) A further embodiment of the invention relates to compounds according to any one of embodiments i) to v), wherein X represents C(O).
vii) A further embodiment of the invention relates to compounds according to any one of embodiments i) to vi), wherein n represents 1.
vii) A further embodiment of the invention relates to compounds according to any one of embodiments i), ii), vi), or vii), wherein
A represents aryl or heterocyclyl, wherein the aryl or heterocyclyl is unsubstituted or mono-substituted, wherein the substituent is selected from the group consisting of (C1-4)alkyl, (C3-6)cycloalkyl, (C2-6)alkynyl, hydroxy-(C1-4)alkyl, hydroxy-(C2-6)alkynyl, (C3-6)cycloalkyl-ethynyl, (C1-4)alkoxy, NR2R3, and halogen.
ix) A further embodiment of the invention relates to compounds according to any one of embodiments i), ii), or vi) to viii), wherein
B represents aryl or heterocyclyl, wherein the aryl or heterocyclyl is unsubstituted or independently mono-, di-, or trisubstituted, wherein the substituents are independently selected from the group consisting of (C1-4)alkyl, (C1-4)alkoxy, cyano, trifluoromethyl, NR2R3, and halogen.
x) A further embodiment of the invention relates to compounds according to any one of embodiments i), ii), or vi) to ix), wherein
R1 represents aryl or heterocyclyl, wherein the aryl or heterocyclyl is unsubstituted or independently mono-, di-, or trisubstituted wherein the substituents are independently selected from the group consisting of (C1-4)alkyl, (C1-4)alkoxy, halogen, hydroxy, cyano, trifluoromethyl, and COOR2; or R1 represents a 2,3-dihydro-benzofuranyl-, a benzo[1,3]dioxolyl-, a 2,3-dihydro-benzo[1,4]dioxinyl-, a 2H-chromenyl, a chromanyl-, a 4H-benzo[1,3]dioxinyl-, a 2,3-dihydro-thieno[3,4-b][1,4]dioxinyl-, a 3,4-dihydro-2H-benzo[1,4]oxazinyl- or a 2,3,6,7-tetrahydro-benzo[1,2-b;4,5-b′]difuranyl-group, wherein said groups are unsubstituted or independently mono- or di-substituted wherein the substituents are independently selected from the group consisting of (C1-4)alkyl, (C1-4)alkoxy, and halogen.
xi) A further embodiment of the invention relates to compounds according to any one of embodiments i), ii), or vi) to x), wherein
A represents aryl, wherein the aryl is unsubstituted or mono-substituted, wherein the substituent is selected from the group consisting of (C1-4)alkyl, (C3-6)cycloalkyl, (C3-6)cycloalkyl-ethynyl, and halogen.
xii) A further embodiment of the invention relates to compounds according to any one of embodiments i), ii), or vi) to x), wherein
A represents heterocyclyl, wherein the heterocyclyl is unsubstituted or mono-substituted, wherein the substituent is selected from the group consisting of (C1-4)alkyl, (C3-6)cycloalkyl, hydroxy-(C1-4)alkyl, hydroxy-(C2-6)alkynyl, (C1-4)alkoxy, NR2R3, and halogen.
xiii) A further embodiment of the invention relates to compounds according to any one of embodiments i), ii), or vi) to xii), wherein
B represents phenyl, wherein the phenyl is unsubstituted or independently mono-, di-, or trisubstituted, wherein the substituents are independently selected from the group consisting of (C1-4)alkyl, (C1-4)alkoxy, trifluoromethyl, and halogen.
xiv) A further embodiment of the invention relates to compounds according to any one of embodiments i) to iii), or vi) to xiii), wherein
R1 represents heterocyclyl, wherein the heterocyclyl is unsubstituted or independently mono-, di-, or trisubstituted wherein the substituents are independently selected from the group consisting of (C1-4)alkyl, (C1-4)alkoxy, halogen, and trifluoromethyl.
xv) A further embodiment of the invention relates to compounds according to any one of embodiments i) to iii), or vi) to xiii), wherein
R1 represents aryl, wherein the aryl is unsubstituted or independently mono-, di-, or trisubstituted wherein the substituents are independently selected from the group consisting of (C1-4)alkyl, (C1-4)alkoxy, halogen, hydroxy, cyano, and trifluoromethyl.
xvi) A further embodiment of the invention relates to compounds according to any one of embodiments i), ii), or vi) to xiii), wherein
R1 represents a 2,3-dihydro-benzofuranyl-, a 2,3-dihydro-benzo[1,4]dioxinyl-, a chromanyl-, a 2,3-dihydro-thieno[3,4-b][1,4]dioxinyl- or a 3,4-dihydro-2H-benzo[1,4]oxazinyl-group, wherein said groups are unsubstituted or mono-substituted wherein the substituent is selected from the group consisting of (C1-4)alkyl, and halogen.
xvii) A further embodiment of the invention relates to compounds according to any one of embodiments i) to iii), or vi) to xiv), wherein, in case R1 represents heterocyclyl, said heterocyclyl is an imidazo[2,1-b]thiazolyl or an imidazo [1,2-a]pyridyl group (especially imidazo[2,1-b]thiazolyl), wherein said groups are unsubstituted or mono-substituted, wherein the substituent is selected from the group consisting of (C1-4)alkyl, halogen, and trifluoromethyl.
xviii) A further embodiment of the invention relates to compounds according to any one of embodiments i), ii), vi) to x), or xii) to xvii), wherein, in case A represents heterocyclyl, said heterocyclyl is a thiazole group, which is unsubstituted or mono-substituted, wherein the substituent is selected from the group consisting of (C1-4)alkyl, hydroxy-(C1-4)alkyl, hydroxy-(C2-6)alkynyl, (C1-4)alkoxy, NR2R3, and halogen.
xix) A further embodiment of the invention relates to compounds according to any one of embodiments i), ii), vi), vii), x), or xiv) to xvii), wherein
A represents mono-, or di-substituted phenyl, wherein one substituent is selected from the group consisting of (C2-6)alkynyl, and (C3-6)cycloalkyl-ethynyl; and the other substituent (if present) is selected from the group consisting of (C1-4)alkyl, (C1-4)alkoxy, and trifluoromethoxy (especially (C1-4)alkyl); and
B represents hydrogen.
xx) A further embodiment of the invention comprises compounds of the formula (Ib), wherein the stereogenic centers are in a (1R,2S,5S)-configuration
whereby any preference indicated for the compounds of formula (I) or (Ia) (whether for the compounds themselves as indicated in embodiments iii) to xix), salts thereof, compositions containing the compounds or salts thereof, uses of the compounds or salts thereof, etc.) apply mutatis mutandis to compounds of formula (Ib).
xxi) Examples of compounds according to embodiment i) are selected from the group consisting of:
4-fluoro-N-{(1R*,2S*,5S*)-3-[5-(3-fluoro-phenyl)-2-methyl-thiazole-4-carbonyl]-3-aza-bicyclo[3.1.0]hex-2-ylmethyl}-benzamide;
benzofuran-4-carboxylic acid [(1R*,2S*,5S*)-3-(biphenyl-2-carbonyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide;
benzofuran-4-carboxylic acid [(1R*,2S*,5S*)-3-(2-methyl-5-m-tolyl-thiazole-4-carbonyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide;
benzofuran-4-carboxylic acid {(1R*,2S*,5S*)-3-[5-(4-fluoro-phenyl)-2-methyl-thiazole-4-carbonyl]-3-aza-bicyclo[3.1.0]hex-2-ylmethyl}-amide;
benzofuran-4-carboxylic acid {(1R*,2S*,5S*)-3-[5-(3-fluoro-phenyl)-2-methyl-thiazole-4-carbonyl]-3-aza-bicyclo[3.1.0]hex-2-ylmethyl)-amide;
benzofuran-4-carboxylic acid [(1R*,2S*,5S*)-3-(2-methyl-5-p-tolyl-thiazole-4-carbonyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide;
benzofuran-4-carboxylic acid {(1R*,2S*,5S*)-3-[5-(4-ethyl-phenyl)-2-methyl-thiazole-4-carbonyl]-3-aza-bicyclo[3.1.0]hex-2-ylmethyl}-amide;
benzofuran-4-carboxylic acid {(1R*,2S*,5S*)-3-[5-(2-fluoro-phenyl)-2-methyl-thiazole-4-carbonyl]-3-aza-bicyclo[3.1.0]hex-2-ylmethyl}-amide;
benzofuran4-carboxylic acid {(1R*,2S*,5S*)-3-[5-(2-chloro-phenyl)-2-methyl-thiazole-4-carbonyl]-3-aza-bicyclo[3.1.0]hex-2-ylmethyl}-amide;
benzofuran4-carboxylic acid {(1R*,2S*,5S*)-3-[5-(3-chloro-phenyl)-2-methyl-thiazole-4-carbonyl]-3 -aza-bicyclo[3.1.0]hex-2-ylmethyl}-amide;
benzofuran-4-carboxylic acid {(1R*,2S*,5S*)-3-[5-(2-methoxy-phenyl)-2-methyl-thiazole-4-carbonyl]-3-aza-bicyclo[3.1.0]hex-2-ylmethyl}-amide;
benzofuran-4-carboxylic acid {(1R*,2S*,5S*)-3-[5-(3-methoxy-phenyl)-2-methyl-thiazole-4-carbonyl]-3-aza-bicyclo[3.1.0]hex-2-ylmethyl}-amide;
benzofuran4-carboxylic acid {(1R*,2S*,5S*)-3-[2-methyl-5-(3-trifluoromethylphenyl)-thiazole-4-carbonyl]-3-aza-bicyclo[3.1.0]hex-2-ylmethyl)-amide;
benzofuran4-carboxylic acid {(1R*,2S*,5S*)-3-[2-methyl-5-(2-trifluoromethylphenyl)-thiazole-4-carbonyl]-3-aza-bicyclo[3.1.0]hex-2-ylmethyl}-amide;
benzofuran-4-carboxylic acid [(1R*,2S*,5S*)-3-(2-methyl-5-o-tolyl-thiazole-4-carbonyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide;
benzofuran-4-carboxylic acid {(1R*,2S*,5S*)-3-[5-(3,4-dimethyl-phenyl)-2-methyl-thiazole-4-carbonyl]-3-aza-bicyclo[3.1.0]hex-2-ylmethyl}-amide;
benzofuran-4-carboxylic acid [(1R*,2S*,5S*)-3-(2-amino-5-m-tolyl-thiazole-4-carbonyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide;
benzofuran-4-carboxylic acid {(1R*,2S*,5S*)-3-[2-amino-5-(3-fluoro-phenyl)-thiazole-4-carbonyl]-3-aza-bicyclo[3.1.0]hex-2-ylmethyl}-amide;
benzofuran-4-carboxylic acid [(1R*,2S*,5S*)-3-(2-methyl-4-phenyl-pyrimidine-5-carbonyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide;
benzofuran-4-carboxylic acid {(1R*,2S*,5S*)-3-[2-(2-amino-thiazol-4-yl)-benzoyl]-3-aza-bicyclo[3.1.0]hex-2-ylmethyl}-amide;
benzofuran-4-carboxylic acid [(1R*,2S*,5S*)-3-(9H-fluorene-4-carbonyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide;
benzofuran-4-carboxylic acid [(1R*,2S*,5S*)-3-(3-phenyl-pyrazine-2-carbonyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide;
benzofuran-4-carboxylic acid {(1R*,2S*,5S*)-3-[5-(4-methoxy-phenyl)-oxazole-4-carbonyl]-3-aza-bicyclo[3.1.0]hex-2-ylmethyl}-amide;
benzofuran-4-carboxylic acid [(1R*,2S*,5S*)-3-(2′-fluoro-biphenyl-2-carbonyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide;
benzofuran-4-carboxylic acid [(1R*,2S*,5S*)-3-(4′-fluoro-biphenyl-2-carbonyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide;
benzofuran-4-carboxylic acid [(1R*,2S*,5S*)-3-(2′-chloro-biphenyl-2-carbonyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide;
benzofuran-4-carboxylic acid [(1R*,2S*,5S*)-3-(3′-chloro-biphenyl-2-carbonyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide;
benzofuran-4-carboxylic acid [(1R*,2S*,5S*)-3-(4′-chloro-biphenyl-2-carbonyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide;
benzofuran-4-carboxylic acid [(1R*,2S*,5S*)-3-(4′-methyl-biphenyl-2-carbonyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide;
benzofuran-4-carboxylic acid [(1R*,2S*,5S*)-3-(3′-methyl-biphenyl-2-carbonyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide;
benzofuran-4-carboxylic acid [(1R*,2S*,5S*)-3-(3′-methoxy-biphenyl-2-carbonyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide;
benzofuran-4-carboxylic acid [(1R*,2S*,5S*)-3-(4′-methoxy-biphenyl-2-carbonyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide;
benzofuran-4-carboxylic acid [(1R*,2S*,5S*)-3-(3′-trifluoromethyl-biphenyl-2-carbonyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide;
benzofuran-4-carboxylic acid [(1R*,2S*,5S*)-3-(2-pyridin-3-yl-benzoyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide;
6-methyl-imidazo[2,1-b]thiazole-5-carboxylic acid [(1R*,2S*,5S*)-3-(2-methyl-5-p-tolyl-thiazole-4-carbonyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide;
6-methyl-imidazo[2,1-b]thiazole-5-carboxylic acid [(1R*,2S*,5S*)-3-(2-methyl-5-m-tolyl-thiazole-4-carbonyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide;
6-methyl-imidazo[2,1-b]thiazole-5-carboxylic acid {(1R*,2S*,5S*)-3-[5-(3-fluorophenyl)-2-methyl-thiazole4-carbonyl]-3-aza-bicyclo[3.1.0]hex-2-ylmethyl}-amide;
6-methyl-imidazo[2,1-b]thiazole-5-carboxylic acid {(1R*,2S*,5S*)-3-[5-(4-ethylphenyl)-2-methyl-thiazole-4-carbonyl]-3-aza-bicyclo[3.1.0]hex-2-ylmethyl}-amide;
6-methyl-imidazo[2,1-b]thiazole-5-carboxylic acid {(1R*,2S*,5S*)-3-[5-(4-fluorophenyl)-2-methyl-thiazole-4-carbonyl]-3-aza-bicyclo[3.1.0]hex-2-ylmethyl}-amide;
6-methyl-imidazo[2,1-b]thiazole-5-carboxylic acid [(1R*,2S*,5S*)-3-(biphenyl-2-carbonyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide;
{(1R*,2S*,5S*)-2-[(6,7-difluoro-quinoxalin-2-ylamino)-methyl]-3-aza-bicyclo[3.1.0]hex-3-yl}-(2-methyl-5-m-tolyl-thiazol-4-yl)-methanone;
{(1R*,2S*,5S*)-2-[(6,7-difluoro-quinoxalin-2-ylamino)-methyl]-3-aza-bicyclo[3.1.0]hex-3-yl}-[5-(4-fluoro-phenyl)-2-methyl-thiazol-4-yl]-methanone;
{(1R*,2S*,5S*)-2-[(5-bromo-pyrimidin-2-ylamino)-methyl]-3-aza-bicyclo[3.1.0]hex-3-yl}-(2-methyl-5-m-tolyl-thiazol-4-yl)-methanone;
naphthalene-2-carboxylic acid [(1R*,2S*,5S*)-3-(2-methyl-5-m-tolyl-thiazole-4-carbonyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide;
naphthalene-1-carboxylic acid [(1R*,2S*,5S*)-3-(2-methyl-5 -m-tolyl-thiazole-4-carbonyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide;
2,3-dihydro-benzofuran-7-carboxylic acid [(1R*,2S*,5S*)-3-(2-methyl-5-m-tolyl-thiazole-4-carbonyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide;
1H-indole-5-carboxylic acid [(1R*,2S*,5S*)-3-(2-methyl-5-m-tolyl-thiazole-4-carbonyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide;
2-hydroxy-N-[(1R*,2S* ,5S*)-3-(2-methyl-5-m-tolyl-thiazole-4-carbonyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-benzamide;
2-bromo-4-methyl-thiazole-5-carboxylic acid [(1R*,2S*,5S*)-3-(2-methyl-5-m-tolyl-thiazole-4-carbonyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide;
furan-3-carboxylic acid [(1R*,2S*,5S*)-3-(2-methyl-5-m-tolyl-thiazole-4-carbonyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide;
3,5-dimethyl-isoxazole-4-carboxylic acid [(1R*,2S*,5S*)-3-(2-methyl-5-m-tolyl-thiazole-4-carbonyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide;
3,5-dimethoxy-N-[(1R*,2S*,5S*)-3-(2-methyl-5-m-tolyl-thiazole-4-carbonyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-benzamide;
benzo[1,3]dioxole-5-carboxylic acid [(1R*,2S*,5S*)-3-(2-methyl-5-m-tolyl-thiazole-4-carbonyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide;
2,4-dimethoxy-N-[(1R*,2S*,5S*)-3-(2-methyl-5-m-tolyl-thiazole-4-carbonyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-benzamide;
2,4-dimethyl-thiazole-5-carboxylic acid [(1R*,2S*,5S*)-3-(2-methyl-5-m-tolyl-thiazole-4-carbonyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide;
1-methyl-1H-indole-2-carboxylic acid [(1R*,2S*,5S*)-3-(2-methyl-5-m-tolyl-thiazole-4-carbonyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide;
3H-benzoimidazole-5-carboxylic acid [(1R*,2S*,5S*)-3-(2-methyl-5-m-tolyl-thiazole-4-carbonyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide;
benzo[2,1,3]oxadiazole-5-carboxylic acid [(1R*,2S*,5S*)-3-(2-methyl-5-m-tolyl-thiazole-4-carbonyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide;
2,3-dihydro-benzo[1,4]dioxine-5-carboxylic acid [(1R*,2S*,5S*)-3-(2-methyl-5-m-tolyl-thiazole-4-carbonyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide;
5-chloro-1,3-dimethyl-1H-pyrazole-4-carboxylic acid [(1R*,2S*,5S*)-3-(2-methyl-5-m-tolyl-thiazole4-carbonyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide;
benzo[b]thiophene-2-carboxylic acid [(1R*,2S*,5S*)-3-(2-methyl-5-m-tolyl-thiazole-4-carbonyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide;
5-tert-butyl-2-methyl-2H-pyrazole-3-carboxylic acid [(1R*,2S*,5S*)-3-(2-methyl-5-m-tolyl-thiazole-4-carbonyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide;
1-methyl-1H-indazole-3-carboxylic acid [(1R*,2S*,5S*)-3-(2-methyl-5-m-tolyl-thiazole-4-carbonyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide;
1-methyl-1H-pyrrole-2-carboxylic acid [(1R*,2S*,5S*)-3-(2-methyl-5-m-tolyl-thiazole-4-carbonyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide;
2,8-dimethyl-imidazo[1,2-a]pyridine-3-carboxylic acid [(1R*,2S*,5S*)-3-(2-methyl-5-m-tolyl-thiazole4-carbonyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide;
6-isobutyl-5-methyl-N-[(1R*,2S*,5S*)-3-(2-methyl-5-m-tolyl-thiazole-4-carbonyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-nicotinamide;
pyrazolo[1,5-a]pyridine-3-carboxylic acid [(1R*,2S*,5S*)-3-(2-methyl-5-m-tolyl-thiazole-4-carbonyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl)-amide;
benzo[d]isoxazole-3-carboxylic acid [(1R*,2S*,5S*)-3-(2-methyl-5-m-tolyl-thiazole-4-carbonyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide;
6-fluoro-4H-benzo[1,3]dioxine-8-carboxylic acid [(1R*,2S*,5S*)-3-(2-methyl-5-m-tolyl-thiazole-4-carbonyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide;
2,3-dihydro-benzofuran-4-carboxylic acid [(1R*,2S *,5S*)-3-(2-methyl-5-m-tolyl-thiazole-4-carbonyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide;
isoquinoline-1-carboxylic acid [(1R*,2S*,5S*)-3-(2-methyl-5-m-tolyl-thiazole-4-carbonyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide;
quinoline-8-carboxylic acid [(1R*,2S *,5S*)-3-(2-methyl-5-m-tolyl-thiazole-4-carbonyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide;
quinoline-2-carboxylic acid [(1R*,2S *,5S*)-3-(2-methyl-5-m-tolyl-thiazole-4-carbonyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide;
imidazo[2,1-b]thiazole-5-carboxylic acid [(1R*,2S*,5S*)-3-(2-methyl-5-m-tolyl-thiazole-4-carbonyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide;
3-methyl-imidazo[2,1-b]thiazole-2-carboxylic acid [(1R*,2S*,5S*)-3-(2-methyl-5-m-tolyl-thiazole-4-carbonyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide;
1-methyl-1H-indole-3-carboxylic acid [(1R*,2S*,5S *)-3-(2-methyl-5-m-tolyl-thiazole-4-carbonyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide;
1H-indole-3-carboxylic acid [(1R*,2S*,5S*)-3-(2-methyl-5-m-tolyl-thiazole-4-carbonyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide;
1H-indazole-3-carboxylic acid [(1R*,2S*,5S*)-3-(2-methyl-5-m-tolyl-thiazole-4-carbonyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide;
imidazo[1,2-a]pyridine-3-carboxylic acid [(1R*,2S*,5S*)-3-(2-methyl-5-m-tolyl-thiazole-4-carbonyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide;
2,3-dihydro-thieno[3,4-b][1,4]dioxine-5-carboxylic acid [(1R*,2S*,5S*)-3-(2-methyl-5-m-tolyl-thiazole-4-carbonyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide;
3-bromo-N-[(1R*,2S*,5S*)-3-(2-methyl-5-m-tolyl-thiazole-4-carbonyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-benzamide;
N-[(1R*,2S*,5S*)-3-(2-methyl-5-m-tolyl-thiazole-4-carbonyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-3-trifluoromethyl-benzamide;
3-methoxy-N-[(1R*,2S*,5S*)-3-(2-methyl-5-m-tolyl-thiazole4-carbonyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-benzamide;
3-fluoro-4-methoxy-N-[(1R*,2S*,5S*)-3-(2-methyl-5-m-tolyl-thiazole-4-carbonyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-benzamide;
3,4-dichloro-N-[(1R*,2S*,5S*)-3-(2-methyl-5-m-tolyl-thiazole-4-carbonyl)-3 -aza-bicyclo[3.1.0]hex-2-ylmethyl]-benzamide;
2-chloro-4,5-difluoro-N-[(1R*,2S*,5S *)-3-(2-methyl-5-m-tolyl-thiazole-4-carbonyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-benzamide;
2-fluoro-5-methyl-N-[(1R*,2S*,5S *)-3-(2-methyl-5-m-tolyl-thiazole-4-carbonyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-benzamide;
3-fluoro-2-methyl-N-[(1R*,2S*,5*)-3-(2-methyl-5-m-tolyl-thiazole-4-carbonyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-benzamide;
5-fluoro-2-methoxy-N-[(1R*,2S*,5S*)-3-(2-methyl-5-m-tolyl-thiazole-4-carbonyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-benzamide;
2-chloro-3-fluoro-N-[(1R*,2S*,5S*)-3-(2-methyl-5-m-tolyl-thiazo-4-carbonyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-benzamide;
2,5-dimethyl-N-[(1R*,2S*,5S*)-3-(2-methyl-5-m-tolyl-thiazole-4-carbonyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-benzamide;
3,4-dimethyl-N-[(1R*,2S*,5S*)-3-(2-methyl-5-m-tolyl-thiazole-4-carbonyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-benzamide;
2,5-dimethoxy-N-[(1R*,2S*,5S*)-3-(2-methyl-5-m-tolyl-thiazole-4-carbonyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-benzamide;
N-[(1R*,2S*,5S*)-3-(2-methyl-5-m-tolyl-thiazole-4-carbonyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-isophthalamic acid methyl ester;
2-chloro-4-fluoro-N-[(1R*,2S*,5S*)-3-(2-methyl-5-m-tolyl-thiazole-4-carbonyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-benzamide;
2-chloro-3-methyl-N-[(1R*,2S*,5S*)-3-(2-methyl-5-m-tolyl-thiazole-4-carbonyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-benzamide;
3,5-dichloro-4-hydroxy-N-[(1R*,2S*,5S*)-3-(2-methyl-5-m-tolyl-thiazole-4-carbonyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-benzamide;
2,4-dichloro-N-[(1R*,2S*,5S*)-3-(2-methyl-5-m-tolyl-thiazole-4-carbonyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-benzamide;
4-methyl-N-[(1R*,2S*,5S*)-3-(2-methyl-5-m-tolyl-thiazole-4-carbonyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-3-trifluoromethyl-benzamide;
4-methoxy-2-methyl-N-[(1R*,2S*,5S*)-3-(2-methyl-5-m-tolyl-thiazole-4-carbonyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-benzamide;
4-ethyl-N-[(1R*,2S*,5S*)-3-(2-methyl-5-m-tolyl-thiazole-4-carbonyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-benzamide;
4-methoxy-3-methyl-N-[(1R*,2S*,5S*)-3-(2-methyl-5-m-tolyl-thiazol4-carbonyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-benzamide;
3,5-dimethyl-N-[(1R*,2S*,5S*)-3-(2-methyl-5-m-tolyl-thiazole-4-carbonyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-benzamide;
5-bromo-2-chloro-N-[(1R*,2S*,5S*)-3-(2-methyl-5-m-tolyl-thiazole-4-carbonyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-benzamide;
3-cyano-N-[(1R*,2S*,5S*)-3-(2-methyl-5-m-tolyl-thiazole-4-carbonyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-benzamide;
4-cyano-N-[(1R*,2S*,5S*)-3-(2-methyl-5-m-tolyl-thiazole-4-carbonyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-benzamide;
4-chloro-N-[(1R*,2S*,5S*)-3-(2-methyl-5-m-tolyl-thiazole-4-carbonyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-benzamide;
3-iodo-N-[(1R*,2S*,5S*)-3-(2-methyl-5-m-tolyl-thiazole-4-carbonyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-benzamide;
2-bromo-3-methyl-N-[(1R*,2S*,5S*)-3-(2-methyl-5-m-tolyl-thiazol-4-carbonyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-benzamide;
5-methyl-imidazo[2,1-b]thiazole-6-carboxylic acid [(1R*,2S*,5S*)-3-(2-methyl-5-m-tolyl-thiazole-4-carbonyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide;
3,5-dimethyl-imidazo[2,1-b]thiazole-6-carboxylic acid [(1R*,2S*,5S*)-3-(2-methyl-5-m-tolyl-thiazole-4-carbonyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide;
2,6-dimethyl-imidazo[2,1-b]thiazole-5-carboxylic acid [(1R*,2S*,5S*)-3-(2-methyl-5-m-tolyl-thiazole-4-carbonyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide;
2,3,5-trimethyl-imidazo[2,1-b]thiazole-6-carboxylic acid [(1R*,2S*,5S*)-3-(2-methyl-5-m-tolyl-thiazole-4-carbonyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide;
2-methyl-imidazo[2,1-b]thiazole-5-carboxylic acid [(1R*,2S*,5S*)-3-(2-methyl-5-m-tolyl-thiazole-4-carbonyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide;
6-trifluoromethyl-imidazo[2,1-b]thiazole-5-carboxylic acid [(1R*,2S*,5S*)-3-(2-methyl-5-m-tolyl-thiazole-4-carbonyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide;
3,6-dimethyl-imidazo[2,1-b]thiazole-5-carboxylic acid [(1R*,2S*,5S*)-3-(2-methyl-5-m-tolyl-thiazole-4-carbonyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide;
3-methyl-imidazo[2,1-b]thiazole-5-carboxylic acid [(1R*,2S*,5S*)-3-(2-methyl-5-m-tolyl-thiazole-4-carbonyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide;
6-chloro-imidazo[2,1-b]thiazole-5-carboxylic acid [(1R*,2S*,5S*)-3-(2-methyl-5-m-tolyl-thiazole-4-carbonyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide;
2H-chromene-5-carboxylic acid [(1R*,2S*,5S*)-3-(2-methyl-5-m-tolyl-thiazole-4-carbonyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide;
4-methyl-3,4-dihydro-2H-benzo[1,4]oxazine-8-carboxylic acid [(1R*,2S*,5S*)-3-(2-methyl-5-m-tolyl-thiazole-4-carbonyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide;
chroman-8-carboxylic acid [(1R*,2S*,5S*)-3-(2-methyl-5-m-tolyl-thiazole-4-carbonyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide;
3-oxo-3,4-dihydro-2H-benzo[1,4]oxazine-5-carboxylic acid [(1R*,2S*,5S*)-3-(2-methyl-5-m-tolyl-thiazole-4-carbonyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide;
3,4-dihydro-2H-benzo[1,4]oxazine-8-carboxylic acid [(1R*,2S*,5S*)-3-(2-methyl-5-m-tolyl-thiazole-4-carbonyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide;
3,4-dihydro-2H-benzo[1,4]oxazine-5-carboxylic acid [(1R*,2S*,5S*)-3-(2-methyl-5-m-tolyl-thiazole4-carbonyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide;
2-methyl-benzofuran-4-carboxylic acid [(1R*,2S*,5S*)-3-(2-methyl-5-m-tolyl-thiazole-4-carbonyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide;
benzo[d]isoxazole-3-carboxylic acid {(1R*,2S*,5S*)-3-[5-(3-chloro-phenyl)-2-methyl-thiazole-4-carbonyl]-3-aza-bicyclo[3.1.0]hex-2-ylmethyl}-amide;
2,3-dihydro-benzo[1,4]dioxine-5-carboxylic acid {(1R*,2S*,5S*)-3-[5-(3-chloro-phenyl)-2-methyl-thiazole-4-carbonyl]-3-aza-bicyclo[3.1.0]hex-2-ylmethyl}-amide;
6-fluoro-4H-benzo[1,3]dioxine-8-carboxylic acid {(1R*,2S*,5S*)-3-[5-(3-chloro-phenyl)-2-methyl-thiazole-4-carbonyl]-3-aza-bicyclo[3.1.0]hex-2-ylmethyl}-amide;
2,3-dihydro-benzofuran-4-carboxylic acid {(1R*,2S*,5S*)-3-[5-(3-chloro-phenyl)-2-methyl-thiazole-4-carbonyl]-3-aza-bicyclo[3.1.0]hex-2-ylmethyl}-amide;
isoquinoline-1-carboxylic acid {(1R*,2S*,5S*)-3-[5-(3-chloro-phenyl)-2-methyl-thiazole-4-carbonyl]-3 -aza-bicyclo[3.1.0]hex-2-ylmethyl}-amide;
quinoline-8-carboxylic acid {(1R*,2S*,5S*)-3-[5-(3-chloro-phenyl)-2-methyl-thiazole-4-carbonyl]-3 -aza-bicyclo[3.1.0]hex-2-ylmethyl}-amide;
quinoline-2-carboxylic acid {(1R*,2S*,5S*)-3-[5-(3-chloro-phenyl)-2-methyl-thiazole-4-carbonyl]-3-aza-bicyclo[3.1.0]hex-2-ylmethyl}-amide;
imidazo[2,1-b]thiazole-5-carboxylic acid {(1R*,2S*,5S*)-3-[5-(3-chloro-phenyl)-2-methyl-thiazole-4-carbonyl]-3-aza-bicyclo[3.1.0]hex-2-ylmethyl}-amide;
3-methyl-imidazo[2,1-b]thiazole-2-carboxylic acid {(1R*,2S*,5S*)-3-[5-(3-chloro-phenyl)-2-methyl-thiazole-4-carbonyl]-3-aza-bicyclo[3.1.0]hex-2-ylmethyl}-amide;
1-methyl-1H-indole-3 -carboxylic acid {(1R*,2S*,5S*)-3-[5-(3-chloro-phenyl)-2-methyl-thiazole-4-carbonyl]-3-aza-bicyclo[3.1.0]hex-2-ylmethyl}-amide;
1,2-dimethyl-1H-indole-3-carboxylic acid {(1R*,2S*,5S*)-3-[5-(3-chloro-phenyl)-2-methyl-thiazole-4-carbonyl]-3-aza-bicyclo[3.1.0]hex-2-ylmethyl}-amide;
1H-indole-3-carboxylic acid {(1R*,2S*,5S*)-3-[5-(3-chloro-phenyl)-2-methyl-thiazole-4-carbonyl]-3-aza-bicyclo[3.1.0]hex-2-ylmethyl}-amide;
1H-indazole-3-carboxylic acid {(1R*,2S*,5S*)-3-[5-(3-chloro-phenyl)-2-methyl-thiazole-4-carbonyl]-3-aza-bicyclo[3.1.0]hex-2-ylmethyl}-amide;
imidazo[1,2-a]pyridine-3-carboxylic acid {(1R*,2S*,5S*)-3-[5-(3-chloro-phenyl)-2-methyl-thiazole-4-carbonyl]-3-aza-bicyclo[3.1.0]hex-2-ylmethyl}-amide;
2,5-dimethyl-2H-pyrazole-3-carboxylic acid {(1R*,2S*,5S*)-3-[5-(3-chloro-phenyl)-2-methyl-thiazole-4-carbonyl]-3-aza-bicyclo[3.1.0]hex-2-ylmethyl}-amide;
2-ethyl-5-methyl-2H-pyrazole-3-carboxylic acid {(1R*,2S*,5S*)-3-[5-(3-chloro-phenyl)-2-methyl-thiazole-4-carbonyl]-3-aza-bicyclo[3.1.0]hex-2-ylmethyl}-amide;
2,3-dihydro-thieno[3,4-b][1,4]dioxine-5-carboxylic acid {(1R*,2S*,5S*)-3-[5-(3-chloro-phenyl)-2-methyl-thiazole-4-carbonyl]-3-aza-bicyclo[3.1.0]hex-2-ylmethyl}-amide;
3-bromo-N-{(1R*,2S*,5S*)-3-[5-(3-chloro-phenyl)-2-methyl-thiazole-4-carbonyl]-3-aza-bicyclo[3.1.0]hex-2-ylmethyl}-benzamide;
N-{(1R*,2S*,5S*)-3-[5-(3-chloro-phenyl)-2-methyl-thiazole-4-carbonyl]-3-aza-bicyclo[3.1.0]hex-2-ylmethyl}-3-trifluoromethyl-benzamide;
N-((1R*,2S*,5S*)-3-[5-(3-chloro-phenyl)-2-methyl-thiazole-4-carbonyl]-3-aza-bicyclo[3.1.0]hex-2-ylmethyl}-3-methoxy-benzamide;
3-Methyl-imidazo[2,1-b]thiazole-5-carboxylic acid {(1R*,2S*,5S*)-3-[5-(3-fluoro-phenyl)-2-methyl-thiazole-4-carbonyl]-3-aza-bicyclo[3.1.0]hex-2-ylmethyl}-amide;
2-methyl-imidazo[2,1-b]thiazole-5-carboxylic acid {(1R*,2S*,5S*)-3-[5-(3-fluoro-phenyl)-2-methyl-thiazole-4-carbonyl]-3-aza-bicyclo[3.1.0]hex-2-ylmethyl}-amide;
imidazo[2,1-b]thiazole-5-carboxylic acid {(1R*,2S*,5S*)-3-[5-(3-fluoro-phenyl)-2-methyl-thiazole-4-carbonyl]-3-aza-bicyclo[3.1.0]hex-2-ylmethyl}-amide;
1-methyl-1H-indole-3-carboxylic acid {(1R*,2S*,5S*)-3-[5-(3-fluoro-phenyl)-2-methyl-thiazole-4-carbonyl]-3-aza-bicyclo[3.1.0]hex-2-ylmethyl}-amide;
3-methyl-imidazo[2,1-b]thiazole-2-carboxylic acid {(1R*,2S*,5S*)-3-[5-(3-fluoro-phenyl)-2-methyl-thiazole-4-carbonyl]-3-aza-bicyclo[3.1.0]hex-2-ylmethyl}-amide;
1-ethyl-3-methyl-1H-pyrazole-4-carboxylic acid {(1R*,2S*,5S*)-3-[5-(3-fluoro-phenyl)-2-methyl-thiazole-4-carbonyl]-3-aza-bicyclo[3.1.0]hex-2-ylmethyl}-amide;
5-tert-butyl-2-methyl-2H-pyrazole-3-carboxylic acid {(1R*,2S*,5S*)-3-[5-(3-fluoro-phenyl)-2-methyl-thiazole-4-carbonyl]-3-aza-bicyclo[3.1.0]hex-2-ylmethyl}-amide;
isoquinoline-1-carboxylic acid {(1R*,2S*,5S*)-3-[5-(3-fluoro-phenyl)-2-methyl-thiazole-4-carbonyl]-3-aza-bicyclo[3.1.0]hex-2-ylmethyl}-amide;
1H-indazole-3-carboxylic acid {(1R*,2S*,5S*)-3-[5-(3-fluoro-phenyl)-2-methyl-thiazole-4-carbonyl]-3-aza-bicyclo[3.1.0]hex-2-ylmethyl}-amide;
4-methoxy-quinoline-2-carboxylic acid {(1R*,2S*,5S*)-3-[5-(3-fluoro-phenyl)-2-methyl-thiazole-4-carbonyl]-3-aza-bicyclo[3.1.0]hex-2-ylmethyl}-amide;
quinoline-2-carboxylic acid {(1R*,2S*,5S*)-3-[5-(3-fluoro-phenyl)-2-methyl-thiazole-4-carbonyl]-3-aza-bicyclo[3.1.0]hex-2-ylmethyl}-amide;
1H-indole-3-carboxylic acid {(1R*,2S*,5S*)-3-[5-(3-fluoro-phenyl)-2-methyl-thiazole-4-carbonyl]-3-aza-bicyclo[3.1.0]hex-2-ylmethyl}-amide;
6-fluoro-4H-benzo[1,3]dioxine-8-carboxylic acid {(1R*,2S*,5S*)-3-[5-(3-fluoro-phenyl)-2-methyl-thiazole-4-carbonyl]-3-aza-bicyclo[3.1.0]hex-2-ylmethyl}-amide;
benzo[d]isoxazole-3-carboxylic acid {(1R*,2S*,5S*)-3-[5-(3-fluoro-phenyl)-2-methyl-thiazole-4-carbonyl]-3-aza-bicyclo[3.1.0]hex-2-ylmethyl}-amide;
benzo[1,3]dioxole-4-carboxylic acid {(1R*,2S*,5S*)-3-[5-(3-fluoro-phenyl)-2-methyl-thiazole-4-carbonyl]-3-aza-bicyclo[3.1.0]hex-2-ylmethyl}-amide;
2-ethyl-5-methyl-2H-pyrazole-3-carboxylic acid ((1R*,2S*,5S *)-3 -[5-(3 -fluoro-phenyl)-2-methyl-thiazole-4-carbonyl]-3-aza-bicyclo[3.1.0]hex-2-ylmethyl}-amide;
imidazo[1,2-a]pyridine-3-carboxylic acid {(1R*,2S*,5S*)-3-[5-(3-fluoro-phenyl)-2-methyl-thiazole-4-carbonyl]-3-aza-bicyclo[3.1.0]hex-2-ylmethyl}-amide;
1-methyl-5-trifluoromethyl-1H-pyrazole4-carboxylic acid {(1R*,2S*,5S*)-3-[5-(3-fluoro-phenyl)-2-methyl-thiazole-4-carbonyl]-3-aza-bicyclo[3.1.0]hex-2-ylmethyl}-amide;
1,5-dimethyl-1H-pyrazole-3-carboxylic acid {(1R*,2S*,5S*)-3-[5-(3-fluoro-phenyl)-2-methyl-thiazole-4-carbonyl]-3-aza-bicyclo[3.1.0]hex-2-ylmethyl}-amide;
2,5-dimethyl-2H-pyrazole-3-carboxylic acid {(1R*,2S*,5S*)-3-[5-(3-fluoro-phenyl)-2-methyl-thiazole-4-carbonyl]-3-aza-bicyclo[3.1.0]hex-2-ylmethyl}-amide;
2,5-dimethyl-oxazole-4-carboxylic acid {(1R*,2S*,5S*)-3-[5-(3-fluoro-phenyl)-2-methyl-thiazole-4-carbonyl]-3-aza-bicyclo[3.1.0]hex-2-ylmethyl}-amide;
2,3-dihydro-benzo[1,4]dioxine-5-carboxylic acid {(1R*,2S*,5S*)-3-[5-(3-fluoro-phenyl)-2-methyl-thiazole-4-carbonyl]-3-aza-bicyclo[3.1.0]hex-2-ylmethyl}-amide;
2,3-dihydro-benzofuran-4-carboxylic acid {(1R*,2S*,5S*)-3-[5-(3-fluoro-phenyl)-2-methyl-thiazole-4-carbonyl]-3-aza-bicyclo[3.1.0]hex-2-ylmethyl}-amide;
1,3-dimethyl-1H-pyrazole-4-carboxylic acid {(1R*,2S*,5S*)-3-[5-(3-fluoro-phenyl)-2-methyl-thiazole-4-carbonyl]-3-aza-bicyclo[3.1.0]hex-2-ylmethyl}-amide;
7-fluoro-1H-indole-2-carboxylic acid {(1R*,2S*,5S*)-3-[5-(3-fluoro-phenyl)-2-methyl-thiazole-4-carbonyl]-3-aza-bicyclo[3.1.0]hex-2-ylmethyl}-amide;
2-trifluoromethyl-1H-benzoimidazole-5-carboxylic acid {(1R*,2S*,5S*)-3-[5-(3-fluoro-phenyl)-2-methyl-thiazole-4-carbonyl]-3-aza-bicyclo[3.1.0]hex-2-ylmethyl}-amide;
3-bromo-N-{(1R*,2S*,5S*)-3-[5-(3-fluoro-phenyl)-2-methyl-thiazole-4-carbonyl]-3-aza-bicyclo[3.1.0]hex-2-ylmethyl}-benzamide;
N-{(1R*,2S*,5S*)-3-[5-(3-fluoro-phenyl)-2-methyl-thiazole-4-carbonyl]-3-aza-bicyclo[3.1.0]hex-2-ylmethyl}-3-trifluoromethyl-benzamide;
benzo[d]isoxazole-3-carboxylic acid [(1R*,2S*,5S*)-3-(2-amino-5-m-tolyl-thiazole-4-carbonyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide;
2,3-dihydro-benzo[1,4]dioxine-5-carboxylic acid [(1R*,2S*,5S*)-3-(2-amino-5-m-tolyl-thiazole-4-carbonyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide;
6-fluoro-4H-benzo[1,3]dioxine-8-carboxylic acid [(1R*,2S*,5S*)-3-(2-amino-5-m-tolyl-thiazole-4-carbonyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide;
2,3-dihydro-benzofuran-4-carboxylic acid [(1R*,2S*,5S*)-3-(2-amino-5-m-tolyl-thiazole-4-carbonyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide;
2,2-dimethyl-2,3-dihydro-benzofuran-7-carboxylic acid [(1R*,2S*,5S*)-3-(2-amino-5-m-tolyl-thiazole-4-carbonyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide;
isoquinoline-1-carboxylic acid [(1R*,2S*,5S*)-3-(2-amino-5-m-tolyl-thiazole-4-carbonyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide;
quinoline-8-carboxylic acid [(1R*,2S*,5S*)-3-(2-amino-5-m-tolyl-thiazole-4-carbonyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide;
imidazo[2,1-b]thiazole-5-carboxylic acid [(1R*,2S*,5S*)-3-(2-amino-5-m-tolyl-thiazole-4-carbonyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide;
3-methyl-imidazo[2,1-b]thiazole-2-carboxylic acid [(1R*,2S*,5S*)-3-(2-amino-5-m-tolyl-thiazole-4-carbonyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide;
1-methyl-1H-indole-3-carboxylic acid [(1R*,2S*,5S*)-3-(2-amino-5-m-tolyl-thiazole-4-carbonyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide;
1H-indole-3-carboxylic acid [(1R*,2S*,5S*)-3-(2-amino-5-m-tolyl-thiazole-4-carbonyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide;
1H-indazole-3-carboxylic acid [(1R*,2S*,5S*)-3-(2-amino-5-m-tolyl-thiazole-4-carbonyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide;
imidazo[1,2-a]pyridine-3-carboxylic acid [(1R*,2S*,5S*)-3-(2-amino-5-m-tolyl-thiazole-4-carbonyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide;
2-ethyl-5-methyl-2H-pyrazole-3-carboxylic acid [(1R*,2S*,5S*)-3-(2-amino-5-m-tolyl-thiazole-4-carbonyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide;
1-ethyl-3-methyl-1H-pyrazole-4-carboxylic acid [(1R*,2S*,5S*)-3-(2-amino-5-m-tolyl-thiazole-4-carbonyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide;
2,3-dihydro-thieno[3,4-b][1,4]dioxine-5-carboxylic acid [(1R*,2S*,5S*)-3-(2-amino-5-m-tolyl-thiazole-4-carbonyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide;
N-[(1R*,2S*,5S*)-3-(2-amino-5-m-tolyl-thiazole-4-carbonyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-3-bromo-benzamide;
N-[(1R*,2S*,5S*)-3-(2-amino-5-m-tolyl-thiazole-4-carbonyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-3-methoxy-benzamide;
benzo[d]isoxazole-3-carboxylic acid {(1R*,2S*,5S*)-3-[2-amino-5-(3-chloro-phenyl)-thiazole-4-carbonyl]-3-aza-bicyclo[3.1.0]hex-2-ylmethyl}-amide;
2,3-dihydro-benzo[1,4]dioxine-5-carboxylic acid {(1R*,2S*,5S*)-3-[2-amino-5-(3-chloro-phenyl)-thiazole-4-carbonyl]-3-aza-bicyclo[3.1.0]hex-2-ylmethyl}-amide;
6-fluoro-4H-benzo[1,3]dioxine-8-carboxylic acid {(1R*,2S*,5S*)-3-[2-amino-5-(3-chloro-phenyl)-thiazole-4-carbonyl]-3-aza-bicyclo[3.1.0]hex-2-ylmethyl}-amide;
2,3-dihydro-benzofuran-4-carboxylic acid {(1R*,2S*,5S*)-3-[2-amino-5-(3-chloro-phenyl)-thiazole-4-carbonyl]-3-aza-bicyclo[3.1.0]hex-2-ylmethyl}-amide;
isoquinoline-1-carboxylic acid ((1R*,2S*,5S*)-3-[2-amino-5-(3-chloro-phenyl)-thiazole-4-carbonyl]-3-aza-bicyclo[3.1.0]hex-2-ylmethyl}-amide;
quinoline-8-carboxylic acid {(1R*,2S*,5S*)-3-[2-amino-5-(3-chloro-phenyl)-thiazole-4-carbonyl]-3-aza-bicyclo[3.1.0]hex-2-ylmethyl}-amide;
imidazo[2,1-b]thiazole-5-carboxylic acid {(1R*,2S*,5S*)-3-[2-amino-5-(3-chloro-phenyl)-thiazole-4-carbonyl]-3-aza-bicyclo[3.1.0]hex-2-ylmethyl}-amide;
1-methyl-1H-indole-3-carboxylic acid {(1R*,2S*,5S*)-3-[2-amino-5-(3-chloro-phenyl)-thiazole-4-carbonyl]-3-aza-bicyclo[3.1.0]hex-2-ylmethyl}-amide;
1H-indole-3-carboxylic acid {(1R*,2S*,5S*)-3-[2-amino-5-(3-chloro-phenyl)-thiazole-4-carbonyl]-3-aza-bicyclo[3.1.0]hex-2-ylmethyl}-amide;
1H-indazole-3-carboxylic acid {(1R*,2S*,5S*)-3-[2-amino-5-(3-chloro-phenyl)-thiazole-4-carbonyl]-3-aza-bicyclo[3.1.0]hex-2-ylmethyl}-amide;
2,5-dimethyl-2H-pyrazole-3-carboxylic acid {(1R*,2S*,5S*)-3-[2-amino-5-(3-chloro-phenyl)-thiazole-4-carbonyl]-3-aza-bicyclo[3.1.0]hex-2-ylmethyl}-amide;
2-ethyl-5-methyl-2H-pyrazole-3-carboxylic acid {(1R*,2S*,5S*)-3-[2-amino-5-(3-chloro-phenyl)-thiazole-4-carbonyl]-3-aza-bicyclo[3.1.0]hex-2-ylmethyl}-amide;
2,3-dihydro-thieno[3,4-b][1,4]dioxine-5-carboxylic acid {(1R*,2S*,5S*)-3-[2-amino-5-(3-chloro-phenyl)-thiazole-4-carbonyl]-3-aza-bicyclo[3.1.0]hex-2-ylmethyl}-amide;
N-{(1R*,2S*,5S*)-3-[2-amino-5-(3-chloro-phenyl)-thiazole-4-carbonyl]-3-aza-bicyclo[3.1.0]hex-2-ylmethyl}-3-bromo-benzamide;
N-{(1R*,2S*,5S*)-3-[2-amino-5-(3-chloro-phenyl)-thiazole-4-carbonyl]-3-aza-bicyclo[3.1.0]hex-2-ylmethyl}-3-methoxy-benzamide;
6-methyl-imidazo[2,1-b]thiazole-5-carboxylic acid [(1R*,2S*,5S*)-3-(3′-fluoro-5-methyl-biphenyl-2-carbonyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide;
imidazo[1,2-a]pyridine-3-carboxylic acid [(1R*,2S*,5S*)-3-(3′-fluoro-5-methyl-biphenyl-2-carbonyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide;
2,3-dihydro-benzofuran-4-carboxylic acid [(1R*,2S*,5S*)-3-(3′-fluoro-5-methyl-biphenyl-2-carbonyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide;
2,3-dihydro-benzofuran-7-carboxylic acid [(1R*,2S*,5S*)-3-(3′-fluoro-5-methyl-biphenyl-2-carbonyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide;
6-methyl-imidazo[2,1-b]thiazole-5-carboxylic acid {(1R*,2S*,5S*)-3-[5-(3-cyano-phenyl)-2-methyl-thiazole-4-carbonyl]-3-aza-bicyclo[3.1.0]hex-2-ylmethyl}-amide;
benzofuran-4-carboxylic acid ((1R*,2S*,5S*)-3-[5-(3-cyano-phenyl)-2-methyl-thiazole-4-carbonyl]-3-aza-bicyclo[3.1.0]hex-2-ylmethyl}-amide;
2,3-dihydro-benzo[1,4]dioxine-5-carboxylic acid {(1R*,2S*,5S*)-3-[5-(3-cyano-phenyl)-2-methyl-thiazole-4-carbonyl]-3-aza-bicyclo[3.1.0]hex-2-ylmethyl}-amide;
2,3-dihydro-benzo[1,4]dioxine-5-carboxylic acid [(1R*,2S*,5S*)-3-(5-methyl-biphenyl-2-carbonyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide;
2,3-dihydro-benzo[1,4]dioxine-5-carboxylic acid [(1R*,2S*,5S*)-3-(2′-fluoro-5-methyl-biphenyl-2-carbonyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide;
2,3-dihydro-benzo[1,4]dioxine-5-carboxylic acid [(1R*,2S*,5S*)-3-(5,3′-dimethyl-biphenyl-2-carbonyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide;
2,3-dihydro-benzo[1,4]dioxine-5-carboxylic acid [(1R*,2S*,5S*)-3-(3′-chloro-5-methyl-biphenyl-2-carbonyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide;
2,3-dihydro-benzo[1,4]dioxine-5-carboxylic acid [(1R*,2S*,5S*)-3-(3′-methoxy-5-methyl-biphenyl-2-carbonyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide;
2,3-dihydro-benzo[1,4]dioxine-5-carboxylic acid [(1R*,2S*,5S*)-3-(5-methyl-3′-trifluoromethyl-biphenyl-2-carbonyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide;
2,3-dihydro-benzo[1,4]dioxine-5-carboxylic acid [(1R*,2S*,5S*)-3-(3′-fluoro-5-methyl-biphenyl-2-carbonyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide;
2,3-dihydro-benzo[1,4]dioxine-5-carboxylic acid [(1R*,2S*,5S*)-3-(5,4′-dimethyl-biphenyl-2-carbonyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide;
2,3-dihydro-benzo[1,4]dioxine-5-carboxylic acid [(1R*,2S*,5S*)-3-(4′-fluoro-5,3′-dimethyl-biphenyl-2-carbonyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide;
2,3-dihydro-benzo[1,4]dioxine-5-carboxylic acid {(1R*,2S*,5S*)-3-[4-methyl-2-(4-methyl-thiophen-2-yl)-benzoyl]-3-aza-bicyclo[3.1.0]hex-2-ylmethyl}-amide;
2,3-dihydro-benzo[1,4]dioxine-5-carboxylic acid [(1R*,2S*,5S*)-3-(4′-fluoro-4,3′-dimethyl-biphenyl-2-carbonyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide;
2,3-dihydro-benzo[1,4]dioxine-5-carboxylic acid [(1R*,2S*,5S*)-3-(6-methyl-biphenyl-2-carbonyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide;
2,3-dihydro-benzo[1,4]dioxine-5-carboxylic acid [(1R*,2S*,5S*)-3-(3′-fluoro-6-methyl-biphenyl-2-carbonyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide;
2,3-dihydro-benzo[1,4]dioxine-5-carboxylic acid [(1R*,2S*,5S*)-3-(2-cyclopropylethynyl-4-methyl-benzoyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide;
benzofuran-4-carboxylic acid [(1R,2S,5S)-3-(2-methyl-5-m-tolyl-thiazole-4-carbonyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide;
benzofuran-4-carboxylic acid {(1R,2S,5S)-3-[5-(3-fluoro-phenyl)-2-methyl-thiazole-4-carbonyl]-3-aza-bicyclo[3.1.0]hex-2-ylmethyl}-amide;
2,3-dihydro-benzo[1,4]dioxine-5-carboxylic acid [(1R,2S,5S)-3-(2-methyl-5-m-tolyl-thiazole-4-carbonyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide;
6-methyl-imidazo[2,1-b]thiazole-5-carboxylic acid [(1R*,2S*,5S*)-3-(2-bromo-5-m-tolyl-thiazole-4-carbonyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide;
6-methyl-imidazo[2,1-b]thiazole-5-carboxylic acid [(1R*,2S*,5S*)-3-(5-m-tolyl-2-trimethylsilanylethynyl-thiazole-4-carbonyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide;
6-methyl-imidazo[2,1-b]thiazole-5-carboxylic acid {(1R*,2S*,5S*)-3-[2-(3-hydroxy-prop-1-ynyl)-5-m-tolyl-thiazole-4-carbonyl]-3-aza-bicyclo[3.1.0]hex-2-ylmethyl}-amide;
6-methyl-imidazo[2,1-b]thiazole-5-carboxylic acid [(1R*,2S*,5S*)-3-(2-ethyl-5-m-tolyl-thiazole-4-carbonyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide;
6-methyl-imidazo[2,1-b]thiazole-5-carboxylic acid {(1R*,2S*,5S*)-3-[2-(3-hydroxy-propyl)-5-m-tolyl-thiazole-4-carbonyl]-3-aza-bicyclo[3.1.0]hex-2-ylmethyl}-amide;
6-methyl-imidazo[2,1-b]thiazole-5-carboxylic acid [(1R*,2S*,5S*)-3-(5-m-tolyl-thiazole-4-carbonyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide; and
6-methyl-imidazo[2,1-b]thiazole-5-carboxylic acid [(1R*,2S*,5S*)-3-(2-methoxy-5-m-tolyl-thiazole-4-carbonyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide;
wherein, in case the above compounds have the relative configuration (1R*,2S*,5S*), the respective enantiomers having either the absolute configuration (1R,2S,5S) or (1S,2R,5R), especially the enantiomers having the absolute configuration (1R,2S,5S), are also encompassed.
Where the plural form is used for compounds, salts, pharmaceutical compositions, diseases or the like, this is intended to mean also a single compound, salt, disease or the like.
The compounds of formula (I) and their pharmaceutically acceptable salts can be used as medicaments, e.g. in the form of pharmaceutical compositions for enteral or parental administration.
A further aspect of the invention is a pharmaceutical composition containing at least one compound according to formula (I), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier material.
The production of the pharmaceutical compositions can be effected in a manner which will be familiar to any person skilled in the art (see for example Mark Gibson, Editor, Pharmaceutical Preformulation and Formulation, IHS Health Group, Englewood, Colo., USA, 2001; Remington, The Science and Practice of Pharmacy, 20th Edition, Philadelphia College of Pharmacy and Science) by bringing the described compounds of formula (I) and their pharmaceutically acceptable salts, optionally in combination with other therapeutically valuable substances, into a galenical administration form together with suitable, non-toxic, inert, therapeutically compatible solid or liquid carrier materials and, if desired, usual pharmaceutical adjuvants.
The compounds according to formula (I) may be used for the preparation of a medicament, and are suitable, for the prevention or treatment of diseases selected from the group consisting of dysthymic disorders including major depression and cyclothymia, affective neurosis, manic depression, delirium, psychotic disorders, schizophrenia, delusional paranoia, adjustement disorders and all clusters of personality disorders; anxiety disorders including generalized anxiety, obsessive compulsive disorder, posttraumatic stress disorder, panic attacks, all types of phobic anxiety and avoidance; stress-related syndromes; psychoactive substance use, abuse, seeking and reinstatement; all types of psychological or physical addictions, dissociative disorders including multiple personality syndromes and psychogenic amnesias; sexual dysfunction; psychosexual dysfunction and addiction; tolerance to narcotics or withdrawal from narcotics; hypothalamic-adrenal dysfunctions; disturbed biological and circadian rhythms; all types of sleep disorders; sleep disturbances associated with diseases such as neurological disorders including neuropathic pain and restless leg syndrome; sleep apnea; narcolepsy; insomnias related to psychiatric disorders; all types of idiopathic insomnias and parasomnias; sleep-wake schedule disorders including jet-lag; all dementias and cognitive dysfunctions in the healthy population and in psychiatric and neurologic disorders; mental dysfunctions of aging; severe mental retardation; dyskinesias and muscular diseases; neurodegenerative disorders including Huntington's, Creutzfeld-Jacob's, Alzheimer's diseases and Tourette syndrome; Amyotrophic lateral sclerosis; Parkinson's disease; Cushing's syndrome; traumatic lesions; demyelinating diseases; spinal and cranial nerve diseases; epilepsy; seizure disorders; absence seizures, complex partial and generalized seizures; Lennox-Gastaut syndrome; migraine and headache; pain disorders; anesthesia and analgesia; enhanced or exaggerated sensitivity to pain such as hyperalgesia, causalgia, and allodynia; acute pain; burn pain; atypical facial pain; neuropathic pain; back pain; complex regional pain syndrome I and II; arthritic pain; sports injury pain; pain related to infection e.g. by HIV; post-chemotherapy pain; post-stroke pain; post-operative pain; neuralgia; conditions associated with visceral pain such as irritable bowel syndrome; eating disorders; diabetes; toxic and dysmetabolic disorders including cerebral anoxia, diabetic neuropathies and alcoholism; appetite, taste, eating, or drinking disorders; somatoform disorders including hypochondriasis; vomiting/nausea; inflammatory bowel disease; gastric dyskinesia; gastric ulcers; Kallman's syndrome (anosmia); impaired glucose tolerance; intestinal motility dyskinesias; hypothalamic diseases; hypophysis diseases; hyperthermia syndromes, pyrexia, febrile seizures; idiopathic growth deficiency; dwarfism; gigantism; acromegaly; basophil adenoma; prolactinoma; hyperprolactinemia; brain tumors, adenomas; benign prostatic hypertrophy, prostate cancer; all types of testicular dysfunctions, fertility control; hypothalamic hypogonadism, functional or psychogenic amenorrhea; urinary bladder incontinence asthma; allergies; all types of dermatitis, acne and cysts, sebaceous gland dysfunctions; cardiovascular disorders; heart and lung diseases, acute and congestive heart failure; hypotension; hypertension; urinary retention; osteoporosis; angina pectoris; myocardial infarction; ischemic or haemorrhagic stroke; all types of cerebrovascular disorders including subarachnoid haemorrhage, ischemic and hemorrhagic stroke and vascular dementia; chronic renal failure and other renal diseases; and other diseases related to general orexin system dysfunctions. Compounds of formula (I) are particularly suitable for use in the treatment of diseases or disorders selected from the group consisting of all types of sleep disorders, of stress-related syndromes, of psychoactive substance use and abuse, of cognitive dysfunctions in the healthy population and in psychiatric and neurologic disorders, of eating or drinking disorders. Eating disorders may be defined as comprising metabolic dysfunction; dysregulated appetite control; compulsive obesities; emeto-bulimia or anorexia nervosa. Pathologically modified food intake may result from disturbed appetite (attraction or aversion for food); altered energy balance (intake vs. expenditure); disturbed perception of food quality (high fat or carbohydrates, high palatability); disturbed food availability (unrestricted diet or deprivation) or disrupted water balance. Drinking disorders include polydipsias in psychiatric disorders and all other types of excessive fluid intake. Sleep disorders include all types of insomnias, narcolepsy and other disorders of excessive sleepiness, sleep-related dystonias; restless leg syndrome; sleep apneas; jet-lag syndrome; shift-work syndrome, delayed or advanced sleep phase syndrome or insomnias related to psychiatric disorders. Insomnias are defined as comprising sleep disorders associated with aging; intermittent treatment of chronic insomnia; situational transient insomnia (new environment, noise) or short-term insomnia due to stress; grief; pain or illness. Insomnia also include stress-related syndromes including post-traumatic stress disorders as well as other types and subtypes of anxiety disorders such as generalized anxiety, obsessive compulsive disorder, panic attacks and all types of phobic anxiety and avoidance; psychoactive substance use, abuse, seeking and reinstatement are defined as all types of psychological or physical addictions and their related tolerance and dependence components. Cognitive dysfunctions include deficits in all types of attention, learning and memory functions occurring transiently or chronically in the normal, healthy, young, adult or aging population, and also occurring transiently or chronically in psychiatric, neurologic, cardiovascular and immune disorders.
In a further embodiment of the invention, compounds of formula (I) are particularly suitable for use in the treatment of diseases or disorders selected from the group consisting of dysthymic, mood, psychotic and anxiety disorders; diabetes and appetite, taste, eating, or drinking disorders; hypothalamic diseases; disturbed biological and circadian rhythms; all types of sleep disorders; sleep disturbances associated with diseases such as neurological disorders including neuropathic pain and restless leg syndrome; insomnias related to psychiatric disorders; sleep apnea; narcolepsy; idiopathic insomnias; parasomnias; stress-related syndromes; benign prostatic hypertrophy; all types of psychoactive substance use and abuse; all dementias and cognitive dysfunctions in the healthy population and in psychiatric and neurologic disorders; and other diseases related to general orexin system dysfunctions. Another aspect of the present invention is a method for the treatment or prophylaxis of diseases, which are related to the orexin receptors such as eating disorders or sleep disorders comprising the administration to a patient a therapeutically effective amount of a compound of formula (I).
A further aspect of the invention is a process for the preparation of compounds of formula (I). Compounds according to formula (1) of the present invention can be prepared according to the general sequence of reactions outlined in the schemes below wherein A, B, X, n, and R1 are as defined in the description of formula (I). The compounds obtained may also be converted into pharmaceutically acceptable salts thereof in a manner known per se.
In general, all chemical transformations can be performed according to well-known standard methodologies as described in the literature or as described in the procedures below.
Preparation of Compounds of Formula (I):
Abbrevations:
The following abbreviations are used throughout the specification and the examples:
aq. aqueous
Boc tert-Butoxycarbonyl
BSA Bovine serum albumine
CC Column chromatography on silica gel
CHO Chinese hamster ovary
conc Concentrated
cy- Cyclo-
d Day(s)
DBU 1,8-Diazabicyclo-[5.4.0]-undec-7-ene
DCM Dichloromethane
DIBAL Diisobutylaluminium hydride
DIPEA Diisopropylethylamine
DME 1,2-Dimethoxyethane
DMF N,N-Dimethylformamide
ent Enantiomer
eq Equivalent(s)
ES Electron spray
Ether Diethylether
EtOAc Ethyl acetate
EtOH Ethanol
FCS Foatal calf serum
FLIPR Fluorescent imaging plate reader
h Hour(s)
HBSS Hank's balanced salt solution
HEPES 4-(2-hydroxyethyl)-piperazine-1-ethanesulfonic acid
HPLC High performance liquid chromatography
LC Liquid chromatography
M Molar(ity)
MeCN Acetonitrile
MeOH Methanol
min Minute(s)
MS Mass spectroscopy
NEt3 Triethylamine
PPh3 Triphenylphosphine
RT Room temperature
sat Saturated
tR Retention time
TBAF Tetrabutylammonium fluoride
TBME tert-Butyl methyl ether
TBTU O-Benzotriazol-1-yl-N,N,N′,N′-tetramethyluronium tetrafluoroborate
THF Tetrahydrofuran
General Preparation Methods:
Preparation of the Compounds of Formula (I):
The compounds of formula (I) can be prepared for example according to the method outlined in Scheme 1 hereafter.
The preparation of the 3-aza-bicyclo[3.1.0]hexane derivatives started by the protection of the nitrogen atom of the known amino-acid (1) [V. V. Tverezovsky et al. Tetrahedron 1997, 53(43), 14773-14792 and cited literature] with Boc2O. The ester (3) could be obtained e.g. by reaction of acid (2) with methyl iodide in the presence of a base like cesium carbonate in a solvent like DMF. After reduction with DIBAL at low temperatures the respective alcohol (4) was oxidized to the corresponding aldehyde (5) with e.g. Dess-Martin periodinane. After reductive amination of (5) with benzylamine in the presence of a reducing agent like sodium triacetoxyborohydride the benzyl group was removed by hydrogenolysis to yield the primary amine (7). The acylation of (7) with a carboxylic acid R1COOH in the presence of a coupling reagent like TBTU resulted in the formation of amides (8) which after removal of the Boc-group were transferred under amide coupling conditions (e.g. B-A-COOH, TBTU or B-A-COCl) or by reaction with sulfonyl chlorides (B-A-SO2Cl) to compounds (10), which are compounds of formula (I), wherein n is 1. Alternatively, amine (7) was transferred to intermediates (9) by heating a mixture of (7) and a heterocyclyl- or aryl-halide (preferably the chloride or bromide) in a solvent like ethanol in the presence of NEt3 under microwave conditions, or in presence of a palladium catalyst under standard Buchwald or Hartwig amination conditions. After removal of the Boc-group, reaction under amide coupling conditions (e.g. B-A-COOH, TBTU or B-A-COCl) or reaction with sulfonyl chlorides (B-A-SO2Cl) leads to compounds (11), which are compounds of formula (I), wherein n is 0. By determination of the crystal structure of one of the derivatives (9) it was possible to demonstrate that the reductive amination lead to compounds with a relative cis-configuration (see experimental part).
Another approach to compounds of formula (I) started with the protection of amine (7) with ethyl trifluoroacetate to give amides (12), which were Boc-deprotected with an acid like HCl in a solvent or a mixture of solvents like dioxane or THF. The obtained amine (13) was coupled with a carboxylic acid B-A-COOH in the presence of a coupling reagent like TBTU or with an acid chloride B-A-COCl to an amide or with a sulfonyl chloride to a sulfonamide. After deprotection with for instance aq. NaOH or aq. K2CO3, amines (14) were obtained which were coupled with a carboxylic acid R1COOH in the presence of a coupling reagent like TBTU or with an acid chloride R1COCl to compounds (10), which are compounds of formula (I), wherein n is 1.
Compounds (15), which are compounds of formula (I), wherein wherein A represents phenyl substituted with R and B represents an aryl or a heterocyclyl group, could be synthesized according to one of the pathways illustrated in scheme 3.
Starting from 2-bromo-benzamide derivatives (10a), synthesized according to scheme 1, compounds (15) were obtained in a Suzuki-type coupling with aryl- or heterocyclylboronic acids in the presence of Pd(PPh3)4 as catalyst. Alternatively amines (16), obtained according to the procedure illustrated in scheme 2, were protected by reaction with di-tert-butyl dicarbonate in the presence of a base like NEt3 and coupled with aryl- or heterocyclylboronic acids in the presence of a palladium catalyst like Pd(PPh3)4 to give compounds (17). Removal of the Boc group under acidic conditions led to the respective amines which were coupled with a carboxylic acid R1COOH in the presence of a coupling reagent like TBTU to compounds (15).
Compounds (18), which are compounds of formula (I), wherein A represents mono-, or di-substituted phenyl, wherein one substituent is selected from (C2-6)alkynyl, and (C3-6)cycloalkyl-ethynyl; and the other substituent (if present) is (C1-4)alkyl, and B represents hydrogen, were synthesized according to scheme 4.
Compounds (18) were prepared by palladium catalyzed coupling of aryl bromide derivatives (10a) with alkynes in the presence of Pd(PPh3)2Cl2 and copper(I) iodide. In case the alkyne is ethyne, the synthesis is preferably conducted using trimethylsilyl-ethyne in analogy to the method described below.
Thiazole-4-carboxylic acid derivatives of formula B-A-COOH were for instance synthesised according to scheme 5.
By reaction of methyl dichloroacetate (19; commercially available) with an aldehyde in the presence of a base like potassium tert.-butoxide the 3-chloro-2-oxo-propionic ester derivatives (20) were obtained which were transformed in a reaction with thioaniides [R═(C1-4)alkyl] to 2-alkyl-substituted thiazole derivatives (21) or in a reaction with thioureas (R═NR2R3) to 2-amino-substituted thiazole derivatives (21). Saponification of the ester function with an aq. solution of e.g. NaOH in a solvent like MeOH resulted in the formation of the desired carboxylic acids (22, R═(C1-4)alkyl or NR2R3). 2-Bromo-thiazole derivatives (23) were for instance obtained by reaction of the respective 2-amino-thiazole derivative (21, R═NH2) with isoamylnitrite in the presence of copper(II)bromide. The ester derivatives (23) were either saponified to the respective carboxylic acids (24) as described above or transferred to 2-methoxy substituted analogues (25) by reaction with sodium methoxide and subsequent saponification with NaOH. In addition compounds (27) which are unsubsituted in 2-position were synthesized by hydrogenation of (23) in the presence of palladium on charcoal and subsequent saponification of the intermediate ester (26).
Aldehydes B—CHO are commercially available or may be synthesized by procedures known from the literature like for instance reduction of the respective carboxylic acid or their different derivatives with a reducing agent, by reduction of the respective nitrile or by oxidation of benzylic alcohols and their heterocyclic analogues with oxidating agents (e.g.: J. March, Advanced Organic Chemistry, 4th edition, John Wiley & Sons, p. 447-449, 919-920 and 1167-1171).
Compounds (29), which are compounds of formula (I) bearing a 2-substituted thiazole moiety, were for instance synthesized according to scheme 6.
By coupling of 2-bromo-thiazole derivatives (10b), obtained according to scheme 1, with alkyne derivatives in the presence of Pd(PPh3)2Cl2 and copper(I) iodide compounds (28) of formula (I) could be obtained. Compounds (28) could be reduced, eventually after desilylation with TBAF (R′═SiMe3), by hydrogenation in the presence of palladium on charcoal to respective compounds (29).
Carboxylic acids of formula R1—COOH are commercially available or well known in the art (Lit. e.g. WO2001/96302; T. Eicher, S. Hauptmann “The chemistry of Heterocycles: Structure, Reactions, Syntheses, and Applications”, 2nd Edition 2003, Wiley, ISBN 978-3-527-30720-3).
Derivatives of formula R1—COOH wherein R1 is benzo[1,4]oxazine were for instance synthesised according to scheme 7.
By hydrogenation of 3-nitrosalicylate (commercially available) in MeOH 3-amino-2-hydroxy-benzoic acid methyl ester (32, Ra═COOMe, Rb═H) was obtained. The regioisomer (32, Ra═H, Rb═COOMe) was synthesized by esterification of commercially available 3-hydroxyanthranilic acid with (trimethylsilyl)diazomethane. Cyclization of one or the other amino-hydroxy-benzoic acid (32) with chloroacetyl chloride in the presence of a base like K2CO3 lead to 3-oxo-3,4-dihydro-2H-benzo[1,4]oxazine derivatives (33) which were reduced to 3,4-dihydro-2H-benzo[1,4]oxazine derivatives (35) with NaBH4 in the presence of boron trifluoride diethyl etherate. Compounds (33) as well as (35) may be alkylated at the nitrogen atom with methyl iodide in the presence of a base like K2CO3 in a solvent like DMF to give the respective analogues (34) or (36). By saponification of the respective ester derivatives (33, 34, 35 or 36) with NaOH in a solvent mixture like water/ethanol the desired acids (37, 38, 39, 40, 41, 42, 43 or 44) could be obtained.
Derivatives of formula R1—COOH wherein R1 is chroman were for instance synthesised according to scheme 8.
The synthesis of chroman-5-carboxylic acid derivatives started with the alkylation of 3-hydroxy-benzoic acid methyl ester (45; commercially available) with propargyl bromide in the presence of K2CO3 to give phenylether (46) which was cyclised to the chromen derivative (47) by heating to reflux in N,N-diethylaniline. The carboxylic ester was saponified by treatment of (47) mith NaOH in MeOH and water and the obtained chromen derivative (48) was hydrogenated to give the desired acid (49). The corresponding chroman-8-carboxylic acid derivatives were synthesized by reduction of 4-chromanone (50; commercially available) with zinc in acetic acid and subsequent ortho-metalation of the intermediate chroman derivative (51) with n-BuLi and trapping with carbon dioxide to give the desired acid (52).
Derivatives of formula R1—COOH wherein R1 is imidazo[2,1-b]thiazole were for instance synthesised according to one of the different pathways shown in scheme 9.
Following pathway A imidazo[2,1-b]thiazole-carboxylic acid derivatives were synthesized starting from 2-chloro-3-oxo-butyric acid methyl ester (53; commercially available) by reaction with thiourea in a solvent like ethanol at elevated temperatures. The obtained amino-thiazole (54) was converted to the imidazo[2,1-b]thiazole derivative (55) by alkylation and subsequent cyclization with bromoacetaldehyde diethyl acetal in the presence of an acid like concentrated hydrochloric acid. By saponification of (55) with for instance NaOH in solvents like THF and MeOH the desired acids (56) were obtained.
An alternative approach (pathway B) started with the reaction of 2-bromo-3-oxo-butyric acid ester (57; commercially available) with 2-amino-5-methyl-thiazole in a solvent like acetone to give the imidazo[2,1-b]thiazole derivative (58) which was transformed to the desired acid (59) by saponification with for instance NaOH in solvents like THF and MeOH.
By hydrogenation of 2-hydroxyimino-3-oxo-butyric acid ester (60; commercially available) in the presence of palladium on charcoal under acidic conditions (e.g. HCl in EtOH) and subsequent reaction with potassium thiocyanate the imidazole derivative (61) was obtained which was transferred to a mixture of the two possible isomers (62) and (63) by reaction with the respective α-halogenated propanone or butanone derivative (pathway C). After separation of the isomers (62) and (63) by chromatography the desired imidazo[2,1-b]thiazole-carboxylic acid derivatives (64) and (65) were obtained by saponification with for instance NaOH in solvents like THF and MeOH.
Alternatively (pathway D) the imidazole derivative (61) may be transferred to the acetal (66) by alkylation with a bromoacetaldehyde dialkyl acetal derivative in the presence of a base like sodium ethoxide. Cyclization under acidic conditions (e.g. aq. hydrochloric acid) and dehydration of the intermediate (67) with for instance phosphorus oxychloride led to ester (68) which was transformed to the desired acid (69) by saponification with for instance NaOH in solvents like THF and MeOH.
In still an alternative procedure (pathway E) the respective amino-thiazole (70; commercially available) was converted to the formamidine derivative (71) by heating (70; commercially available) with N,N-dimethylformamide dimethylacetale in a solvent like toluene. After alkylation with ethyl bromoacetate the respective thiazolium bromide (72) was cyclised with DBU to yield the ester (73) which was saponified to the desired acid (74) with for instance NaOH in solvents like THF and MeOH.
Finally pathway F started with the alkylation of 2-amino-thiazole with 3-bromo-1,1,1-trifluoroacetone to yield the trifluoromethyl-substituted imidazo[2,1-b]thiazole derivative (75) which was formylated to the aldehyde (76) by reaction with phosphorus oxychloride in a solvent like DMF. By oxidation of aldehyde (75) with sodium chlorite the desired imidazo[2,1-b]thiazole-carboxylic acid (77) was obtained. In analogy, the commercially available chlorinated aldehyde (76, being substituted with Cl instead of CF3) was oxidized to the corresponding acid.
Whenever the compounds of formula (I) are obtained in the form of mixtures of enantiomers, the enantiomers can be separated using methods known to one skilled in the art: e.g. by formation and separation of diastereomeric salts or by HPLC over a chiral stationary phase such as a Regis Whelk-O1(R,R) (10 μm) column, a Daicel ChiralCel OD-H (5-10 μm) column, or a Daicel ChiralPak IA (10 μm) or AD-H (5 μm) column. Typical conditions of chiral HPLC are an isocratic mixture of eluent A (EtOH, in presence or absence of an amine such as NEt3, diethylamine) and eluent B (hexane), at a flow rate of 0.8 to 150 mL/min.
Experimental Section
I-Chemistry
The following examples illustrate the preparation of pharmacologically active compounds of the invention but do not at all limit the scope thereof.
All temperatures are stated in ° C.
Compounds are characterized by:
1H-NMR: 300 MHz Varian Oxford or 400 MHz Bruker Avance; chemical shifts are given in ppm relative to the solvent used; multiplicities: s=singlet, d=doublet, t=triplet, m=multiplet, b=broad, coupling constants are given in Hz;
Compounds are purified by column chromatography on silica gel (CC) or by preparative HPLC using RP-C18 based columns with MeCN/water gradients and formic acid or ammonia additives.
A solution of the respective aldehyde (338 mmol, 1.0 eq) and methyl dichloroacetate (338 mmol, 1.0 eq) in THF (100 mL) is added dropwise to a cold (−60° C.) suspension of KOtBu (335 mmol, 1.0 eq) in THF (420 mL). After 4 h the mixture is allowed to reach RT, stirred over night and concentrated in vacuo. DCM and ice-cold water are added, the layers are separated and the aq. layer is extracted twice with DCM. The combined organic layers are washed with ice-cold water and brine, dried over MgSO4 and concentrated in vacuo to give the desired 3-chloro-2-oxo-propionic ester derivative which is used without further purification.
prepared by reaction of 3-methyl-benzaldehyde with methyl dichloroacetate.
prepared by reaction of 4-methyl-benzaldehyde with methyl dichloroacetate.
prepared by reaction of 4-ethyl-benzaldehyde with methyl dichloroacetate.
prepared by reaction of 3-fluoro-benzaldehyde with methyl dichloroacetate.
prepared by reaction of 4-fluoro-benzaldehyde with methyl dichloroacetate.
prepared by reaction of 4-trifluoromethyl-benzaldehyde with methyl dichloro-acetate.
prepared by reaction of 2-fluoro-benzaldehyde with methyl dichloro-acetate.
prepared by reaction of 2-chloro-benzaldehyde with methyl dichloro-acetate.
prepared by reaction of 3-chloro-benzaldehyde with methyl dichloro-acetate.
prepared by reaction of 2-methyl-benzaldehyde with methyl dichloro-acetate.
prepared by reaction of 2-methoxy-benzaldehyde with methyl dichloro-acetate.
prepared by reaction of 3-methoxy-benzaldehyde with methyl dichloro-acetate.
prepared by reaction of 2-trifluoromethyl-benzaldehyde with methyl dichloro-acetate.
prepared by reaction of 3-trifluoromethyl-benzaldehyde with methyl dichloro-acetate.
prepared by reaction of 3,4-dimethyl-benzaldehyde with methyl dichloro-acetate.
prepared by reaction of 3-cyano-benzaldehyde with methyl dichloro-acetate.
prepared by reaction of 3-benzyloxy-benzaldehyde with methyl dichloro-acetate.
A solution of thioacetamide (132 mmol, 1.0 eq) in MeCN (250 mL) is added to a mixture of the respective 3-chloro-2-oxo-propionic ester derivative (132 mmol, 1.0 eq) and molecular sieves (4 Å, 12 g) in MeCN (60 mL). After stirring for 5 h the mixture is cooled in an ice-bath and the obtained precipitate is filtered off. The residue is washed with cold MeCN, dried, dissolved in MeOH (280 mL) and stirred at 50° C. for 6 h. The solvents are removed in vacuo to give the desired thiazole derivatives as a white solid.
prepared by reaction of 3-chloro-2-oxo-3-m-tolyl-propionic acid methyl ester with thioacetamide. LC-MS: tR=0.94 min; [M+H]+=248.0.
prepared by reaction of 3-chloro-2-oxo-3-p-tolyl-propionic acid methyl ester with thioacetamide. LC-MS: tR=0.92 min; [M+H]+=248.2.
prepared by reaction of 3-chloro-3-(4-ethyl-phenyl)-2-oxo-propionic acid methyl ester with thioacetamide. LC-MS: tR=0.98 min; [M+H]+=262.1.
prepared by reaction of 3-chloro-3-(3-fluoro-phenyl)-2-oxo-propionic acid methyl ester with thioacetamide. LC-MS: tR=0.91 min; [M+H]+=252.1.
prepared by reaction of 3-chloro-3-(4-fluoro-phenyl)-2-oxo-propionic acid methyl ester with thioacetamide. 1H-NMR (CDCl3): δ=2.75 (s, 3H); 3.84 (s, 3H); 7.10 (m, 2H); 7.47 (m, 2H).
prepared by reaction of 3-chloro-3-(4-trifluoromethyl-phenyl)-2-oxo-propionic acid methyl ester with thioacetamide. LC-MS: tR=0.98 min; [M+H]+=302.0.
prepared by reaction of 3-chloro-3-(3-trifluoromethyl-phenyl)-2-oxo-propionic acid methyl ester with thioacetamide. LC-MS: tR=0.98 min; [M+H]+=302.2.
prepared by reaction of 3-chloro-3-(2-trifluoromethyl-phenyl)-2-oxo-propionic acid methyl ester with thioacetamide. LC-MS: tR=0.94 min; [M+H]+=302.3.
prepared by reaction of 3-chloro-3-(2-fluoro-phenyl)-2-oxo-propionic acid methyl ester with thioacetamide. LC-MS: tR=0.89 min; [M+H]+=252.0.
prepared by reaction of 3-chloro-3-(2-chloro-phenyl)-2-oxo-propionic acid methyl ester with thioacetamide. LC-MS: tR=0.92 min; [M+H]+=268.0.
prepared by reaction of 3-chloro-3-(3-chloro-phenyl)-2-oxo-propionic acid methyl ester with thioacetamide. LC-MS: tR=0.95 min; [M+H]+=268.0.
prepared by reaction of 3-chloro-2-oxo-3-o-tolyl-propionic acid methyl ester with thioacetamide. LC-MS: tR=0.92 min; [M+H]+=248.1.
prepared by reaction of 3-chloro-3-(2-methoxy-phenyl)-2-oxo-propionic acid methyl ester with thioacetamide. LC-MS: tR=0.88 min; [M+H]+=264.1.
prepared by reaction of 3-chloro-3-(3-methoxy-phenyl)-2-oxo-propionic acid methyl ester with thioacetamide. LC-MS: tR=0.90 min; [M+H]+=263.9.
prepared by reaction of 3-chloro-3-(3,4-dimethyl-phenyl)-2-oxo-propionic acid methyl ester with thioacetamide. LC-MS: tR=0.96 min; [M+H]+=262.3.
prepared by reaction of 3-chloro-3-(3-cyano-phenyl)-2-oxo-propionic acid methyl ester with thioacetamide. LC-MS: tR=0.86 min; [M+H]+=259.3.
prepared by reaction of 3-(3-benzyloxy-phenyl)-3-chloro-2-oxo-propionic acid methyl ester with thioacetamide. LC-MS: tR=1.07 min; [M+H]+=340.2.
Boron trifluoride diethyl etherate (40.6 mL) is added to a suspension of 5-(3-benzyloxy-phenyl)-2-methyl-thiazole-4-carboxylic acid methyl ester (26.8 mmol) in ethanethiol (50 mL). The mixture is treated with ultrasound for 15 min, stirred for 48 h at RT, poured into a NaOH solution (0.50 M, 500 mL) and extracted twice with EtOAc (250 mL each). The combined organic layers are extracted three times with a solution of NaOH in water (1.0 M, 3×250 mL). The combined aq. layers are made acidic (pH 3) by addition of hydrochloric acid (25%) and the obtained precipitate is filtered off and dried in vacuo to give the desired product as a white solid. LC-MS: tR=0.82 min; [M+H]+=250.4.
Under a nitrogen atmosphere azodicarboxylic acid dipiperidide (5.01 mmol) is added to a mixture of 5-(3-hydroxy-phenyl)-2-methyl-thiazole-4-carboxylic acid methyl ester (4.01 mmol) and 2-methoxyethanol (4.41 mmol) in toluene (25 mL). Tributylphosphine (6.02 mmol) is added dropwise at RT and the suspension is heated for 2 h to 100° C. Heptane (25 mL) is added and the suspension is filtered. The residue is washed with heptane (25 mL) and purified by CC (gradient:heptane to heptane/EtOAc 4/1) to give the desired ether. LC-MS: tR=0.93 min; [M+H]+=308.3.
A solution of the respective 3-chloro-2-oxo-propionic ester derivative (22.1 mmol, 1.0 eq) in acetone (25 mL) is added to a suspension of thiourea (22.1 mmol, 1.0 eq) in acetone (45 mL). The mixture is heated to 57° C. (bath temperature), stirred for 24 h and concentrated to half of the volume. The obtained suspension is filtered and the residue is washed with acetone. After drying the desired amino-thiazole derivative is obtained as a solid.
prepared by reaction of 3-chloro-2-oxo-3-m-tolyl-propionic acid methyl ester with thiourea. LC-MS: tR=0.78 min; [M+H]+=249.0.
prepared by reaction of 3-chloro-3-(3-fluoro-phenyl)-2-oxo-propionic acid methyl ester with thiourea. LC-MS: tR=0.78 min; [M+H]+=252.9.
prepared by reaction of 3-chloro-3-(3-chloro-phenyl)-2-oxo-propionic acid methyl ester with thiourea. LC-MS: tR=0.82 min; [M+H]+=269.2.
At 15° C. under an atmosphere of nitrogen 2-amino-5-m-tolyl-thiazole-4-carboxylic acid methyl ester (7.10 mmol) is added portionwise to a mixture of CuBr2 (7.10 mmol) and isoamyl nitrite (10.6 mmol) in MeCN (30 mL). The mixture is stirred for 20 min at 15° C., for 30 min at 40° C. and for 90 min at 65° C. The solvents are removed in vacuo and the residue is purified by CC (gradient: DCM to DCM/MeOH 98/2) to give the desired product. LC-MS: tR=1.01 min; [M+H]+=311.8.
A solution of 2-bromo-5-m-tolyl-thiazole-4-carboxylic acid methyl ester (0.64 mmol) in ethanol (5.0 mL) is treated with Pd/C (100 mg, 10%) and stirred under a hydrogen atmosphere (1 bar) for 18 h. After filtration through celite and removal of the solvents the desired product is obtained which is used without further purification. LC-MS: tR=0.90 min; [M+H]+=233.9.
A solution of the respective thiazole-4-carboxylic acid ester (96.2 mmol) in a mixture of THF (150 mL) and MeOH (50 mL) is treated with an aq. NaOH solution (1.0 M, 192 mL). After stirring for 3 h a white suspension is formed and the organic volatiles are removed in vacuo. The remaining mixture is diluted with water (100 mL), cooled in an ice-bath and made acidic (pH=3-4) by addition of aq. HCl solution (1.0 M). The suspension is filtered and the residue is washed with cold water. After drying the desired acid is obtained as a white solid.
prepared by saponification of 2-methyl-5-m-tolyl-thiazole-4-carboxylic acid methyl ester. LC-MS: tR=0.83 min; [M+H]+=234.0.
prepared by saponification of 2-methyl-5-p-tolyl-thiazole-4-carboxylic acid methyl ester. LC-MS: tR=0.83 min; [M+H]+=234.0.
prepared by saponification of 5-(4-ethyl-phenyl)-2-methyl-thiazole-4-carboxylic acid methyl ester. LC-MS: tR=0.88 min; [M+H]+=248.0.
prepared by saponification of 5-(3-fluoro-phenyl)-2-methyl-thiazole-4-carboxylic acid methyl ester. LC-MS: tR=0.82 min; [M+H]+=238.1.
prepared by saponification of 5-(4-fluoro-phenyl)-2-methyl-thiazole4-carboxylic acid methyl ester. 1H-NMR (DMSO-6): δ=2.67 (s, 3H); 7.27 (m, 2H); 7.53 (m, 2H); 12.89 (br.s, 1H).
prepared by saponification of 2-methyl-5-(4-trifluoromethyl-phenyl)-thiazole-4-carboxylic acid methyl ester. LC-MS: tR=0.90 min; [M+H]+=288.0.
prepared by saponification of 2-methyl-5-(3-trifluoromethyl-phenyl)-thiazole-4-carboxylic acid methyl ester. LC-MS: tR=0.88 min; [M+H]+=288.0.
prepared by saponification of 2-methyl-5-(2-trifluoromethyl-phenyl)-thiazole-4-carboxylic acid methyl ester. LC-MS: tR=0.84 min; [M+H]+=288.3.
prepared by saponification of 5-(2-fluoro-phenyl)-2-methyl-thiazole-4-carboxylic acid methyl ester. LC-MS: tR=0.78 min; [M+H]+=238.3.
prepared by saponification of 5-(2-chloro-phenyl)-2-methyl-thiazole-4-carboxylic acid methyl ester. LC-MS: tR=0.82 min; [M+H]+=253.9.
prepared by saponification of 5-(3-chloro-phenyl)-2-methyl-thiazole-4-carboxylic acid methyl ester. LC-MS: tR=0.84 min; [M+H]+=254.0.
prepared by saponification of 2-methyl-5-o-tolyl-thiazole-4-carboxylic acid methyl ester. LC-MS: tR=0.80 min; [M+H]+=234.3.
prepared by saponification of 5-(3-methoxy-phenyl)-2-methyl-thiazole-4-carboxylic acid methyl ester. LC-MS: tR=0.80 min; [M+H]+=250.0.
prepared by saponification of 5-(2-methoxy-phenyl)-2-methyl-thiazole-4-carboxylic acid methyl ester. LC-MS: tR=0.78 min; [M+H]+=250.0.
prepared by saponification of 5-(3,4-dimethyl-phenyl)-2-methyl-thiazole-4-carboxylic acid methyl ester. LC-MS: tR=0.86 min; [M+H]+=248.3.
prepared by saponification of 5-(3-cyano-phenyl)-2-methyl-thiazole-4-carboxylic acid methyl ester. LC-MS: tR=0.76 min; [M+H]+=245.3.
prepared by saponification of 5-[3-(2-methoxy-ethoxy)-phenyl]-2-methyl-thiazole-4-carboxylic acid methyl ester. LC-MS: tR=0.83 min; [M+H]+=294.3.
prepared by saponification of 2-amino-5-m-tolyl-thiazole-4-carboxylic acid methyl ester. LC-MS: tR=0.65 min; [M+H]+=235.0.
prepared by saponification of 2-amino-5-(3-fluoro-phenyl)-thiazole-4-carboxylic acid methyl ester. LC-MS: tR=0.62 min; [M+H]+=239.1.
prepared by saponification of 2-amino-5-(3-chloro-phenyl)-thiazole-4-carboxylic acid methyl ester. LC-MS: tR=0.66 min; [M+H]+=255.2.
prepared by saponification of 2-Bromo-5-m-tolyl-thiazole-4-carboxylic acid methyl ester. LC-MS (basic): tR=0.57 min; [M+H]+=297.8.
prepared by saponification of 5-m-tolyl-thiazole-4-carboxylic acid methyl ester. LC-MS: tR=0.86 min; [M+H]+=220.2.
At 0° C. under an atmosphere of nitrogen MeOH (0.96 mmol) is added to a suspension of sodium hydride (0.96 mmol) in THF (2.0 mL). After 5 min a solution of 2-bromo-5-m-tolyl-thiazole-4-carboxylic acid methyl ester (0.48 mmol) in DMF (0.2 mL) and THF (1.0 mL) is added dropwise. The mixture is stirred for 16 h at RT, cooled to 0° C. and treated with water (0.5 mL) and aq. NaOH solution (1.0 M, 0.5 mL). After 2 h the solvents are removed in vacuo and the residue is dissolved in warm water (1.0 mL). Ether is added, the layers are separated and the aq. layer is concentrated partially in vacuo to remove traces of ether. The mixture is cooled to 0° C. and made acidic (pH 4) by addition of hydrochloric acid (2.0 M). The precipitate is filtered off, washed with water and dried in vacuo to give the desired product. LC-MS: tR=0.88 min; [M+H]+=250.3.
A solution of methyl 3-nitrosalicylate (26.6 mmol) in MeOH (50 mL) is treated with Pd/C (10%, 500 mg) and stirred at RT under a hydrogen atmosphere (1 bar) for 16 h. After filtration through celite and removal of the solvents the desired product is obtained which is used without further purification. LC-MS: tR=0.51 min; [M+H]+=168.0.
At RT chloro-acetyl chloride (29.0 mmol) is added dropwise to a solution of 3-amino-2-hydroxy-benzoic acid methyl ester (26.4 mmol) in DMF (100 mL). After 20 min K2CO3 (126 mmol) is added portionwise, the mixture is stirred for 16 h at RT and the solvents are removed in vacuo. Water and DCM are added, the layers are separated and the organic layer is washed with brine and dried over Na2SO4. The solvents are removed in vacuo to give a crude product which is used without further purification. LC-MS: tR=0.68 min; [M+H]+=208.0.
K2CO3 (6.66 mmol) is added to a solution of 3-oxo-3,4-dihydro-2H-benzo[1,4]oxazine-8-carboxylic acid methyl ester (2.90 mmol) in DMF (10 mL). After 30 min methyl iodide (5.79 mmol) is added and the mixture is stirred for 2 h at 75° C. Cold water and EtOAc are added, the layers are separated and the aq. layer is extracted with EtOAc. The combined organic layers are washed with water and brine, dried over MgSO4 and concentrated in vacuo to give a crude product which is used without further purification. LC-MS: tR=0.76 min; [M+H]+=222.2.
Boron trifluoride diethyl etherate (10.1 mmol) is added dropwise to a mixture of 3-oxo-3,4-dihydro-2H-benzo[1,4]oxazine-8-carboxylic acid methyl ester (4.83 mmol) in THF (12 mL) to keep the temperature below 5° C. After 20 min NaBH4 (10.1 mmol) is added and the mixture is stirred at 5° C. for 60 min. EtOAc (6.0 mL) and hydrochloric acid (1.0 M, 6.0 mL) are added dropwise. The mixture is made basic by addition of sat. aq. NaHCO3 solution, the layers are separated and the aq. layer is extracted with EtOAc. The combined organic layers are dried over MgSO4 and concentrated in vacuo to give a crude product which is purified by CC (heptane to heptane/EtOAc 3/7). LC-MS: tR=0.69 min; [M+H]+=194.0.
K2CO3 (4.76 mmol) is added to a solution of 3,4-dihydro-2H-benzo[1,4]oxazine-8-carboxylic acid methyl ester (2.07 mmol) in DMF (3.0 mL). After 30 min methyl iodide (4.14 mmol) is added and the mixture is stirred for 2 h at 75° C. Cold water and EtOAc are added, the layers are separated and the aq. layer is extracted with EtOAc. The combined organic layers are washed with water and brine, dried over MgSO4 and concentrated in vacuo to give a crude product which is used without further purification. LC-MS: tR=0.83 min; [M+H]+=208.1.
A solution of (trimethylsilyl)diazomethane in hexane (2.0 M, 10.9 mmol) is added dropwise (10 min) to a mixture of 3-hydroxyanthranilic acid (9.93 mmol) in MeOH (10.5 mL) and toluene (42 mL). The mixture is stirred for 16 h, concentrated in vacuo, diluted with ether and EtOAc and washed several times with water. The organic layer is dried over MgSO4 and concentrated under reduced pressure. The residue is purified by CC (heptane to heptane/EtOAc 7/3) to give the desired ester as a brown solid. LC-MS: tR=0.70 min; [M+H]+=168.0.
At RT chloro-acetyl chloride (8.06 mmol) is added dropwise to a solution of 2-amino-3-hydroxy-benzoic acid methyl ester (7.33 mmol) in DMF (50 mL). After 20 min K2CO3 (34.9 mmol) is added portionwise, the mixture is stirred for 16 h at RT and the solvents are removed in vacuo. Water and DCM are added, the layers are separated and the organic layer is washed with brine and dried over Na2SO4. The solvents are removed in vacuo to give a crude product which is purified by CC (heptane to heptane/EtOAc 6/4). LC-MS: tR=0.82 min; [M+CH3CN+H]+=249.0.
Boron trifluoride diethyl etherate (7.10 mmol) is added dropwise to a mixture of 3-oxo-3,4-dihydro-2H-benzo[1,4]oxazine-5-carboxylic acid methyl ester (3.38 mmol) in THF (10 mL) to keep the temperature below 5° C. After 20 min NaBH4 (7.10 mmol) is added and the mixture is stirred at 5° C. for 90 min. EtOAc (6.0 mL) and hydrochloric acid (1.0 M, 6.0 mL) are added dropwise. The mixture is made basic by addition of aq. Na2CO3 solution, the layers are separated and the aq. layer is extracted with EtOAc. The combined organic layers are dried over MgSO4 and concentrated in vacuo to give a crude product which is purified by CC (heptane to heptane/EtOAc 3/7). LC-MS: tR=0.90 min; [M+CH3CN+H]+=235.3.
K2CO3 (1.79 mmol) is added to a solution of 3,4-dihydro-2H-benzo[1,4]oxazine-5-carboxylic acid methyl ester (0.78 mmol) in DMF (1.0 mL). After 30 min methyl iodide (1.55 mmol) is added and the mixture is stirred for 2 h at 75° C. Cold water and EtOAc are added, the layers are separated and the aq. layer is extracted with EtOAc. The combined organic layers are washed with water and brine, dried over MgSO4 and concentrated in vacuo to give a crude product which is used without further purification. LC-MS: tR=0.71 min; [M+H]+=208.1.
A solution of NaOH (4.00 mmol) in a mixture of MeOH (3.0 mL) and water (6.8 mL) is added to the respective ester derivative (2.00 mmol). The mixture is stirred at 55° C. for 16 h, partially concentrated in vacuo to remove MeOH and made acidic by addition of hydrochloric acid (1.0M). The respective carboxylic acid precipitates and is collected by filtration.
prepared by saponification of 3,4-dihydro-2H-benzo[1,4]oxazine-8-carboxylic acid methyl ester. LC-MS: tR=0.55 min; [M+H]+=180.0.
prepared by saponification of 4-methyl-3,4-dihydro-2H-benzo[1,4]oxazine-8-carboxylic acid methyl ester. LC-MS: tR=0.72 min; [M+H]+=194.1.
prepared by saponification of 3,4-dihydro-2H-benzo[1,4]oxazine-5-carboxylic acid methyl ester. LC-MS: tR=0.76 min; [M+H]+=180.2.
prepared by saponification of 4-methyl-3,4-dihydro-2H-benzo[1,4]oxazine-5-carboxylic acid methyl ester. LC-MS: tR=0.55 min; [M+H]+=194.1.
prepared by saponification of 3-oxo-3,4-dihydro-2H-benzo[1,4]oxazine-8-carboxylic acid methyl ester. LC-MS: tR=0.56 min; [M+CH3CN+H]+=235.0.
prepared by saponification of 4-methyl-3-oxo-3,4-dihydro-2H-benzo[1,4]oxazine-8-carboxylic acid methyl ester. LC-MS: tR=0.64 min; [M+CH3CN+H]+=249.3.
prepared by saponification of 3-oxo-3,4-dihydro-2H-benzo[1,4]oxazine-5-carboxylic acid methyl ester. LC-MS: tR=0.71 min; [M+CH3CN+H]+=235.1.
A solution of propargyl bromide in toluene (80%, 68.7 mmol, 7.40 mL) is added to a solution of 3-hydroxy-benzoic acid methyl ester (48.6 mmol) in DMF (45 mL). K2CO3 is added and the mixture is stirred at RT for 4 h. Water and ether are added, the layers are separated and the organic layer is washed with aq. NaOH solution (5%) and brine. The solvents are removed in vacuo to give the desired ester as a pale yellow solid. 1H-NMR (CDCl3): δ=2.56 (s, 1H); 3.94 (s, 3H); 4.76 (s, 2H); 7.20 (d, J=8.04 Hz, 1H); 7.39 (t, J=8.16 Hz, 1H); 7.66 (bs, 1H); 7.71 (d, J=7.78 Hz, 1H).
A solution of 3-prop-2-ynyloxy-benzoic acid methyl ester (10.5 mmol) in N,N-diethylaniline (20 mL) is heated to reflux for 15 h. The mixture is cooled to RT, diluted with ether and washed with hydrochloric acid (5%) and brine. The solvents are removed in vacuo and the residue is purified by chromatography (silica, heptane to heptane/EtOAc 95/5) to give the desired chromene derivative. 1H-NMR (CDCl3): δ=3.91 (s, 3H); 4.80 (bs, 2H); 5.93-5.98 (m, 1H); 6.99 (d, J=8.03 Hz, 1H); 7.16 (t, J=7.66 Hz, 1H); 7.34 (d, J=10.3 Hz, 1H); 7.50 (d, J=7.28 Hz, 1H).
A solution of NaOH (7.26 mmol) in a mixture of MeOH (5.4 mL) and water (12.1 mL) is added to 2H-chromene-5-carboxylic acid methyl ester (4.84 mmol). The mixture is stirred at 55° C. for 3 h, partially concentrated in vacuo to remove MeOH and made acidic by addition of hydrochloric acid (1.0M). The desired carboxylic acid precipitates and is collected by filtration. 1H-NMR (DMSO-d6): δ=4.75 (bs, 2H); 5.99-6.05 (m, 1H); 6.98 (d, J=7.78 Hz, 1H); 7.19 (t, J=7.78 Hz, 1H); 7.25 (d, J=10.3 Hz, 1H); 7.40 (d, J=7.78 Hz, 1H); 13.0 (bs, 1H).
A solution of 2H-chromene-5-carboxylic acid (1.42 mmol) in MeOH (5.0 mL) is treated with Pd/C (10%, 50 mg) and stirred at RT under a hydrogen atmosphere (1 bar) for 16 h. After filtration through celite and removal of the solvents the desired product is obtained which is used without further purification. 1H-NMR (DMSO-d6): δ=1.90 (m, 2H); 2.98 (m, 2H); 4.13 (m, 2H); 6.89-6.94 (m, 1H); 7.11-7.17 (m, 1H); 7.31-7.36 (m, 1H); 12.8 (bs, 1H).
A solution of 4-chromanone (19.6 mmol) in HOAc (30 mL) is added to a suspension of zinc powder (445 mmol) in HOAc (60 mL). The mixture is stirred at 100° C. for 4 h, cooled to RT, filtered through celite and concentrated in vacuo. EtOAc and aq. NaOH solution (1.0 M) are added, the layers are separated and the aq. layer is extracted twice with EtOAc. The combined organic layers are dried over MgSO4 and concentrated in vacuo to give the desired product which is used without further purification. 1H-NMR (CDCl3): δ=2.04 (m, 2H); 2.82 (m, 2H); 4.21 (m, 2H); 6.80-6.89 (m, 2H); 7.04-7.14 (m, 2H).
At RT a solution of chroman (17.7 mmol) in ether (15 mL) is added over 10 min to a solution of n-BuLi (19.5 mmol) in a mixture of hexane (12.2 mL) and ether (15 mL). The mixture is stirred at reflux for 150 min, allowed to reach RT and poured into a mixture of dry ice and ether. Ice water is added and the layers are separated. The aq. layer is made acidic and extracted with a mixture of ether and EtOAc. The combined organic layers are washed with water, dried over Na2SO4 and concentrated in vacuo to give a crude product which is purified by CC (heptane/EtOAc 9/1 to EtOAc). LC-MS: tR=0.76 min; [M+CH3CN+H]+=220.1.
Benzofuran-4-carboxylic acid (30.8 mmol, M. A. Eissenstat et al. J. Med. Chem. 1995, 38, 3094-3105) is added to a suspension of Pd/C (10%, 2.00 g) in EtOH (25 mL). Additional EtOH (75 mL) is added and the mixture is stirred at RT under a hydrogen atmosphere (4 bar) for 16 h. After filtration through celite and removal of the solvents the desired product is obtained which is used without further purification. 1H-NMR (DMSO-d6): δ=3.45 (t, J=8.79 Hz, 2H); 4.55 (t, J=8.79 Hz, 2H); 6.99 (d, J=7.78 Hz, 1H); 7.21 (t, J=7.91 Hz, 1H); 7.39 (d, J=7.78 Hz, 1H); 12.9 (bs, 1H).
2,3,6,7-Tetrahydro-benzo[1,2-b;4,5-b′]difuran-4-carbaldehyde (0.25 mmol; D. E. Nichols et al. J. Med. Chem. 1996, 39, 2953-2961) is added to a suspension of silver oxide (0.38 mmol) in aq. NaOH solution (5%, 2.0 mL). After stirring for 5 h the mixture is filtered and the residue is washed with water (2.0 mL). The filtrate is cooled to 0° C., made acidic by addition of hydrochloric acid (25%) and filtered. The residue is washed with cold water (2.0 mL) and heptane and dried in vacuo to give the desired product. LC-MS (basic): tR=0.20 min; [M−H]−=205.2.
A mixture of thiourea (59.8 mmol) and 2-chloro-3-oxo-butyric acid methyl ester (59.8 mmol) in EtOH (140 mL) is heated at reflux for 14 h and concentrated in vacuo. Water and aq. NaHCO3 are added and the mixture is extracted several times with EtOAc. The combined organic layers are dried and concentrated in vacuo to give the desired amino-thiazole derivative. LC-MS: tR=0.51 min; [M+H]+=173.0.
A mixture of bromoacetaldehyde diethyl acetal (29.3 mmol, 1.26 eq) in water (200 mL) is treated dropwise with conc. hydrochloric acid (3.0 mL), stirred for 14 h at RT and heated for additional 30 min at 80° C. After cooling to RT NaHCO3 (37.9 mmol) is added carefully and the mixture is stirred for 2 h and treated with 2-Amino-4-methyl-thiazole-5-carboxylic acid methyl ester (23.2 mmol, 1.00 eq). After 1 h dioxane (130 mL) is added and the mixture is stirred at RT for 30 min and at 100° C. for 48 h. The organic solvents are removed in vacuo and the mixture is extracted several times with DCM and chloroform. The combined organic layers are dried over Na2SO4 and concentrated in vacuo to give the desired ester which is used without further purification. LC-MS: tR=0.55 min; [M+H]+=197.0.
At −5° C. trimethylsilyl trifluoromethanesulfonate (36.9 mmol) is added dropwise to a solution of ethyl acetoacetate (30.7 mmol) and NEt3 (36.9 mmol) in DCM (50 mL). The solution is stirred for 90 min at 0° C. and treated over 30 min with a solution of bromine (30.7 mmol) in DCM (20 mL). After 60 min water (100 mL) is added, the layers are separated and the aq. layer is extracted three times with water (100 mL each). The organic layer is dried over MgSO4 and concentrated under reduced pressure to give the desired product which is used without further purification. 1H-NMR (CDCl3): δ=1.34 (t, J=7.16 Hz, 3H); 2.46 (s, 3H); 4.31 (q, J=7.20 Hz, 2H); 4.77 (s, 1H).
A mixture of 5-methyl-2-aminothiazole (7.09 mmol) and 2-bromo-3-oxo-butyric acid ethyl ester (8.51 mmol) in acetone (17 mL) is stirred for 16 h at RT and for additional 7 h at reflux. The solvents are removed in vacuo, chloroform and sat aq. NaHCO3 solution are added, the layers are separated and the aq. layer is extracted with chloroform. The combined organic layers are dried over MgSO4 and concentrated in vacuo to give a crude product which is purified by CC (heptane to heptane/EtOAc 6/4). LC-MS: tR=0.80 min; [M+H]+=225.3.
Pd/C (10%, 1.00 g) is added to a solution of 2-hydroxyimino-3-oxo-butyric acid ethyl ester (62.8 mmol) in hydrochloric acid (1.25 M in EtOH, 75 mL) and the mixture is stirred at RT under a hydrogen atmosphere (4 bar) for 48 h. After filtration through celite and removal of the solvents crude 2-amino-3-oxo-butyric acid ethyl ester hydrochloride is obtained which is dissolved in a mixture of water (220 mL), EtOH (30 mL) and conc hydrochloric acid (37%, 2.5 mL). A solution of potassium thiocyanate (49.9 mmol) in water (25 mL) is added and the mixture is stirred for 2 h at reflux. By cooling in an ice bath the desired product precipitates and is collected by filtration. LC-MS: tR=0.59 min; [M+H]+=187.2.
A mixture of 5-methyl-2-thioxo-2,3-dihydro-1H-imidazole-4-carboxylic acid ethyl ester (5.37 mmol) and chloroacetone (6.44 mmol) in EtOH (10 mL) is heated at reflux for 150 min. The solvents are removed in vacuo and a solution of POCl3 (16.1 mmol) in MeCN (10 mL) is added. The mixture is stirred at reflux for 60 h, concentrated in vacuo and diluted with chloroform. Ice water is added and the mixture is neutralized by addition of Na2CO3. The layers are separated and the aq. layer is extracted with chloroform. The combined organic layers are dried over Na2SO4 and concentrated in vacuo to give a mixture of two regioisomers (see A.6.7) which are separated by CC (heptane to heptane/EtOAc 3/7). LC-MS: tR=0.71 min; [M+H]+=225.0.
3,6-dimethyl-imidazo[2,1-b]thiazole-5-carboxylic acid ethyl ester is obtained as a side-product in the synthesis of 3,5-dimethyl-imidazo[2,1-b]thiazole-6-carboxylic acid ethyl ester (see A.6.6). LC-MS: tR=0.81 min; [M+H]+=225.0.
A mixture of 2-thioxo-2,3-dihydro-1H-imidazole-4-carboxylic acid ethyl ester (5.81 mmol) and chloroacetone (6.97 mmol) in EtOH (8.0 mL) is heated at reflux for 120 min. The solvents are removed in vacuo and POCl3 (87.1 mmol) is added. The mixture is stirred at RT for 16 h and at reflux for 4 h, concentrated in vacuo and diluted with chloroform. Ice water is added and the mixture is neutralized by addition of Na2CO3. The layers are separated and the aq. layer is extracted with chloroform. The combined organic layers are dried over Na2SO4 and concentrated in vacuo to give a crude product which is purified by CC (heptane/EtOAc 9/1 to heptane/EtOAc 3/7). LC-MS: tR=0.73 min; [M+H]+=211.0.
A mixture of 5-methyl-2-thioxo-2,3-dihydro-1H-imidazole-4-carboxylic acid ethyl ester (10.7 mmol) and 3-bromo-2-butanone (10.7 mmol) in EtOH (16 mL) is heated at reflux for 3 h. The solvents are removed in vacuo and POCl3 (161 mmol) is added. The mixture is stirred at reflux for 3 h, concentrated in vacuo and diluted with chloroform. Ice water is added and the mixture is neutralized by addition of Na2CO3. The layers are separated and the aq. layer is extracted with chloroform. The combined organic layers are dried over Na2SO4 and concentrated in vacuo to give a mixture of two regioisomers which are separated by CC (heptane/EtOAc 9/1 to EtOAc). 2,3,6-trimethyl-imidazo[2,1-b]thiazole-5-carboxylic acid ethyl ester is obtained as major isomer. LC-MS: tR=0.84 min; [M+H]+=239.0; 2,3,5-trimethyl-imidazo[2,1-b]thiazole-6-carboxylic acid ethyl ester is obtained as minor isomer. LC-MS: tR=0.76 min; [M+H]+=239.0.
A solution of sodium ethoxide (5.37 mmol) in ethanol (3.3 mL) is added to a solution of 5-methyl-2-thioxo-2,3-dihydro-1H-imidazole-4-carboxylic acid ethyl ester (5.37 mmol) in ethanol (7.0 mL). The respective alkyl bromide (5.37 mmol) is added and the mixture is stirred at reflux for 12 h. After cooling to RT the mixture is filtered and concentrated in vacuo to give the desired product which is used without further purification.
prepared by reaction of 5-methyl-2-thioxo-2,3-dihydro-1H-imidazole-4-carboxylic acid ethyl ester with bromoacetaldehyde diethyl acetal. LC-MS: tR=0.70 min; [M+H]+=303.4.
prepared by reaction of 5-methyl-2-thioxo-2,3-dihydro-1H-imidazole-4-carboxylic acid ethyl ester with 2-bromo-1,1-dimethoxy-propane. LC-MS: tR=0.67 min; [M+H]+=289.0.
A mixture of the respective 2-(2,2-dialkoxy-ethylsulfanyl)-5-methyl-1H-imidazole-4-carboxylic acid ethyl ester derivative (10.0 mmol) in hydrochloric acid (15%, 8.0 mL) is stirred for 1 h at RT and neutralized by addition of aq. Na2CO3 solution. The obtained precipitate is filtered off to give the desired product which is used without further purification.
prepared by cyclization of 2-(2,2-diethoxy-ethylsulfanyl)-5-methyl-1H-imidazole-4-carboxylic acid ethyl ester. LC-MS: tR=0.55 min; [M+H]+=229.3.
prepared by cyclization of 2-(2,2-Dimethoxy-1-methyl-ethylsulfanyl)-5-methyl-1H-imidazole-4-carboxylic acid ethyl ester. LC-MS: tR=0.60 min; [M+H]+=243.2.
The respective 3-hydroxy-2,3-dihydro-imidazo[2,1-b]thiazole-6-carboxylic acid ethyl ester derivative (4.00 mmol) is added to POCl3 (9.3 mL), stirred at reflux for 3 h (respectively 16 h) and concentrated in vacuo. Chloroform and ice-water are added successively and the mixture is neutralized by addition of Na2CO3. The layers are separated and the aq. layer is extracted with chloroform. The combined organic layers are dried over Na2SO4 and concentrated in vacuo to give the desired product which is purified by CC (heptane/EtOAc 1/1 to EtOAc).
prepared by dehydration of 3-hydroxy-5-methyl-2,3-dihydro-imidazo[2,1-b]thiazole-6-carboxylic acid ethyl ester. LC-MS: tR=0.66 min; [M+H]+=211.0.
prepared by dehydration of 3-hydroxy-2,5-dimethyl-2,3-dihydro-imidazo[2,1-b]thiazole-6-carboxylic acid ethyl ester. LC-MS: tR=0.72 min; [M+H]+=225.0.
N,N-Dimethylformamide dimethyl acetale (89.9 mmol, 2.0 eq) is added dropwise to a solution of the respective 2-aminothiazole (44.9 mmol, 1.0 eq) in toluene (30 mL). The mixture is heated at reflux for 22 h, cooled to RT and concentrated in vacuo. A small amount of hexane is added and the obtained precipitate is filtered off to give the respective formamidine derivative.
prepared by reaction of 2-aminothiazole with N,N-dimethylformamide dimethyl acetale. LC-MS: tR=0.40 min; [M+H]+=156.0.
prepared by reaction of 5-methyl-thiazol-2-ylamine with N,N-dimethylformamide dimethyl acetale. LC-MS: tR=0.52 min; [M+H]+=170.2.
prepared by reaction of 4-methyl-thiazol-2-ylamine with N,N-dimethylformamide dimethyl acetale. LC-MS: tR=0.51 min; [M+H]+=170.1.
prepared by reaction of 4,5-dimethyl-thiazol-2-ylamine with N,N-dimethylformamide dimethyl acetale. LC-MS: tR=0.56 min; [M+H]+=184.1.
The respective N,N-dimethyl-N′-thiazol-2-yl-formamidine derivative (45.1 mmol, 1.00 eq) is added portionwise to vigorously stirred ethyl bromoacetate (225 mmol, 5.0 eq). After 2 h toluene (12 mL) is added and the mixture is stirred for 24 h. The obtained precipitate is filtered off and the residue is recrystallized from MeCN to give the respective thiazolium bromide.
prepared by reaction of ethyl bromoacetate with N,N-dimethyl-N′-thiazol-2-yl-formamidine. LC-MS: tR=0.58 min; [M+H]+=242.1.
prepared by reaction of ethyl bromoacetate with N,N-dimethyl-N′-(5-methyl-thiazol-2-yl)-formamidine. LC-MS: tR=0.63 min; [M+H]+=256.2.
prepared by reaction of ethyl bromoacetate with N,N-dimethyl-N′-(4-methyl-thiazol-2-yl)-formamidine. LC-MS: tR=0.61 min; [M+H]+=256.0.
prepared by reaction of ethyl bromoacetate with N′-(4,5-dimethyl-thiazol-2-yl)-N,N-dimethyl-formamidine. LC-MS: tR=0.67 min; [M+H]+=270.1.
DBU (68.9 mmol, 1.58eq) is added to a suspension of the respective thiazolium bromide derivative (43.6 mmol, 1.00 eq) in DMF (50 mL). The solution is stirred for 24 h and diluted with ice-cold water. The obtained precipitate is filtered off to give the respective imidazo-thiazole derivative.
prepared by cyclisation of 2-(dimethylamino-methyleneamino)-3-ethoxycarbonyl-methyl-thiazol-3-ium bromide. LC-MS: tR=0.76 min; [M+H]+=197.0.
prepared by cyclisation of 2-(dimethylamino-methyleneamino)-3-ethoxycarbonyl-methyl-5-methyl-thiazol-3-ium bromide. LC-MS: tR=0.83 min; [M+H]+=211.0.
prepared by cyclisation of 2-(dimethylamino-methyleneamino)-3-ethoxycarbonyl-methyl-4-methyl-thiazol-3-ium bromide. LC-MS: tR=0.83 min; [M+H]+=211.0.
prepared by cyclisation of 2-(dimethylamino-methyleneamino)-3-ethoxycarbonylmethyl-4,5-dimethyl-thiazol-3-ium bromide. LC-MS: tR=0.88 min; [M+H]+=225.0.
An aq. NaOH solution (1.0M, 23 mL) is added to a solution of the respective carboxylic ester derivative (11.3 mmol) in THF (12 mL) and MeOH (4.0 mL). The mixture is stirred for 16 h, the organic volatiles are removed in vacuo and water (10 mL) is added. The mixture is cooled to 0° C. and made acidic (pH=3-4) by addition of hydrochloric acid (1.0 M). The obtained precipitate is filtered off, washed with cold water and dried in vacuo to give the desired acid which is used without further purification.
prepared by saponification of 3-methyl-imidazo[2,1-b]thiazole-2-carboxylic acid methyl ester. LC-MS: tR=0.24 min; [M+H]+=183.0.
prepared by saponification of 2,6-dimethyl-imidazo[2,1-b]thiazole-5-carboxylic acid ethyl ester. LC-MS: tR=0.55 min; [M+H]+=197.3.
prepared by saponification of 3,5-dimethyl-imidazo[2,1-b]thiazole-6-carboxylic acid ethyl ester. LC-MS: tR=0.50 min; [M+H]+=197.0.
prepared by saponification of 3,6-dimethyl-imidazo[2,1-b]thiazole-5-carboxylic acid ethyl ester. LC-MS: tR=0.51 min; [M+H]+=197.0.
prepared by saponification of 3-methyl-imidazo[2,1-b]thiazole-6-carboxylic acid ethyl ester. LC-MS: tR=0.46 min; [M+H]+=183.0.
prepared by saponification of 2,3,6-trimethyl-imidazo[2,1-b]thiazole-5-carboxylic acid ethyl ester. LC-MS: tR=0.56 min; [M+H]+=211.0.
prepared by saponification of 2,3,5-trimethyl-imidazo[2,1-b]thiazole-6-carboxylic acid ethyl ester. LC-MS: tR=0.57 min; [M+H]+=211.0.
prepared by saponification of 5-methyl-imidazo[2,1-b]thiazole-6-carboxylic acid ethyl ester. LC-MS: tR=0.39 min; [M+H]+=183.0.
prepared by saponification of 2,5-dimethyl-imidazo[2,1-b]thiazole-6-carboxylic acid ethyl ester. LC-MS: tR=0.51 min; [M+H]+=197.0.
prepared by saponification of imidazo[2,1-b]thiazole-5-carboxylic acid ethyl ester. LC-MS: tR=0.39 min; [M+H]+=169.0.
prepared by saponification of 2-methyl-imidazo[2,1-b]thiazole-5-carboxylic acid ethyl ester. LC-MS: tR=0.51 min; [M+H]+=183.0.
prepared by saponification of 3-methyl-imidazo[2,1-b]thiazole-5-carboxylic acid ethyl ester. LC-MS: tR=0.53 min; [M+H]+=183.0.
prepared by saponification of 2,3-Dimethyl-imidazo[2,1-b]thiazole-5-carboxylic acid ethyl ester. LC-MS: tR=0.59 min; [M+H]+=197.0
3-Bromo-1,1,1-trifluoroacetone (11.0 mmol) is added to a solution of 2-aminothiazole (10.0 mmol) in acetone (20 mL) and the mixture is stirred at reflux for 20 h. The obtained precipitate is filtered off, treated with hydrobromic acid (2.0 M, 40 mL), stirred at reflux for 1 h and cooled to RT. The mixture is made basic by addition of ammonium hydroxide solution (15%) and the resulting free base is crystallized from EtOH to give the desired product. LC-MS: tR=0.78 min; [M+H]+=192.95.
At 0° C. POCl3 (17.1 mmol) is added dropwise to a solution of DMF (20.6 mmol) in chloroform (5.0 mL). A solution of 6-trifluoromethyl-imidazo[2,1-b]thiazole (3.17 mmol) in chloroform (15 mL) is added dropwise at 0° C. and the mixture is stirred for 3 h at RT. After heating for 2.5 d to reflux the mixture is poured into ice, extracted three times with DCM, dried over MgSO4 and concentrated under reduced pressure. DCM is added, the obtained precipitate is filtered off and the filtrate is concentrated in vacuo to give a crude product which is dissolved in tert.-butanol (19.5 mL). A solution of sodium chlorite (23.0 mmol) and NaH2PO4 (17.6 mmol) in water (19.5 mL) is added dropwise and the mixture is stirred for 90 min at RT. The solvents are partially removed in vacuo and the obtained precipitate is filtered off to give the desired product as a white solid. LC-MS: tR=0.73 min; [M+H]+=237.2.
A solution of NaOCl (230 mmol) and NaH2PO4 (176 mmol) in water (195 mL) is added dropwise to a solution of 6-chloro-imidazo[2,1-b]thiazole-5-carbaldehyde (26.8 mmol) in tert.-butanol (195 mL) and the mixture is stirred for 8 h at RT. The solvents are partially removed in vacuo and the obtained precipitate is filtered off. The filtrate is made acidic and the obtained precipitate is filtered off to give the desired product as a white solid. LC-MS: tR=0.67 min; [M+H]+=202.9.
2-Methyl-benzofuran-4-carboxylic acid methyl ester (1.31 mmol, Ishikawa T. et al., Heterocycles, 1994, 39, 371-380) is added to a solution of NaOH (32.5 mmol) in MeOH (24.4 mL) and water (54.4 mL). The mixture is stirred at 55° C. for 16 h, partially concentrated in vacuo to remove MeOH and made acidic by addition of hydrochloric acid (1.0 M). The precipitate is filtered off and dried in vacuo to give the desired product. LC-MS: tR=0.84 min; [M+CH3CN+H]+=217.9.
A solution of methyl-3-hydroxybenzoate (32.2 mmol) and 3-chloro-2-butanone (32.2 mmol) in acetone (60 mL) is treated with K2CO3 (96.6 mmol) and KI (8.68 mmol) respectively and stirred at reflux for 16 h. After cooling to RT water and ether are added, the layers are separated and the aq. layer is extracted with ether. The combined organic layers are washed with NaOH solution (1.0 M) and water, dried over Na2SO4 and concentrated in vacuo to give the desired product. LC-MS: tR=0.89 min; [M+CH3CN+H]+=264.1.
Conc. sulfuric acid (3.92 mL, 96%) is added dropwise to 3-(1-methyl-2-oxo-propoxy)-benzoic acid under stirring to keep the temperature below 30° C. After 1 h the mixture is poured into ice-cold water and the obtained precipitate is filtered off and dissolved in ether. The mixture is extracted three times with a sat. NaHCO3 solution and the organic layer is dried over Na2SO4 and concentrated in vacuo to give a crude product which is purified by CC (heptane to heptane/EtOAc 9/1). LC-MS: tR=0.99 min; [M+H]+=205.1.
2,3-Dimethyl-benzofuran-4-carboxylic acid methyl ester (0.12 mmol) is added to a solution of NaOH (0.18 mmol) in MeOH (0.14 mL) and water (0.14 mL). The mixture is stirred at 55° C. for 3 h, partially concentrated in vacuo to remove MeOH and made acidic by addition of hydrochloric acid (1.0 M). The precipitate is filtered off and dried in vacuo to give the desired product. LC-MS: tR=0.86 min; [M+CH3CN+H]+=232.0.
DIPEA (249 mmol, 1.10 eq) and a solution of di-tert-butyl dicarbonate (238 mmol, 1.05 eq) in DCM (100 mL) are added successively to a suspension of 3-aza-bicyclo[3.1.0]hexane-2-carboxylic acid (226 mmol, 1.0 eq) in DCM (400 mL). The mixture is stirred for 22h and concentrated in vacuo to a volume of approximately 100 mL. EtOAc (200 mL) is added and the mixture is made acidic (pH 3) by addition of aq. citric acid solution. The layers are separated and the aq. layer is extracted three times with EtOAc (100 mL each). The combined organic layers are washed with brine, dried over MgSO4 and concentrated in vacuo to give the desired carboxylic acid as an viscous oil which is used without further purification. LC-MS: tR=0.75 min; [M+H]+=228.1.
To a solution of 3-aza-bicyclo[3.1.0]hexane-2,3-dicarboxylic acid 3-tert-butyl ester (226 mmol, 1.0 eq) in DMF (350 mL) is added Cs2CO3 (304 mmol, 1.35 eq). Methyl iodide (397 mmol, 1.75 eq) is added dropwise and the suspension is stirred for 60 min. The mixture is filtered and the filtrate is diluted with water (200 mL) and TBME (150 mL). The layers are separated and the aq. layer is extracted four times with TBME (150 mL each). The combined organic layers are washed three times with brine, dried over Na2SO4 and concentrated in vacuo to give the desired carboxylic ester as an oil which is used without further purification. LC-MS: tR=0.88 min; [M+H]+=242.1.
At −78° C. a solution of DIBAL in toluene (1.7M, 205 mmol, 2.6 eq) is added dropwise to a solution of 3-aza-bicyclo[3.1.0]hexane-2,3-dicarboxylic acid 3-tert-butyl ester 2-methyl ester (78.0 mmol, 1.0 eq) in THF (350 mL). After 20 min the solution is allowed to reach RT and poured into a mixture of aq. NaOH solution (1.0M, 400 mL) and ice. The layers are separated and the aq. layer is extracted three times with EtOAc (300 mL each). The combined organic layers are washed with aq. NaOH solution (1.0M) and brine, dried over Na2SO4 and concentrated in vacuo to give a crude oil which is purified by CC [gradient: heptane to heptane/EtOAc 1/1, Rf=0.12 (cy-hexane/EtOAc 4/1)]. After removal of the solvents the desired alcohol is obtained as a colorless oil. LC-MS: tR=0.83 min; [M+H]+=214.0.
Dess-Martin periodinane (47 mmol, 1.4 eq) is added to a solution of 2-hydroxymethyl-3-aza-bicyclo[3.1.0]hexane-3-carboxylic acid tert-butyl ester (34 mmol, 1.0 eq) in DCM (500 mL, saturated with water). Additional periodinane is added after 90 min (2.1 mmol), 210 min (4.9 mmol), and 15 h (3.7 mmol). After additional 2 h ether, sat. NaHCO3 solution and aq. Na2S2O3 solution are added, the layers are separated and the aq. layer is extracted twice with ether. The combined organic layers are washed with sat. NaHCO3 solution, dried over Na2SO4 and concentrated in vacuo to give a crude product which is purified by CC (pentane and pentane/ether 2/1). After removal of the solvents the desired aldehyde is obtained as a colourless oil. LC-MS: tR=0.87 min; [M+H]+=212.2.
Benzylamine (40 mmol, 1.3 eq) is added to a solution of 2-formyl-3-aza-bicyclo[3.1.0]hexane-3-carboxylic acid tert-butyl ester (31 mmol, 1.0 eq) in chloroform (62 mL). After 15 min the mixture is treated with sodium triacetoxyborohydride (38 mmol, 1.2 eq), stirred for additional 2 h and poured into a sat. aq. NaHCO3 solution. The layers are separated and the aq. layer is extracted twice with chloroform. The combined organic layers are washed with sat. NaHCO3 solution, dried over Na2SO4 and concentrated in vacuo to give a crude yellow oil which is dissolved in ether (100 mL). A mixture of hydrochloride acid (0.1M) and citric acid (5% in water) is added, the layers are separated and the aq. layer is extracted once with ether. The aq. layer is made basic by addition of solid NaHCO3 and extracted with ether. After removal of the solvents the desired benzylamine derivative is obtained as a colourless oil. LC-MS: tR=0.81 min; [M+H]+=303.2.
A solution of (1R*,2S*,5S*)-2-(benzylamino-methyl)-3-aza-bicyclo[3.1.0]hexane-3-carboxylic acid tert-butyl ester (36 mmol) in ethanol (65 mL) is treated with Pd/C (950 mg, 50% H2O) and stirred under a hydrogen atmosphere (1 bar) for 16 h. An additional amount of Pd/C (300 mg) is added and the mixture is stirred for further 16 h. After filtration through celite and removal of the solvents the desired (1R*,2S*,5S*)-2-aminomethyl-3-aza-bicyclo[3.1.0]hexane-3-carboxylic acid tert-butyl ester is obtained which is used without further purification. LC-MS: tR=0.65 min; [M+H]+=213.1.
To a solution of the respective carboxylic acid (3.2 mmol, 1.10 eq) in DMF (5.0 mL) is added successively DIPEA (8.8 mmol, 3.0 eq) and a solution of TBTU (3.7 mmol, 1.25 eq) in DMF (5.0 mL). The obtained mixture is added to a solution of (1R*,2S*,5S*)-2-aminomethyl-3-aza-bicyclo[3.1.0]hexane-3-carboxylic acid tert-butyl ester (2.9 mmol, 1.0 eq) in DMF (5.0 mL). After 10 min sat. aq. NaHCO3 solution and ether are added, the layers are separated and the organic layer is washed with sat. NaHCO3 solution, citric acid (5% in water) and water. After drying over Na2SO4 and removal of solvents in vacuo the desired amides are obtained which are used without further purification.
prepared by reaction of (1R*,2S*,5S*)-2-aminomethyl-3-aza-bicyclo[3.1.0]hexane-3-carboxylic acid tert-butyl ester with 4-fluorobenzoic acid. LC-MS: tR=0.99 min; [M+H]+=335.1.
prepared by reaction of (1R*,2S*,5S*)-2-aminomethyl-3-aza-bicyclo[3.1.0]hexane-3-carboxylic acid tert-butyl ester with benzofuran-4-carboxylic acid (M. A. Eissenstat et al. J. Med. Chem. 1995, 38, 3094-3105). LC-MS: tR=1.01 min; [M+H]+=357.1.
prepared by reaction of (1R*,2S*,5S*)-2-aminomethyl-3-aza-bicyclo[3.0]hexane-3-carboxylic acid tert-butyl ester with pyridine-2-carboxylic acid. LC-MS: tR=0.94 min; [M+H]+=318.1.
prepared by reaction of (1R*,2S*,5S*)-2-aminomethyl-3-aza-bicyclo[3.1.0]hexane-3-carboxylic acid tert-butyl ester with 6-methyl-imidazo[2,1-b]thiazole-5-carboxylic acid (A. Andreani et al. Eur. J. Med. Chem 1982, 17, 271-274). LC-MS: tR=0.87 min; [M+H]+=377.2.
prepared by reaction of (1R*,2S*,5S*)-2-aminomethyl-3-aza-bicyclo[3.1.0]hexane-3-carboxylic acid tert-butyl ester with 2,3-dihydro-benzo[1,4]dioxine-5-carboxylic acid. LC-MS: tR=0.98 min; [M+H]+=375.1.
prepared by reaction of (1R*,2S*,5S*)-2-aminomethyl-3-aza-bicyclo[3.1.0]hexane-3-carboxylic acid tert-butyl ester with imidazo[2,1-b]thiazole-6-carboxylic acid. LC-MS (basic): tR=0.81 min; [M+H]+=362.8.
A solution of the respective heterocyclyl halogenide (1.03 mmol, 1.1 eq) and of (1R*,2S*,5S*)-2-aminomethyl-3-aza-bicyclo[3.1.0]hexane-3-carboxylic acid tert-butyl ester (0.94 mmol, 1.0 eq) in EtOH (2.0 mL) is treated with NEt3 (1.17 mmol, 1.2 eq) and heated under microwave conditions (120° C., 200 W) for 10 min. The crude mixture is purified by prep. HPLC to give the respective products.
prepared by reaction of (1R*,2S*,5S*)-2-aminomethyl-3-aza-bicyclo[3.1.0]hexane-3-carboxylic acid tert-butyl ester with 5-bromo-2-chloro-pyrimidine. LC-MS: tR=1.03 min; [M+H]+=369.1.
Single crystals are obtained by crystallization from chloroform. The relative cis-configuration of the product has been demonstrated.
prepared by reaction of (1R*,2S*,5S*)-2-aminomethyl-3-aza-bicyclo[3.1.0]hexane-3-carboxylic acid tert-butyl ester with 2-chloro-6,7-difluoro-quinoxaline (S. Piras, M. Loriga, G. Paglietti Farmaco 2004, 59, 185-194). LC-MS: tR=1.05 min; [M+H]+=377.2.
A solution of HCl in dioxane (4.0 M, 4.0 mL) is added to a solution of the respective Boc-protected 3-aza-bicyclo[3.1.0]-hexane derivative (2.9 mmol) in isopropanol or dioxane (2.0 mL). After LC-MS indicated complete reaction (30 min to several hours) the mixture is concentrated in vacuo. The remaining residue is again dissolved in isopropanol (1.0 mL) and concentrated to dryness to give the respective deprotected product which is used without further purification.
prepared by deprotection of (1R*,2S*,5S*)-2-[(4-fluoro-benzoylamino)-methyl]-3-aza-bicyclo[3.1.0]hexane-3-carboxylic acid tert-butyl ester. LC-MS: tR=0.57 min; [M+H]+=235.1.
prepared by deprotection of (1R*,2S*,5S*)-2-{[(benzofuran-4-carbonyl)-amino]-methyl}-3-aza-bicyclo[3.1.0]hexane-3-carboxylic acid tert-butyl ester. LC-MS: tR=0.62 min; [M+H]+=257.1.
prepared by deprotection of (1R*,2S*,5S*)-2-{[(pyridine-2-carbonyl)-amino]-methyl}-3-aza-bicyclo[3.1.0]hexane-3-carboxylic acid tert-butyl ester. LC-MS: tR=0.50 min; [M+H]+=218.0.
prepared by deprotection of (1R*,2S*,5S*)-2-{[(6-methyl-imidazo[2,1-b]thiazole-5-carbonyl)-amino]-methyl}-3-aza-bicyclo[3.1.0]hexane-3-carboxylic acid tert-butyl ester. LC-MS: tR=0.62 min; [M+H]+=277.2.
prepared by deprotection of (1R*,2S*,5S*)-2-{[(2,3-dihydro-benzo[1,4]dioxine-5-carbonyl)-amino]-methyl}-3-aza-bicyclo[3.1.0]hexane-3-carboxylic acid tert-butyl ester. LC-MS: tR=0.60 min; [M+H]+=275.0.
prepared by deprotection of (1R*,2S*,5S*)-2-{[(imidazo[2,1-b]thiazole-6-carbonyl)-amino]-methyl}-3-aza-bicyclo[3.1.0]hexane-3-carboxylic acid tert-butyl ester. LC-MS (basic): tR=0.59 min; [M+H]+=263.1.
prepared by deprotection of (1R*,2S*,5S*)-2-[(5-bromo-pyrimidin-2-ylamino)-methyl]-3-aza-bicyclo[3.1.0]hexane-3-carboxylic acid tert-butyl ester. LC-MS: tR=0.58 min; [M+H]+=268.9.
prepared by deprotection of (1R*,2S*,5S*)-2-[(6,7-difluoro-quinoxalin-2-ylamino)-methyl]-3-aza-bicyclo[3.1.0]hexane-3-carboxylic acid tert-butyl ester. LC-MS: tR=0.68 min; [M+H]+=277.1.
To a solution of the respective carboxylic acid (1.37 mmol, 1.00 eq) and DIPEA (2.06 mmol, 1.50 eq) in DMF (2.0 mL) is added TBTU (1.47 mmol, 1.05 eq). The obtained mixture is treated with a solution of the respective (1R*,2S*,5S*)-3-aza-bicyclo[3.1.0]-hexane derivative (1.37 mmol, 1.00 eq) and DIPEA (2.06 mmol, 1.50 eq) in DMF (2.0 mL). After 40 min sat. water and TBME are added, the layers are separated and the organic layer is washed with water, hydrochloric acid (0.5 M), aq. NaOH solution (0.5 M) and brine. After drying over Na2SO4 and removal of solvents in vacuo the desired amides are obtained which are used without further purification.
prepared by reaction of 2,3-dihydro-benzo[1,4]dioxine-5-carboxylic acid [(1R*,2S*,5S*)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide with 2-bromo-4-methyl-benzoic acid. LC-MS: tR=0.89 min; [M+H]+=471.1.
prepared by reaction of 2,3-dihydro-benzo[1,4]dioxine-5-carboxylic acid [(1R*,2S*,5S*)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide with 2-bromo-5-methyl-benzoic acid. LC-MS: tR=0.89 min; [M+H]+=471.1.
prepared by reaction of 2,3-dihydro-benzo[1,4]dioxine-5-carboxylic acid [(1R*,2S*,5*)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide with 2-bromo-3-methyl-benzoic acid. LC-MS: tR=0.88 min; [M+H]+=471.1.
Ethyl trifluoroacetate (4.25 mmol, 1.36 eq) is added to a solution of (1R*,2S*,5S*)-2-aminomethyl-3-aza-bicyclo[3.1.0]hexane-3-carboxylic acid tert-butyl ester (3.12 mmol, 1.00 eq) in THF (10 mL). After 50 min the solvents are removed in vacuo to give the desired product which is used without further purification in the next step. LC-MS: tR=0.98 min; [M+H]+=309.1.
A solution of HCl in dioxane (4 M, 4.0 mL) is added to a solution of (1R*,2S*,5S*)-2-[(2,2,2-trifluoro-acetylamino)-methyl]-3-aza-bicyclo[3.1.0]hexane-3-carboxylic acid tert-butyl ester (3.11 mmol) in THF (4.0 mL) and the mixture is stirred for 5 min at RT and for 30 min at 45° C. The solvents are removed in vacuo and the obtained solid is washed once with a small volume of CHCl3 to give the desired product which is used without further purification in the next step. LC-MS: tR=0.63 min; [M+H]+=209.3.
A solution of the respective carboxylic acid (1.80 mmol, 1.1 eq), DIPEA (4.91 mmol, 3.0 eq) and TBTU (1.97 mmol, 1.2 eq) in DMF (10 mL) is added to a solution of N-[(1R*,2S*,5S*)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-2,2,2-trifluoro-acetamide (1.64 mmol, 1.0 eq) in DMF (4.0 mL). The mixture is stirred for 15-60 min and poured into a mixture of ice, hydrochloric acid (0.5 M) and TBME. The layers are separated and the aq. layer is extracted with TBME. The combined organic layers are washed twice with sat. aq. NaHCO3 solution and once with brine. The solvents arc removed in vacuo to give the desired product which is either used without further purification or purified by CC [gradient: DCM to DCM/MeOH 98/2].
prepared by reaction of N-[(1R*,2S*,5S*)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-2,2,2-trifluoro-acetamide with 2-methyl-5-m-tolyl-thiazole-4-carboxylic acid. LC-MS: tR=0.92 min; [M+H]+=424.1.
prepared by reaction of N-[(1R*,2S*,5S*)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-2,2,2-trifluoro-acetamide with 5-(3-chloro-phenyl)-2-methyl-thiazole-4-carboxylic acid. LC-MS (basic): tR=0.92 min; [M+H]+=444.2.
prepared by reaction of N-[(1R*,2S*,5S*)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-2,2,2-trifluoro-acetamide with 5-(3-fluoro-phenyl)-2-methyl-thiazole-4-carboxylic acid. LC-MS (basic): tR=0.90 min; [M+H]+=428.0.
prepared by reaction of N-[(1R*,2S*,5S*)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-2,2,2-trifluoro-acetamide with 2-amino-5-m-tolyl-thiazole-4-carboxylic acid. LC-MS (basic): tR=0.81 min; [M+H]+=425.2.
prepared by reaction of N-[(1R*,2S*,5S*)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-2,2,2-trifluoro-acetamide with 2-amino-5-(3-chloro-phenyl)-thiazole-4-carboxylic acid. LC-MS (basic): tR=0.83 min; [M+H]+=445.2.
prepared by reaction of N-[(1R*,2S*,5S*)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-2,2,2-trifluoro-acetamide with 2-bromo-4-methyl-benzoic acid. LC-MS (basic): tR=0.92 min; [M+H]+=404.9.
Procedure 1:
A solution of the respective 2,2,2-trifluoro-acetamide derivative (1.42 mmol) in THF (15 mL) is treated with an aq. NaOH solution (2.0 M, 5 mL). The mixture is stirred over night, diluted with MeOH (15 mL), and stirred for additional 16 h. Water and EtOAc are added, the layers are separated and the aq. layer is extracted twice with EtOAc. The solvents are removed in vacuo and the residue is purified by prep. HPLC to give the desired amine as a colourless oil.
Procedure 2:
A solution of the respective 2,2,2-trifluoro-acetamide derivative (7.65 mmol) in MeOH (25 mL) is treated with a sat. solution of K2CO3 in water (2-20 mL) and stirred at 60° C. for 6 h. The mixture is concentrated in vacuo, diluted with citric acid (5%) and washed with TBME. The aq. layer is made basic by addition of aq. NaOH solution (5.0 M) and extracted four times with DCM. The combined organic layers are dried over Na2SO4 and concentrated in vacuo to give a crude product which is either used without further purification or purified by prep. HPLC.
prepared by deprotection of 2,2,2-trifluoro-N-[(1R*,2S*,5S*)-3-(2-methyl-5-m-tolyl-thiazole4-carbonyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-acetamide. LC-MS: tR=0.79 min; [M+H]+=328.3.
prepared by deprotection of N-{(1R*,2S*,5S*)-3-[5-(3-chloro-phenyl)-2-methyl-thiazole-4-carbonyl]-3-aza-bicyclo[3.1.0]hex-2-ylmethyl}-2,2,2-trifluoro-acetamide. LC-MS (basic): tR=0.78 min; [M+H]+=348.3.
prepared by deprotection of N-{(1R*,2S*,5S*)-3-[5-(3-fluoro-phenyl)-2-methyl-thiazole-4-carbonyl]-3-aza-bicyclo[3.1.0]hex-2-ylmethyl}-2,2,2-trifluoro-acetamide. LC-MS (basic): tR=0.77 min; [M+H]+=332.2.
prepared by deprotection of N-[(1R*,2S*,5S*)-3-(2-amino-5-m-tolyl-thiazole-4-carbonyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-2,2,2-trifluoro-acetamide. LC-MS (basic): tR=0.69 min; [M+H]+=329.2.
prepared by deprotection of N-{(1R*,2S*,5S*)-3-[2-amino-5-(3-chloro-phenyl)-thiazole-4-carbonyl]-3-aza-bicyclo[3.1.0]hex-2-ylmethyl}-2,2,2-trifluoro-acetamide. LC-MS (basic): tR=0.70 min; [M+H]+=349.3.
prepared by deprotection of N-[(1R*,2S*,5S*)-3-(2-bromo-4-methyl-benzoyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-2,2,2-trifluoro-acetamide. LC-MS (basic): tR=0.88 min; [M+H]+=309.0.
NEt3 (7.30 mmol, 1.05 eq) and a solution of di-tert-butyl dicarbonate (7.09 mmol, 1.02 eq) in DCM (15 mL) are added successively to a solution of [(1R*,2S*,5S*)-2-Aminomethyl-3-aza-bicyclo[3.1.0]hex-3-yl]-(2-bromo-4-methyl-phenyl)-methanone (6.95 mmol, 1.0 eq) in DCM (10 mL). The mixture is stirred for 15 min and made acidic by addition of aq. citric acid solution (5%). The layers are separated and the organic layer is washed twice with aq. citric acid solution (5%), water and brine. After drying over Na2SO4 the mixture is concentrated in vacuo to give the desired product as a white solid which is used without further purification. LC-MS (basic): tR=0.96 min; [M+H]+=408.9.
A solution of [(1R*,2S*,5S*)-3-(2-bromo-4-methyl-benzoyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-carbamic acid tert-butyl ester (2.44 mmol) and 3-fluoro-phenylboronic acid (2.93 mmol) in a mixture of ethanol (7.0 mL) and toluene (7.0 mL) is prepared by gentle heating. An aq. Na2CO3 solution (2.0 M) is added and a flow of argon is bubbled through the mixture. After addition of Pd(PPh3)4 the mixture is heated to 75° C., stirred for 22 h and cooled to RT. Water (20 mL) is added and the mixture is extracted three times with EtOAc (20 mL each). The combined organic layers are washed three times with water and once with brine, dried over MgSO4 and concentrated in vacuo to give a crude product which is purified by CC (gradient: DCM to DCM/MeOH 98/2). LC-MS (basic): tR=1.00 min; [M+H]+=425.0.
A solution of HCl in dioxane (4.0 M, 7.2 mL) is added to a solution of [(1R*,2S*,5S*)-3-(3′-fluoro-5-methyl-biphenyl-2-carbonyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-carbamic acid tert-butyl ester (2.24 mmol) in dioxane (3.0 mL). After 1 h the mixture is concentrated in vacuo to give the desired deprotected product which is used without further purification. LC-MS (basic): tR=0.85 min; [M+H]+=325.1.
Phosphoroxychloride (183 mL, 2 mol) is heated at 90° C. and a mixture of commercially available 2-methyl-2-butennitrile (73 g, 0.9 mol) and DMF (154 mL, 2 mol) is added slowly while keeping the temperature at 100 to 110° C. The mixture is stirred at 110° C. for 15 h, cooled to RT and diluted with DCM (500 mL). The mixture is cooled at 0° C. and carefully quenched with water (500 mL). The layers are separated and the aq. layer is extracted with DCM (total of 800 mL). The combined organic extracts are dried (Na2SO4), filtered and evaporated. The residue is crystallised from cyclohexane to provide 6-chloro-3-formyl-5-methyl-pyridine as slightly yellow crystals; LC-MS: tR=0.76 min, [M+H]+=156.1.
A solution of 6-chloro-3-formyl-5-methyl-pyridine (10 g, 64 mmol) in formic acid (200 mL) is cooled to 0° C. and an aq. 50% wt solution of H2O2 in water (9.6 mL, 360 mmol) is added at this temperature. The mixture is stirred at 0° C. for 15 h, carefully diluted with water (200 mL) and extracted with DCM (8×100 mL). The combined organic extracts are washed with 1M aq. HCl (100 mL) (check for remaining peroxide), dried (MgSO4) and filtered. The residue is concentrated in vacuo to give 6-chloro-5-methyl-nicotinic acid; LC-MS: tR=0.72 min, [M+H]+=172.0.
A solution of 6-chloro-5-methyl-nicotinic acid (13.9 g, 80.8 mmol) in dry ethanol (200 mL) containing some drops of concentrated H2SO4 is stirred at reflux for 2 days. The solution is cooled to RT, the solvent evaporated, the residue dissolved in EtOAc (200 mL) and washed with a solution of sat. aq. Na2CO3 (2×80 mL), 1M aq. KHSO4 (2×80 mL) and brine (50 mL). The organic phase is dried over MgSO4, filtered and evaporated to give 6-chloro-5-methyl-nicotinic acid ethyl ester as a solid; LC-MS: tR=0.92 min; [M+H]+=200.1; 1H NMR (CDCl3) δ 1.43 (t, J=7.0 Hz, 3H), 2.46 (s, 3H), 4.43 (q, J=7.3 Hz, 2H), 8.16 (m, 1H), 8.84 (d, J=2.0 Hz, 1H).
2-chloro-6-methyl-isonicotinic acid ethyl ester is prepared in analogy to 6-chloro-5-methyl-nicotinic acid ethyl ester by esterification of 2-chloro-6-methyl-isonicotinic acid with ethanol; LC-MS: tR=0.92 min; [M+H]+=200.0;
To a solution of 6-chloro-5-methyl-nicotinic acid ethyl ester (4.98 g, 24.9 mmol), 2,4,6-tri-(2-methyl-propenyl)-cycloboroxane pyridine complex (5.74 g, 17.7 mmol, prepared in analogy to a procedure given by F. Kerins, D. F. O'Shea J. Org. Chem. 67 (2002) 4968-4971), and PPh3 (1.15 g, 4.4 mmol) in DME (60 mL), a solution of 2 M aq. K2CO3 (20 mL) is added. The mixture is degassed and flushed with N2 before Pd(PPh3)4 (460 mg, 0.4 mmol) is added. The mixture is stirred at 90° C. for 20 h before it is cooled to RT, diluted with EtOAc (150 mL) and washed with sat. aq. NaHCO3 (2×50 mL). The organic extract is dried over MgSO4, filtered and evaporated. The crude product is purified by FC (SiO2, heptane/EtOAc) to give 5-methyl-6-(2-methyl-propenyl)-nicotinic acid ethyl ester as an orange oil; LC-MS: tR=0.72 min, [M+H]+=220.2.
2-Methyl-6-(2-methyl-propenyl)-isonicotinic acid ethyl ester is prepared in analogy to 5-methyl-6-(2-methyl-propenyl)-nicotinic acid ethyl ester by Pd-catalyzed coupling of 2-chloro-6-methyl-isonicotinic acid ethyl ester with 2,4,6-tri-(2-methyl-propenyl)-cycloboroxane pyridine complex; LC-MS: tR=0.66 min, [M+H]+=220.4.
5-Methyl-6-(2-methyl-propenyl)-nicotinic acid ethyl ester (3.98 g, 18.2 mmol) is dissolved in THF (100 mL) and MeOH (100 mL), Pd/C (500 mg, 10% Pd) is added and the mixture is stirred under 1 atm H2 at RT for 15 h. The catalyst is filtered off and the filtrate is evaporated to give 6-isobutyl-5-methyl-nicotinic acid ethyl ester as a colourless oil; LC-MS: tR=0.75 min; [M+H]+=222.2; 1H NMR (CDCl3) δ 0.97 (d, J=6.8 Hz, 6H), 1.42 (t, J=7.3 Hz, 3H), 2.20 (hept, J=6.8 Hz, 1H), 2.38 (s, 3H), 2.75 (d, J=7.0 Hz, 2H), 4.41 (q, J=7.3 Hz, 2 H), 8.03 (d, J=1.8 Hz, 1H), 9.00 (d, J=2.0 Hz, 1H).
2-Isobutyl-6-methyl-isonicotinic acid ethyl ester is prepared in analogy to 6-isobutyl-5-methyl-nicotinic acid ethyl ester by hydrogenation of 2-methyl-6-(2-methyl-propenyl)-isonicotinic acid ethyl ester; LC-MS: tR=0.71 min; [M+H]+=222.1.
A solution of 6-isobutyl-5-methyl-nicotinic acid ethyl ester (3.75 g, 16.95 mmol) in 12.5% aq. HCl (50 mL) is stirred at 65° C. for 24 h before the solvent is evaporated. The residue is dried in vacuo to give 6-isobutyl-5-methyl-nicotinic acid as a white powder; LC-MS: tR=0.57 min, [M+H]+=194.3.
2-Isobutyl-6-methyl-isonicotinic acid is prepared in analogy to 6-isobutyl-5-methyl-nicotinic acid by saponification of 2-isobutyl-6-methyl-isonicotinic acid ethyl ester; LC-MS: tR=0.52 min; [M+H]+=194.1.
A solution of the respective sulfonyl chloride (0.03 mmol, 1.2 eq) in MeCN (0.20 mL) is added to a solution of the respective 3-aza-bicyclo[3.1.0]hexane derivative (0.025 mmol, 1.0 eq, hydrochloride salt) and DIPEA (0.06 mmol, 2.5 eq) in DMF (0.20 mL). The mixture is shaken over night and purified by prep. HPLC to give the respective sulfonamide derivatives.
prepared by reaction of benzofuran-4-carboxylic acid [(1R*,2S*,5S*)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide with biphenyl-2-sulfonyl chloride. LC-MS: tR=1.06 min; [M+H]+=473.2.
prepared by reaction of benzofuran-4-carboxylic acid [(1R*,2S*,5S*)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide with 2-trifluoromethoxy-benzenesulfonyl chloride. LC-MS: tR=1.04 min; [M+H]+=481.1.
prepared by reaction of 6-methyl-imidazo[2,1-b]thiazole-5-carboxylic acid [(1R*,2S*,5S*)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide with 2-trifluoromethoxy-benzenesulfonyl chloride. LC-MS: tR=0.87 min; [M+H]+=501.1.
prepared by reaction of 6-methyl-imidazo[2,1-b]thiazole-5-carboxylic acid [(1R*,2S*,5S*)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide with naphthalene-1-sulfonyl chloride. LC-MS: tR=0.87 min; [M+H]+=467.0.
To the respective carboxylic acid (0.030 mmol, 1.2 eq) is added successively DIPEA (0.075 mmol, 3.0 eq) and a solution of TBTU (0.030 mmol, 1.2 eq) in DMF (0.20 mL). The obtained mixture is added to a solution of the respective 3-aza-bicyclo[3.1.0]hexane derivative (0.025 mmol, 1.0 eq, free base or hydrochloride salt) in DMF (0.20 mL). The mixture is shaken over night and purified by prep. HPLC to give the respective amide derivatives.
prepared by reaction of N-[(1R*,2S*,5S*)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-4-fluoro-benzamide with 2-methyl-5-p-tolyl-thiazole-4-carboxylic acid. LC-MS: tR=1.00 min; [M+H]+=450.0.
prepared by reaction of N-[(1R*,2S*,5S*)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-4-fluoro-benzamide with 5-(4-ethyl-phenyl)-2-methyl-thiazole-4-carboxylic acid. LC-MS: tR=1.03 min; [M+H]+=464.2.
prepared by reaction of N-[(1R*,2S*,5S*)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-4-fluoro-benzamide with biphenyl-2-carboxylic acid. LC-MS: tR=1.02 min; [M+H]+=415.1.
prepared by reaction of N-[(1R*,2S*,5S*)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-4-fluoro-benzamide with 5-(3-fluoro-phenyl)-2-methyl-thiazole-4-carboxylic acid. LC-MS: tR=0.98 min; [M+H]+=454.1.
prepared by reaction of N-[(1R*,2S*,5S*)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-4-fluoro-benzamide with 2-methyl-5-(4-trifluoromethyl-phenyl)-thiazole-4-carboxylic acid. LC-MS: tR=1.03 min; [M+H]+=504.1.
prepared by reaction of N-[(1R*,2S*,5S*)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-4-fluoro-benzamide with 2-methyl-5-m-tolyl-thiazole-4-carboxylic acid. LC-MS: tR=1.00 min; [M+H]+=450.1.
prepared by reaction of benzofuran-4-carboxylic acid [(1R*,2S*,5S*)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide with biphenyl-2-carboxylic acid. LC-MS: tR=1.04 min; [M+H]+=437.1.
prepared by reaction of benzofuran-4-carboxylic acid [(1R*,2S*,5S*)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide with 2-methyl-5-m-tolyl-thiazole-4-carboxylic acid. LC-MS: tR=1.02 min; [M+H]+=472.1.
prepared by reaction of benzofuran-4-carboxylic acid [(1R*,2S*,5S*)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide with 5-(4-fluoro-phenyl)-2-methyl-thiazole-4-carboxylic acid. LC-MS: tR=0.99 min; [M+H]+=476.1.
prepared by reaction of benzofuran-4-carboxylic acid [(1R*,2S*,5S*)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide with 5-(3-fluoro-phenyl)-2-methyl-thiazole-4-carboxylic acid. LC-MS: tR=1.00 min; [M+H]+=476.1.
prepared by reaction of benzofuran-4-carboxylic acid [(1R*,2S*,5S*)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide with 2-methyl-5-p-tolyl-thiazole-4-carboxylic acid. LC-MS: tR=1.02 min; [M+H]+=472.2.
prepared by reaction of benzofuran-4-carboxylic acid [(1R*,2S*,5S*)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide with 5-(4-ethyl-phenyl)-2-methyl-thiazole-4-carboxylic acid. LC-MS: tR=1.05 min; [M+H]+=486.2.
prepared by reaction of pyridine-2-carboxylic acid [(1R*,2S*,5S*)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide with 2-methyl-5-m-tolyl-thiazole-4-carboxylic acid. LC-MS: tR=0.96 min; [M+H]+=433.1.
prepared by reaction of benzofuran-4-carboxylic acid [(1R*,2S*,5S*)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide with 5-(2-fluoro-phenyl)-2-methyl-thiazole-4-carboxylic acid. LC-MS: tR=0.91 min; [M+H]+=476.1.
prepared by reaction of benzofuran-4-carboxylic acid [(1R*,2S*,5S*)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide with 5-(2-chloro-phenyl)-2-methyl-thiazole-4-carboxylic acid. LC-MS: tR=0.94 min; [M+H]+=492.0.
prepared by reaction of benzofuran-4-carboxylic acid [(1R*,2S*,5S*)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide with 5-(3-chloro-phenyl)-2-methyl-thiazole-4-carboxylic acid. LC-MS: tR=0.94 min; [M+H]+=492.0.
prepared by reaction of benzofuran-4-carboxylic acid [(1R*,2S*,5S*)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide with 5-(2-methoxy-phenyl)-2-methyl-thiazole-4-carboxylic acid. LC-MS: tR=0.90 min; [M+H]+=488.1.
prepared by reaction of benzofuran-4-carboxylic acid [(1R*,2S*,5S*)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide with 5-(3-methoxy-phenyl)-2-methyl-thiazole-4-carboxylic acid. LC-MS: tR=0.90 min; [M+H]+=488.2.
prepared by reaction of benzofuran-4-carboxylic acid [(1R*,2S*,5S*)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide with 2-methyl-5-(3-trifluoromethyl-phenyl)-thiazole-4-carboxylic acid. LC-MS: tR=0.95 min; [M+H]+=526.1.
prepared by reaction of benzofuran-4-carboxylic acid [(1R*,2S*,5S*)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide with 2-methyl-5-(2-trifluoromethyl-phenyl)-thiazole-4-carboxylic acid. LC-MS: tR=0.97 min; [M+H]+=526.1.
prepared by reaction of benzofuran-4-carboxylic acid [(1R*,2S*,5S*)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide with 2-methyl-5-o-tolyl-thiazole-4-carboxylic acid. LC-MS: tR=0.93 min; [M+H]+=472.2.
prepared by reaction of benzofuran-4-carboxylic acid [(1R*,2S*,5S*)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide with 5-(3,4-dimethyl-phenyl)-2-methyl-thiazole-4-carboxylic acid. LC-MS: tR=0.97 min; [M+H]+=486.2.
prepared by reaction of benzofuran-4-carboxylic acid [(1R*,2S*,5S*)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide with 2-amino-5-m-tolyl-thiazole-4-carboxylic acid. LC-MS: tR=0.85 min; [M+H]+=473.1.
prepared by reaction of benzofuran-4-carboxylic acid [(1R*,2S*,5S*)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide with 2-amino-5-(3-fluoro-phenyl)-thiazole-4-carboxylic acid. LC-MS: tR=0.84 min; [M+H]+=477.1.
prepared by reaction of benzofuran-4-carboxylic acid [(1R*,2S*,5S*)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide with 2-methyl-4-phenyl-pyrimidine-5-carboxylic acid. LC-MS: tR=0.84 min; [M+H]+=453.2.
prepared by reaction of benzofuran-4-carboxylic acid [(1R*,2S*,5S*)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide with 2-(2-amino-thiazol-4-yl)-benzoic acid. LC-MS: tR=0.82 min; [M+H]+=458.9.
prepared by reaction of benzofuran-4-carboxylic acid [(1R*,2S*,5S*)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide with 9H-fluorene-4-carboxylic acid. LC-MS: tR=0.96 min; [M+H]+=449.1.
prepared by reaction of benzofuran-4-carboxylic acid [(1R*,2S*,5S*)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide with 3-phenyl-pyrazine-2-carboxylic acid. LC-MS: tR=0.84 min; [M+H]+=439.1.
prepared by reaction of benzofuran-4-carboxylic acid [(1R*,2S*,5S*)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide with 5-(4-methoxy-phenyl)-oxazole-4-carboxylic acid. LC-MS: tR=0.87 min; [M+H]+=457.8.
prepared by reaction of benzofuran-4-carboxylic acid [(1R*,2S*,5S*)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide with 2-pyrazol-1-yl-benzoic acid. LC-MS: tR=0.84 min; [M+H]+=426.9.
prepared by reaction of benzofuran-4-carboxylic acid [(1R*,2S*,5S*)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide with 2-phenyl-2H-pyrazole-3-carboxylic acid. LC-MS: tR=0.85 min; [M+H]+=427.0.
prepared by reaction of benzofuran-4-carboxylic acid [(1R*,2S*,5S*)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide with 2-methyl-3-phenyl-quinoline-4-carboxylic acid. LC-MS: tR=0.92 min; [M+H]+=502.2.
prepared by reaction of benzofuran-4-carboxylic acid [(1R*,2S*,5S*)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide with 5-phenyl-2H-[1,2,3]triazole-4-carboxylic acid. LC-MS: tR=0.61 min; [M+H]+=428.1.
prepared by reaction of benzofuran-4-carboxylic acid [(1R*,2S*,5S*)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide with 2′-fluoro-biphenyl-2-carboxylic acid. LC-MS: tR=0.94 min; [M+H]+=455.1.
prepared by reaction of benzofuran-4-carboxylic acid [(1R*,2S*,5S*)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide with 4′-fluoro-biphenyl-2-carboxylic acid. LC-MS: tR=0.95 min; [M+H]+=455.1.
prepared by reaction of benzofuran-4-carboxylic acid [(1R*,2S*,5S*)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide with 2′-chloro-biphenyl-2-carboxylic acid. LC-MS: tR=0.97 min; [M+H]+=471.1.
prepared by reaction of benzofuran-4-carboxylic acid [(1R*,2S*,5S*)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide with 3′-chloro-biphenyl-2-carboxylic acid. LC-MS: tR=0.98 min; [M+H]+=471.1.
prepared by reaction of benzofuran-4-carboxylic acid [(1R*,2S*,5S*)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide with 4′-chloro-biphenyl-2-carboxylic acid. LC-MS: tR=0.98 min; [M+H]+=471.1.
prepared by reaction of benzofuran-4-carboxylic acid [(1R*,2S*,5S*)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide with 4′-methyl-biphenyl-2-carboxylic acid. LC-MS: tR=0.98 min; [M+H]+=451.2.
prepared by reaction of benzofuran-4-carboxylic acid [(1R*,2S*,5S*)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide with 3′-methyl-biphenyl-2-carboxylic acid. LC-MS: tR=0.98 min; [M+H]+=451.2.
prepared by reaction of benzofuran-4-carboxylic acid [(1R*,2S*,5S*)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide with 3′-methoxy-biphenyl-2-carboxylic acid. LC-MS: tR=0.95 min; [M+H]+=467.2.
prepared by reaction of benzofuran-4-carboxylic acid [(1R*,2S*,5S*)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide with 4′-methoxy-biphenyl-2-carboxylic acid. LC-MS: tR=0.95 min; [M+H]+=467.2.
prepared by reaction of benzofuran-4-carboxylic acid [(1R*,2S*,5S*)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide with 2′-methoxy-biphenyl-2-carboxylic acid. LC-MS: tR=0.94 min; [M+H]+=467.2.
prepared by reaction of benzofuran-4-carboxylic acid [(1R*,2S*,5S*)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide with 3′-trifluoromethyl-biphenyl-2-carboxylic acid. LC-MS: tR=0.99 min; [M+H]+=505.2.
prepared by reaction of benzofuran-4-carboxylic acid [(1R*,2S*,5S*)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide with 4′-trifluoromethyl-biphenyl-2-carboxylic acid. LC-MS: tR=0.99 min; [M+H]+=505.2.
prepared by reaction of benzofuran-4-carboxylic acid [(1R*,2S*,5S*)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide with 3′,4′-dimethyl-biphenyl-2-carboxylic acid. LC-MS: tR=1.01 min; [M+H]+=465.3.
prepared by reaction of benzofuran-4-carboxylic acid [3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide with 2-pyridin-3-yl-benzoic acid. LC-MS: tR=0.82 min; [M+H]+=438.2.
prepared by reaction of 6-methyl-imidazo[2,1-b]thiazole-5-carboxylic acid [(1R*,2S*,5S*)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide with 2-methyl-5-p-tolyl-thiazole-4-carboxylic acid. LC-MS: tR=0.87 min; [M+H]+=492.2.
prepared by reaction of 6-methyl-imidazo[2,1-b]thiazole-5-carboxylic acid [(1R*,2S*,5S*)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide with 2-methyl-5-m-tolyl-thiazole-4-carboxylic acid. LC-MS: tR=0.86 min; [M+H]+=492.1.
prepared by reaction of 6-methyl-imidazo[2,1-b]thiazole-5-carboxylic acid [(1R*,2S*,5S*)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide with 5-(3-fluoro-phenyl)-2-methyl-thiazole-4-carboxylic acid. LC-MS: tR=0.84 min; [M+H]+=496.1.
prepared by reaction of 6-methyl-imidazo[2,1-b]thiazole-5-carboxylic acid [(1R*,2S*,5S*)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide with 5-(4-ethyl-phenyl)-2-methyl-thiazole-4-carboxylic acid. LC-MS: tR=0.91 min; [M+H]+=506.0.
prepared by reaction of 6-methyl-imidazo[2,1-b]thiazole-5-carboxylic acid [(1R*,2S*,5S*)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide with 5-(4-fluoro-phenyl)-2-methyl-thiazole-4-carboxylic acid. LC-MS: tR=0.83 min; [M+H]+=496.1.
prepared by reaction of 6-methyl-imidazo[2,1-b]thiazole-5-carboxylic acid [(1R*,2S*,5S*)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide with biphenyl-2-carboxylic acid. LC-MS: tR=0.88 min; [M+H]+=457.0.
prepared by reaction of 6-methyl-imidazo[2,1-b]thiazole-5-carboxylic acid [(1R*,2S*,5S*)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide with 3-trifluoromethyl-benzoic acid. LC-MS: tR=0.85 min; [M+H]+=449.1.
prepared by reaction of (1R*,2S*,5S*)-(3-aza-bicyclo[3.1.0]hex-2-ylmethyl)-(6,7-difluoro-quinoxalin-2-yl)-amine with 2-methyl-5-m-tolyl-thiazole-4-carboxylic acid. LC-MS: tR=1.00 min; [M+H]+=492.1.
prepared by reaction of (1R*,2S*,5S*)-(3-aza-bicyclo[3.1.0]hex-2-ylmethyl)-(6,7-difluoro-quinoxalin-2-yl)-amine with 5-(4-fluoro-phenyl)-2-methyl-thiazole-4-carboxylic acid. LC-MS: tR=0.96 min; [M+H]+=496.1.
prepared by reaction of (1R*,2S*,5S*)-(3-aza-bicyclo[3.1.0]hex-2-ylmethyl)-(6,7-difluoro-quinoxalin-2-yl)-amine with biphenyl-2-carboxylic acid. LC-MS: tR=1.01 min; [M+H]+=457.0.
prepared by reaction of (1R*,2S*,5S*)-(3-aza-bicyclo[3.1.0]hex-2-ylmethyl)-(6,7-difluoro-quinoxalin-2-yl)-amine with naphthalene-1-carboxylic acid. LC-MS: tR=0.97 min; [M+H]+=431.1.
prepared by reaction of (1R*,2S*,5S*)-(3-aza-bicyclo[3.1.0]hex-2-ylmethyl)-(5-bromo-pyrimidin-2-yl)-amine with 2-methyl-5-m-tolyl-thiazole-4-carboxylic acid. LC-MS: tR=0.97 min; [M+H]+=484.0.
prepared by reaction of (1R*,2S*,5S*)-(3-aza-bicyclo[3.1.0]hex-2-ylmethyl)-(5-bromo-pyrimidin-2-yl)-amine with biphenyl-2-carboxylic acid. LC-MS: tR=0.99 min; [M+H]+=449.1.
To a solution of the respective carboxylic acid (0.030 mmol, 1.8 eq) in DMF (0.25 mL) is added successively a solution of DIPEA (0.075 mmol, 4.4 eq) in DMF (0.15 mL) and a solution of TBTU (0.030 mmol, 1.8 eq) in DMF (0.15 mL). The obtained mixture is treated with a solution of the respective 3-aza-bicyclo[3.1.0]hexane derivative (0.017 mmol, 1.0 eq, free base) in DMF (0.15 mL). The mixture is shaken over night and purified by prep. HPLC to give the respective amide derivatives.
prepared by reaction of [(1R*,2S*,5S*)-2-aminomethyl-3-aza-bicyclo[3.1.0]hex-3-yl]-(2-methyl-5-m-tolyl-thiazol-4-yl)-methanone with imidazo[2,1-b]thiazole-6-carboxylic acid. LC-MS: tR=0.84 min; [M+H]+=478.1.
prepared by reaction of [(1R*,2S*,5S*)-2-aminomethyl-3-aza-bicyclo[3.1.0]hex-3-yl]-(2-methyl-5-m-tolyl-thiazol-4-yl)-methanone with 3-furan-2-yl-acrylic acid. LC-MS: tR=0.88 min; [M+H]+=448.2.
prepared by reaction of [(1R*,2S*,5S*)-2-aminomethyl-3-aza-bicyclo[3.1.0]hex-3-yl]-(2-methyl-5-m-tolyl-thiazol-4-yl)-methanone with naphthalene-2-carboxylic acid. LC-MS: tR=0.97 min; [M+H]+=482.2.
prepared by reaction of [(1R*,2S*,5S*)-2-aminomethyl-3-aza-bicyclo[3.1.0]hex-3-yl]-(2-methyl-5-m-tolyl-thiazol-4-yl)-methanone with naphthalene-1-carboxylic acid. LC-MS: tR=0.95 min; [M+H]+=482.2.
prepared by reaction of [(1R*,2S*,5S*)-2-aminomethyl-3-aza-bicyclo[3.1.0]hex-3-yl]-(2-methyl-5-m-tolyl-thiazol-4-yl)-methanone with 2,3-dihydro-benzofuran-7-carboxylic acid. LC-MS: tR=0.92 min; [M+H]+=474.2.
prepared by reaction of [(1R*,2S*,5S*)-2-aminomethyl-3-aza-bicyclo[3.1.0]hex-3-yl]-(2-methyl-5-m-tolyl-thiazol-4-yl)-methanone with 2-methyl-thiazole4-carboxylic acid. LC-MS: tR=0.88 min; [M+H]+=453.1.
prepared by reaction of [(1R*,2S*,5S*)-2-aminomethyl-3-aza-bicyclo[3.1.0]hex-3-yl]-(2-methyl-5-m-tolyl-thiazol-4-yl)-methanone with 1H-indole-5-carboxylic acid. LC-MS: tR=0.87 min; [M+H]+=471.2.
prepared by reaction of [(1R*,2S*,5S )-2-aminomethyl-3-aza-bicyclo[3.1.0]hex-3-yl]-(2-methyl-5-m-tolyl-thiazol-4-yl)-methanone with 3-hydroxy-benzoic acid. LC-MS: tR=0.78 min; [M+H]+=448.1.
prepared by reaction of [(1R*,2S*,5S*)-2-aminomethyl-3-aza-bicyclo[3.1.0]hex-3-yl]-(2-methyl-5-m-tolyl-thiazol-4-yl)-methanone with 2-hydroxy-benzoic acid. LC-MS: tR=0.73 min; [M+H]+=448.2.
prepared by reaction of [(1R*,2S*,5S*)-2-aminomethyl-3-aza-bicyclo[3.1.0]hex-3-yl]-(2-methyl-5-m-tolyl-thiazol-4-yl)-methanone with 2-bromo-4-methyl-thiazole-5-carboxylic acid. LC-MS: tR=0.96 min; [M+H]+=531.0.
prepared by reaction of [(1R*,2S*,5S*)-2-aminomethyl-3-aza-bicyclo[3.1.0]hex-3-yl]-(2-methyl-5-m-tolyl-thiazol-4-yl)-methanone with furan-3-carboxylic acid. LC-MS: tR=0.85 min; [M+H]+=422.2.
prepared by reaction of [(1R*,2S*,5S*)-2-aminomethyl-3-aza-bicyclo[3.1.0]hex-3-yl]-(2-methyl-5-m-tolyl-thiazol-4-yl)-methanone with (naphthalen-2-yloxy)-acetic acid. LC-MS: tR=0.98 min; [M+H]+=512.2.
prepared by reaction of [(1R*,2S*,5S*)-2-aminomethyl-3-aza-bicyclo[3.1.0]hex-3-yl]-(2-methyl-5-m-tolyl-thiazol-4-yl)-methanone with 3,5-dimethyl-isoxazole-4-carboxylic acid. LC-MS: tR=0.88 min; [M+H]+=451.2.
prepared by reaction of [(1R*,2S*,5S*)-2-aminomethyl-3-aza-bicyclo[3.1.0]hex-3-yl]-(2-methyl-5-m-tolyl-thiazol-4-yl)-methanone with 4-oxo-4H-chromene-2-carboxylic acid. LC-MS: tR=0.90 min; [M+H]+=500.2.
prepared by reaction of [(1R*,2S*,5S*)-2-aminomethyl-3-aza-bicyclo[3.1.0]hex-3-yl]-(2-methyl-5-m-tolyl-thiazol-4-yl)-methanone with 3,5-dimethoxy-benzoic acid. LC-MS: tR=0.92 min; [M+H]+=492.1.
prepared by reaction of [(1R*,2S*,5S*)-2-aminomethyl-3-aza-bicyclo[3.1.0]hex-3-yl]-(2-methyl-5-m-tolyl-thiazol-4-yl)-methanone with benzo[1,3]dioxole-5-carboxylic acid. LC-MS: tR=0.89 min; [M+H]+=476.2.
prepared by reaction of [(1R*,2S*,5S*)-2-aminomethyl-3-aza-bicyclo[3.1.0]hex-3-yl]-(2-methyl-5-m-tolyl-thiazol-4-yl)-methanone with 2,4-dimethoxy-benzoic acid. LC-MS: tR=0.92 min; [M+H]+=492.2.
prepared by reaction of [(1R*,2S*,5S*)-2-aminomethyl-3-aza-bicyclo[3.1.0]hex-3-yl]-(2-methyl-5-m-tolyl-thiazol-4-yl)-methanone with 2,4-dimethyl-thiazole-5-carboxylic acid. LC-MS: tR=0.86 min; [M+H]+=467.2.
prepared by reaction of [(1R*,2S*,5S*)-2-aminomethyl-3-aza-bicyclo[3.1.0]hex-3-yl]-(2-methyl-5-m-tolyl-thiazol-4-yl)-methanone with 1-methyl-1H-indole-2-carboxylic acid. LC-MS: tR=0.98 min; [M+H]+=485.2.
prepared by reaction of [(1R*,2S*,5S*)-2-aminomethyl-3-aza-bicyclo[3.1.0]hex-3-yl]-(2-methyl-5-m-tolyl-thiazol-4-yl)-methanone with 3H-benzoimidazole-5-carboxylic acid. LC-MS: tR=0.78 min; [M+H]+=472.2.
prepared by reaction of [(1R*,2S*,5S*)-2-aminomethyl-3-aza-bicyclo[3.1.0]hex-3-yl]-(2-methyl-5-m-tolyl-thiazol-4-yl)-methanone with (2-methoxy-phenoxy)-acetic acid. LC-MS: tR=0.91 min; [M+H]+=492.1.
prepared by reaction of [(1R*,2S*,5S*)-2-aminomethyl-3-aza-bicyclo[3.1.0]hex-3-yl]-(2-methyl-5-m-tolyl-thiazol-4-yl)-methanone with benzo[2,1,3]oxadiazole-5-carboxylic acid. LC-MS: tR=0.93 min; [M+H]+=474.2.
prepared by reaction of [(1R*,2S*,5S*)-2-aminomethyl-3-aza-bicyclo[3.1.0]hex-3-yl]-(2-methyl-5-m-tolyl-thiazol-4-yl)-methanone with 2,3-dihydro-benzo[1,4]dioxine-5-carboxylic acid. LC-MS: tR=0.91 min; [M+H]+=489.8.
prepared by reaction of [(1R*,2S*,5S*)-2-aminomethyl-3-aza-bicyclo[3.1.0]hex-3-yl]-(2-methyl-5-m-tolyl-thiazol4-yl)-methanone with [1,6]naphthyridine-2-carboxylic acid. LC-MS: tR=0.86 min; [M+H]+=484.2.
prepared by reaction of [(1R*,2S*,5S*)-2-aminomethyl-3-aza-bicyclo[3.1.0]hex-3-yl]-(2-methyl-5-m-tolyl-thiazol-4-yl)-methanone with (3-methoxy-phenoxy)-acetic acid. LC-MS: tR=0.92 min; [M+H]+=492.2.
prepared by reaction of [(1R*,2S*,5S*)-2-aminomethyl-3-aza-bicyclo[3.1.0]hex-3-yl]-(2-methyl-5-m-tolyl-thiazol-4-yl)-methanone with (2,5-dimethyl-thiazol-4-yl)-acetic acid. LC-MS: tR=0.86 min; [M+H]+=481.2.
prepared by reaction of [(1R*,2S*,5S*)-2-aminomethyl-3-aza-bicyclo[3.1.0]hex-3-yl]-(2-methyl-5-m-tolyl-thiazol-4-yl)-methanone with 5 -chloro-1,3-dimethyl-1H-pyrazole-4-carboxylic acid. LC-MS: tR=0.86 min; [M+H]+=484.2.
prepared by reaction of [(1R*,2S*,5S*)-2-aminomethyl-3-aza-bicyclo[3.1.0]hex-3-yl]-(2-methyl-5-m-tolyl-thiazol4-yl)-methanone with benzo[b]thiophene-2-carboxylic acid. LC-MS: tR=0.98 min; [M+H]+=488.2.
prepared by reaction of [(1R*,2S*,5S*)-2-aminomethyl-3-aza-bicyclo[3.1.0]hex-3-yl]-(2-methyl-5-m-tolyl-thiazol-4-yl)-methanone with 5-tert-butyl-2-methyl-2H-pyrazole-3-carboxylic acid. LC-MS: tR=0.97 min; [M+H]+=492.2.
prepared by reaction of [(1R*,2S*,5S*)-2-aminomethyl-3-aza-bicyclo[3.1.0]hex-3-yl]-(2-methyl-5-m-tolyl-thiazol-4-yl)-methanone with 1-methyl-1H-indazole-3-carboxylic acid. LC-MS: tR=0.93 min; [M+H]+=486.2.
prepared by reaction of [(1R*,2S*,5S*)-2-aminomethyl-3-aza-bicyclo[3.1.0]hex-3-yl]-(2-methyl-5-m-tolyl-thiazol-4-yl)-methanone with pyrazolo[1,5-a]pyrimidine-3-carboxylic acid. LC-MS: tR=0.81 min; [M+H]+=473.2.
prepared by reaction of [(1R*,2S*,5S*)-2-aminomethyl-3-aza-bicyclo[3.1.0]hex-3-yl]-(2-methyl-5-m-tolyl-thiazol-4-yl)-methanone with quinoxaline-2-carboxylic acid. LC-MS: tR=0.93 min; [M+H]+=484.2.
prepared by reaction of [(1R*,2S*,5S*)-2-aminomethyl-3-aza-bicyclo[3.1.0]hex-3-yl]-(2-methyl-5-m-tolyl-thiazol-4-yl)-methanone with 1-methyl-1H-pyrrole-2-carboxylic acid. LC-MS: tR=0.90 min; [M+H]+=435.2.
prepared by reaction of [(1R*,2S*,5S*)-2-aminomethyl-3-aza-bicyclo[3.1.0]hex-3-yl]-(2-methyl-5-m-tolyl-thiazol-4-yl)-methanone with 2,8-dimethyl-imidazo[1,2-a]pyridine-3-carboxylic acid. LC-MS: tR=0.88 min; [M+H]+=500.2.
prepared by reaction of [(1R*,2S*,5S*)-2-aminomethyl-3-aza-bicyclo[3.1.0]hex-3-yl]-(2-methyl-5-m-tolyl-thiazol-4-yl)-methanone with 2,6-dimethyl-imidazo[1,2-a]pyridine-3-carboxylic acid. LC-MS: tR=0.88 min; [M+H]+=500.2.
prepared by reaction of [(1R*,2S*,5S*)-2-aminomethyl-3-aza-bicyclo[3.1.0]hex-3-yl]-(2-methyl-5-m-tolyl-thiazol-4-yl)-methanone with 6-isobutyl-5-methyl-nicotinic acid. LC-MS: tR=0.95 min; [M+H]+=503.3.
prepared by reaction of [(1R*,2S*,5S*)-2-aminomethyl-3-aza-bicyclo[3.1.0]hex-3-yl]-(2-methyl-5-m-tolyl-thiazol-4-yl)-methanone with 2-isobutyl-6-methyl-isonicotinic acid. LC-MS: tR=0.95 min; [M+H]+=503.3.
prepared by reaction of [(1R*,2S*,5S*)-2-aminomethyl-3-aza-bicyclo[3.1.0]hex-3-yl]-(2-methyl-5-m-tolyl-thiazol-4-yl)-methanone with benzo[c]isoxazole-3-carboxylic acid. LC-MS: tR=0.94 min; [M+H]+=473.2.
prepared by reaction of [(1R*,2S*,5S*)-2-aminomethyl-3-aza-bicyclo[3.1.0]hex-3-yl]-(2-methyl-5-m-tolyl-thiazol-4-yl)-methanone with pyrazolo[1,5-a]pyridine-3-carboxylic acid. LC-MS: tR=0.85 min; [M+H]+=472.2.
prepared by reaction of [(1R*,2S*,5S*)-2-aminomethyl-3-aza-bicyclo[3.1.0]hex-3-yl]-(2-methyl-5-m-tolyl-thiazol4-yl)-methanone with 4-methoxy-benzoic acid. LC-MS: tR=0.90 min; [M+H]+=462.2.
The following examples are prepared in analogy by coupling of the respective 3-aza-bicyclo[3.1.0]hexane derivative with the respective carboxylic acid derivative.
Starting from [(1R*,2S*,5S*)-2-aminomethyl-3-aza-bicyclo[3.1.0]hex-3-yl]-(2-methyl-5-m-tolyl-thiazol-4-yl)-methanone:
Starting from [(1R*,2S*,5S*)-(2-aminomethyl-3-aza-bicyclo[3.1.0]hex-3-yl)]-[5-(3-chloro-phenyl)-2-methyl-thiazol4-yl]-methanone:
Starting from [(1R*,2S*,5S*)-(2-aminomethyl-3-aza-bicyclo[3.1.0]hex-3-yl)]-[5-(3-fluoro-phenyl)-2-methyl-thiazol-4-yl]-methanone:
Starting from [(1R*,2S*,5S*)-2-aminomethyl-3-aza-bicyclo[3.1.0]hex-3-yl]-(2-amino-5-m-tolyl-thiazol-4-yl)-methanone:
Starting from [2-amino-5-(3-chloro-phenyl)-thiazol4-yl]-[(1R*,2S*,5S*)-2-aminomethyl-3-aza-bicyclo[3.1.0]hex-3-yl]-methanone:
Starting from [(1R*,2S*,5S*)-2-aminomethyl-3-aza-bicyclo[3.1.0]hex-3-yl]-(3′-fluoro-5-methyl-biphenyl-2-yl)-methanone:
To a solution of the respective carboxylic acid (0.036 mmol) in DMF (0.50 mL) is added successively a solution of DIPEA (0.120 mmol) in DMF (0.20 mL) and a solution of TBTU (0.036 mmol) in DMF (0.30 mL). The obtained mixture is treated with a solution of Imidazo[2,1-b]thiazole-6-carboxylic acid [(1R*,2S*,5S*)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide (0.030 mmol) in DMF (0.50 mL). The mixture is shaken over night and purified by prep. HPLC to give the respective amide derivative.
To the respective carboxylic acid (0.135 mmol) is added successively a solution of TBTU (0.150 mmol) in MeCN (0.50 mL) and DIPEA (0.750 mmol). After 30 min a solution of the respective 3-aza-bicyclo[3.1.0]hexane derivative (benzofuran-4-carboxylic acid [(1R*,2S*,5S*)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide, 6-methyl-imidazo[2,1-b]thiazole-5-carboxylic acid [(1R*,2S*,5S*)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide or 2,3-dihydro-benzo[1,4]dioxine-5-carboxylic acid [(1R*,2S*,5S*)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide; 0.150 mmol) in DMF (0.50 mL) is added. The mixture is shaken over night and purified by prep. HPLC to give the respective amide derivative.
A solution of the respective [(1R*,5S*)-3-aza-bicyclo[3.1.0]hex-3-yl]-(2-bromo-phenyl)-methanone derivative (0.032 mmol) and the respective aryl-boronic acid (0.048 mmol) in a mixture of ethanol (0.20 mL) and toluene (0.20 mL) is prepared by gentle heating. An aq. Na2CO3 solution (2.0 M) is added and a flow of argon is bubbled through the mixture. After addition of Pd(PPh3)4 the mixture is heated to 75° C., stirred for 20 h, cooled to RT and purified by prep. HPLC to give the respective biphenyl derivative.
Heterocyclyl-substituted products are prepared in analogy by coupling of the respective aryl bromide with the respective heterocyclyl-boronic acid in DME as solvent.
Starting from 2,3-dihydro-benzo[1,4]dioxine-5-carboxylic acid [(1R*,2S*,5S*)-3-(2-bromo-4-methyl-benzoyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide:
Starting from 2,3-dihydro-benzo[1,4]dioxine-5-carboxylic acid [(1R*,2S*,5S*)-3-(2-bromo-5-methyl-benzoyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide:
Starting from 2,3-dihydro-benzo[1,4]dioxine-5-carboxylic acid [(1R*,2S*,5S*)-3-(2-bromo-3-methyl-benzoyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide:
Pd(PPh3)2Cl2 (0.51 mg) is added to a mixture of 2,3-dihydro-benzo[1,4]dioxine-5-carboxylic acid [(1R*,2S*,5S*)-3-(2-bromo-4-methyl-benzoyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide (0.036 mmol), copper(I) iodide (0.20 mg) and NEt3 (0.30 mL) in THF (0.10 mL) under nitrogen. After 1 min the respective alkyne (0.079 mmol) is added and the mixture is heated to 80° C. for 2h. Toluene (0.10 mL), another portion of the respective alkyne (0.108 mmol) and additional Pd(PPh3)2Cl2 (0.51 mg) are added. The mixture is heated to 80° C. for 2 h, cooled to RT and purified by prep. HPLC to give the respective product.
The respective mixture of enantiomers is separated by chiral HPLC using the respective column and the respective eluent to give the respective product in enantiomerically highly enriched form.
TBTU (0.19 mmol) is added to a solution of 6-methyl-imidazo[2,1-b]thiazole-5-carboxylic acid [(1R*,2S*,5S*)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide (0.16 mmol), 2-Bromo-5-m-tolyl-thiazole-4-carboxylic acid (0.16 mmol) and DIPEA (0.40 mmol) in DCM (2.50 mL). The mixture is stirred for 2 h at RT, washed twice with water, twice with aq. citric acid solution (10%), once with sat. aq. NaHCO3 solution and once with water, dried over Na2SO4 and concentrated in vacuo to give the crude product which is purified by chromatography (DCM/MeOH 19/1). LC-MS (basic): tR=0.94 min; [M+H]+=556.0.
Pd(PPh3)2Cl2 (0.65 mg) is added to a mixture of 6-methyl-imidazo[2,1-b]thiazole-5-carboxylic acid [(1R*,2S*,5S*)-3-(2-bromo-5-m-tolyl-thiazole-4-carbonyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide (0.054 mmol), copper(I) iodide (0.26 mg) and NEt3 (0.60 mL) in THF (0.30 mL) under nitrogen. After 1 min ethynyltrimethylsilane (0.108 mmol) is added. The mixture is heated to 80° C. for 3.5 h, concentrated in vacuo and purified by chromatography (DCM/MeOH 19/1) to give the desired product. LC-MS: tR=1.06 min; [M+H]+=574.5.
Pd(PPh3)2Cl2 (0.65 mg) is added to a mixture of 6-methyl-imidazo[2,1-b]thiazole-5-carboxylic acid [(1R*,2S*,5S*)-3-(2-bromo-5-m-tolyl-thiazole-4-carbonyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide (0.054 mmol), copper(I) iodide (0.26 mg) and NEt3 (0.60 mL) in THF (0.30 mL) under nitrogen. After 1 min 2-propyn-1-ol (0.108 mmol) is added. The mixture is heated to 80° C. for 3.5 h, concentrated in vacuo and purified by chromatography (DCM/MeOH 19/1) to give the desired product. LC-MS: tR=0.84 min; [M+H]+=532.3.
A solution of 6-methyl-imidazo[2,1-b]thiazole-5-carboxylic acid [(1R*,2S*,5S*)-3-(5-m-tolyl-2-trimethylsilanylethynye-thiazole-4-carbonyl)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide (0.017 mmol) in EtOH (1.0 mL) is treated successively with tetrabutylammonium fluoride hydrate (0.017 mmol) and Pd/C (10%, 10 mg) and stirred at RT under a hydrogen atmosphere (1 bar) for 16 h. After filtration through celite and removal of the solvents in vacuo a crude product is obtained which is purified by chromatography (EtOAc/heptane 2/1). LC-MS (basic): tR=0.92 min; [M+H]+=506.1.
A solution of 6-methyl-imidazo[2,1-b]thiazole-5-carboxylic acid {(1R*,2S*,5S*)-3-[2-(3-hydroxy-prop-1-ynyl)-5-m-tolyl-thiazole-4-carbonyl]-3-aza-bicyclo[3.1.0]hex-2-ylmethyl}-amide (0.033 mmol) in EtOH (1.0 mL) is treated with Pd/C (10%, 10 mg) and stirred at RT under a hydrogen atmosphere (1 bar) for 6 h. Additional Pd/C (10%, 10 mg) is added and the mixture is stirred at RT under a hydrogen atmosphere (1 bar) for 16 h. After filtration through celite and removal of the solvents in vacuo the desired product is obtained. LC-MS (basic): tR=0.79 min; [M+H]+=536.1.
TBTU (0.058 mmol) is added to a solution of 6-methyl-imidazo[2,1-b]thiazole-5-carboxylic acid [(1R*,2S*,5S*)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide (0.048 mmol), 5-m-tolyl-thiazole-4-carboxylic acid (0.048 mmol) and DIPEA (0.12 mmol) in DCM (1.00 mL). The mixture is stirred for 2 h at RT, washed twice with water, twice with aq. citric acid solution (10%), once with sat. aq. NaHCO3 solution and once with water, dried over Na2SO4 and concentrated in vacuo to give the crude product which is purified by chromatography (DCM/MeOH 19/1). LC-MS (basic): tR=0.83 min; [M+H]+=478.1.
TBTU (0.058 mmol) is added to a solution of 6-methyl-imidazo[2,1-b]thiazole-5-carboxylic acid [(1R*,2S*,5S*)-3-aza-bicyclo[3.1.0]hex-2-ylmethyl]-amide (0.048 mmol), 2-methoxy-5-m-tolyl-thiazole-4-carboxylic acid (0.048 mmol) and DIPEA (0.12 mmol) in DCM (1.00 mL). The mixture is stirred for 2 h at RT, washed twice with water, twice with aq. citric acid solution (10%), once with sat. aq. NaHCO3 solution and once with water, dried over Na2SO4 and concentrated in vacuo to give the crude product which is purified by chromatography (DCM/MeOH 19/1). LC-MS (basic): tR=0.91 min; [M+H]+=508.2.
In Vitro Assay
The orexin receptor antagonistic activity of the compounds of formula (I) is determined in accordance with the following experimental method.
Experimental Method:
Intracellular Calcium Measurements:
Chinese hamster ovary (CHO) cells expressing the human orexin-1 receptor and the human orexin-2 receptor, respectively, are grown in culture medium (Ham F-12 with L-Glutamine) containing 300 μg/ml G418, 100 U/ml penicillin, 100 μg/ml streptomycin and 10% inactivated fetal calf serum (FCS). The cells are seeded at 80,000 cells/well into 96-well black clear bottom sterile plates (Costar) which have been precoated with 1% gelatine in Hanks' Balanced Salt Solution (HBSS). All reagents are from Gibco BRL. The seeded plates are incubated overnight at 37° C. in 5% CO2.
Human orexin-A as an agonist is prepared as 1 mM stock solution in MeOH: water (1:1), diluted in HBSS containing 0.1% bovine serum albumin (BSA) and 2 mM HEPES for use in the assay at a final concentration of 10 nM.
Antagonists are prepared as 10 mM stock solution in DMSO, then diluted in 96-well plates, first in DMSO, then in HBSS containing 0.1% bovine serum albumin (BSA) and 2 mM HEPES.
On the day of the assay, 100 μl of loading medium (HBSS containing 1% FCS, 2 mM HEPES, 5 mM probenecid (Sigma) and 3 μM of the fluorescent calcium indicator fluo-3 AM (1 mM stock solution in DMSO with 10% pluronic acid) (Molecular Probes) is added to each well.
The 96-well plates are incubated for 60 min at 37° C. in 5% CO2. The loading solution is then aspirated and cells are washed 3 times with 200 μl HBSS containing 2.5 mM probenecid, 0.1% BSA, 2 mM HEPES. 100 μl of that same buffer is left in each well.
Within the Fluorescent Imaging Plate Reader (FLIPR, Molecular Devices), antagonists are added to the plate in a volume of 50 μl, incubated for 20 min and finally 100 μl of agonist is added. Fluorescence is measured for each well at 1 second intervals, and the height of each fluorescence peak is compared to the height of the fluorescence peak induced by 10 nM orexin-A with buffer in place of antagonist. For each antagonist, IC50 value (the concentration of compound needed to inhibit 50% of the agonistic response) is determined. Antagonistic activities (IC50 values) of all exemplified compounds are below 1000 nM with respect to the OX1 and/or the OX2 receptor. IC50 values of 365 exemplified compounds are in the range of 5-9992 nM with an average of 728 nM with respect to the OX1 receptor. IC50 values of all exemplified compounds are in the range of 2-4055 nM with an average of 187 nM with respect to the OX2 receptor. Antagonistic activities of selected compounds are displayed in Table 1.
| Number | Date | Country | Kind |
|---|---|---|---|
| PCT/IB2006/053570 | Sep 2006 | IB | international |
| Filing Document | Filing Date | Country | Kind | 371c Date |
|---|---|---|---|---|
| PCT/IB2007/053947 | 9/28/2007 | WO | 00 | 3/27/2009 |
